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Preface
In 1982 the world’s human population was estimated to be 4.2 billion and
increasing at a rate of approximately 2% per year. The highest growth rate is in
Africa, where the population is estimated to be growing at 3.2% per year. There
is, therefore, a continually increasing requirement for food on that continent.
Although Africa’s total food production is growing to meet the increasing
demand, production has not kept pace with the expanding population (see Figure
1). Between 1965 and 1982, food production on the continent per person fell
by approximately 12%, and even in the most productive regions total food
production fell by 8% between 1969/71 and 1981/82. By contrast, from 1965
to 1982, food production rose by 6% in the Near East and by at least 49% in
Asia. While Latin America and Asia have become almost self-sufficient in
cereal production, Africa has become more and more dependent on imports and
food aid. In 1963 Africa grew 96% of its cereal requirements; in 1985 it grew
only 78%.
One disease in particular, trypanosomiasis, has had profound adverse effects
on the whole pattern of agriculture in Africa. In sub-Saharan Africa the disease
is transmitted to domestic livestock by the tsetse fly and impedes livestock
production directly and crop production indirectly. The tsetse fly occurs in most
of the humid and sub-humid zones, an area totalling approximately 10 million
square kilometres, or about half the non-desert area of Africa (Figure 2).
Agriculture in Europe and most  of  Asia is  based  on  mixed  arable and
livestock farming, with cattle providing people with protein in the form of meat
and dairy produce, draught power for ploughing and transport, and fertilizer.
Fields requiring a rest from cereal production may be used to grow fodder. In
sub-Saharan Africa, livestock are integrated into crop farming only in the
highlands of East Africa, which are too cool for tsetse, and in a few semi-arid
regions, which are too dry for the fly. In the humid zones, livestock other than
dwarf sheep and goats are sparse. In the sub-humid zones, livestock are at
greatest risk from trypanosomiasis in the rainy season, during which stock
farmers often entrust their cattle to nomadic pastoralists who move the animals
to tsetse-free areas. Integration of crop and livestock farming throughout the
year is therefore impossible. This separation of livestock and arable farming
over much of Africa is a major barrier to agricultural development. Further-
more, of the 10 million square kilometres now infested with tsetse, some 7
million are thought to be otherwise suitable for mixed agriculture and livestock
farming. Thus, in 1963, Africa’s annual loss in meat production due to tsetse
was estimated to be US$5 billion.
Control of trypanosomiasis currently relies on protecting and treating live-
stock with trypanocidal drugs, control of the tsetse fly and, to a lesser extent,
use of trypanotolerant livestock breeds, resistant to the pathogenic effects of the
disease. These control strategies are frequently used in isolation. However, it is
becoming increasingly apparent that sustainable control of trypanosomiasis is
more likely to be achieved by integrating the different control strategies.
Chemotherapy for trypanosomiasis in cattle, sheep and goats currently relies
on use of salts of three compounds: isometamidium, homidium and diminazene.
All three compounds are closely related chemically and have been available for
at least thirty years. Although these drugs have effectively controlled the disease
in the field, the prevalence of resistance to each of the compounds appears to
be increasing. There is, therefore, an urgent need to develop new compounds,
chemically unrelated to those now is use. The development of new drugs, before
drug resistance becomes a widespread problem, will help ensure the long-term
productivity of domestic livestock in Africa.
Chemotherapy for trypanosomiasis in human beings is beset with similar
problems: a limited repertoire of compounds, resistance to the drugs, drug
toxicity and protracted treatment protocols.
In light of the current problems and limitations of chemotherapy for try-
panosomiasis in domestic livestock and human beings, an international work-
shop was held at ILRAD in August 1989 to discuss research aimed at developing
new trypanocides. Because of the scarcity of information on the phenotypic and
genetic basis of drug resistance in trypanosomes, work on other protozoan
parasites was also reviewed for its potential relevance to the development of
new therapeutic agents and diagnostics for trypanocide resistance. The meeting
highlighted areas of trypanosomal chemotherapy research in which develop-
ments are being made as well as areas where more research is required. The
workshop underscored the necessity for collaboration between scientists of
FIGURE 1. Graph showing per capita food production in Latin America, Asia and
sub-Saharan Africa from 1961 to 1983. Source: Financing Adjustment with growth in
sub-Sahara Africa 1986–90, World Bank, Washington D.C., 1986.
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different disciplines for complete development of a new compound to become
a reality.
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manuscript and gave helpful advice. Mr R. Kruska kindly provided the cattle
and tsetse distribution map used in this preface.
Andrew S. Peregrine
International Laboratory for
Research on Animal Diseases
Nairobi, July 1990
FIGURE 2. Major cattle-production areas and tsetse-infested zones in Africa. There is
little overlap except in the regions of West and Central Africa where trypanotolerant
livestock are kept.
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Opening address
A.R. Gray
Director General
International Laboratory for Research on Animal Diseases
P.O. Box 30709
Nairobi, Kenya
ILRAD extends a warm welcome to you all. While here, I hope you will learn
a little more about ILRAD and our research programs aimed at improved control
of livestock diseases.
I would now like to say a few words to introduce the program for this
workshop on `Chemotherapy for Trypanosomiasis’. Trypanosomiasis remains
one of the most important diseases of domestic livestock in sub-Saharan Africa
and constitutes a major impediment to livestock production on the African
continent. Outside Africa, trypanosomiasis poses a significant constraint to
livestock production in both the Middle and the Far East and in some areas of
South America. Human trypanosomiasis, or sleeping sickness, is still a signifi-
cant disease in Africa, where the World Health Organization estimates that
approximately 20,000 new cases are reported each year. Trypanosomiasis in
South America, in the form of Chagas’ disease, is also an important disease of
human beings.
On the African continent, in tsetse-infested areas, chemotherapy plays a vital
role in maintaining and improving the production of domestic livestock. Che-
motherapy ranks highly, alongside tsetse control and the use of trypanotolerant
livestock, as a disease control measure. However, at present there are only a
few drugs available for use as therapeutics and prophylactics against the disease
and significant problems with drug resistance are being reported from many
parts of Africa. Fortunately, the prevalence of significant resistance to some of
the drugs appears to have remained low. The reasons for this are unclear.
However, because there are so few drugs, there is an urgent need for develop-
ment of new trypanocides, most especially drugs that are chemically unrelated
to those currently on the market. Only this approach should overcome current
problems with cross-resistance.
A similar problem exists with drugs for human trypanosomiasis: there is only
a small repertoire of compounds and many of the drugs currently in use often
produce severe toxic side effects. All is not gloom, though, as I am sure we will
be hearing later in this workshop: field trials with the compound difluoromethy-
lorinithine, or DFMO, have shown that it may be particularly efficacious in the
treatment of late-stage Trypanosoma brucei gambiense infections, most particu-
larly those cases that are refractory to treatment with organic arsenicals.
For these reasons, ILRAD two years ago established a chemotherapy re-
search group. In addition to developing improved therapeutic strategies for
combating drug resistance with the drugs currently available, the group has been
asked to develop techniques to identify and quantify problems with drug
resistance within domestic livestock in the field. With such knowledge, it may
be possible to introduce rational corrective therapeutic regimes at the field level.
Studies are also being conducted to gain a clearer understanding of the pheno-
typic and genetic basis of drug resistance in different species of trypanosomes.
During his presentation, Dr. Peregrine will enlarge on the areas of research in
which ILRAD is involved.
You will see that our activities relate very much to aspects of managing
chemotherapy and drug resistance as field problems. However, new leads in the
control of trypanosomiasis by chemotherapy could have a significant impact on
the productivity of livestock in many countries, and could improve the well-be-
ing of millions of people both directly and indirectly. That is why, with some
additional funding from the United Nations Development Programme, we have
invited you all here to participate in this workshop on `Chemotherapy for
Trypanosomiasis’.
The objectives of the workshop are fivefold. First, the workshop will review
the current state of research on aspects of biochemistry, molecular biology and
therapeutics of pathogenic trypanosomes for their immediate and long-term
relevance to the control of human and animal trypanosomiasis. Second, the
workshop will review findings from research on Plasmodium, Leishmania and
mammalian cells for their relevance and possible application to research pro-
grams on trypanosomiasis. Third, the meeting will review findings on new and
potential drug-delivery systems for their possible contribution to the control of
trypanosomiasis. Fourth, we hope that the workshop will identify areas of
research where findings may offer new compounds or techniques for controlling
trypanosomiasis. Fifth, and finally, it is hoped that this meeting will encourage
the formation of links between scientists working in Africa and those working
elsewhere. We particularly hope that such links will benefit and strengthen
ILRAD’s chemotherapy research program. The speakers at this workshop come
from scientific institutions in Belgium, France, Kenya, The Netherlands, the
United Kingdom and the United States of America. In addition, we also have
present scientists from Ethiopia, Indonesia, Nigeria, Sudan, Tanzania and
Zambia who are interested in trypanosomiasis chemotherapy. Unfortunately,
there will not be time for everyone to give full-length presentations. However,
I trust you will all feel that your participation in this workshop is equally
important and useful.
I wish you well in your discussions this week and hope you enjoy your time
at ILRAD and in Kenya.
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As a result of advice given in a review of its research program in 1986, the
International Laboratory for Research on Animal Diseases (ILRAD) incorpo-
rated into its trypanosomiasis research program a chemotherapy component
with a mandate to maintain the long-term efficacy of the three compounds
currently marketed for use in catt le—diminazene, homidium and
isometamidium. It is hoped that detailed information on the phenotypic and
genetic basis of resistance to these drugs, on their mode of action and on their
pharmacokinetics will greatly enhance our knowledge about how the drugs
should be used in the field and how problems with drug resistance should be
combated. Concomitant with this research is the development of field-usable
techniques that will rapidly quantify resistance to each of the drugs. Such
`diagnostics’ would enable one to monitor the prevalence and level of drug
resistance in a given area and to decide rapidly on the most appropriate
therapeutic intervention to use. ILRAD’s research activities on chemotherapy
for trypanosomiasis therefore fall under the following eight broad topics.
DEVELOPMENT OF IN VITRO CULTURE TECHNIQUES FOR
IDENTIFYING AND QUANTIFYING DRUG RESISTANCE
At present the only method available for screening parasites for resistance to
trypanocides is treatment of experimentally induced infections in cattle or mice.
Neither is an ideal system: many field isolates will not grow in mice and it is
costly to purchase cattle and to maintain them in fly-proof isolation. Dr. R.
Kaminsky has been examining the suitability of in vitro cultivation systems for
this purpose and his work is discussed elsewhere in this volume.
EFFICACY OF ISOMETAMIDIUM CHLORIDE AND
DIMINAZENE ACETURATE IN ZEBU CATTLE
Earlier  work has demonstrated that great variation exists  in the  period of
prophylaxis afforded cattle by isometamidium chloride (Robson, 1962; Fair-
clough, 1963; Kirkby, 1964; Wiesenhutter et al., 1968). Results of studies
undertaken to elucidate the reason(s) for this variation suggest that the period
of prophylaxis afforded by isometamidium chloride is dose-dependent, inde-
pendent of the level of metacyclic challenge, unaltered by the presence of
infection at the time of drug administration, and principally dependent on
variation in trypanosome drug sensitivity. The studies also showed that anti-
genic priming of the immune system did not occur in cattle on chemoprophy-
laxis. Therefore, there would appear to be no immunoprophylactic contribution
to cattle maintained in such a manner (Peregrine et al., 1987, 1988).
Development of improved therapeutic regimes for the drugs currently avail-
able forms an equally important part of research within this area. Workers on
the Kenya coast have recently claimed that if isometamidium chloride is given
intravenously it can eliminate infections that do not respond to treatment by the
recommended intramuscular route (Dowler et al., 1989). Since this strategy
would benefit livestock owners who cannot readily obtain diminazene acetu-
rate, studies have been carried out in cattle using three clones of Trypanosoma
congolense that span the entire spectrum of resistance to isometamidum. Al-
though intravenous administration did eliminate fully sensitive infections at
doses up to 1.0 mg/kg it was not efficacious in eliminating infections that
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expressed clinically significant levels of resistance. The apparent efficacy seen
in the field may be due to other factors, such as acquired immunity.
Other studies are under way to determine whether repeat administration of
diminazene aceturate enhances the drug’s therapeutic activity. Since dimi-
nazene has a half-life in excess of 9 hours, it has been suggested that this
approach may enhance the drug’s therapeutic activity (Baggot, 1978).
MODE OF UPTAKE OF ISOMETAMIDIUM
BY CLONES OF T. CONGOLENSE
ILRAD researchers are using well-characterized clones of T. congolense to
determine the mode of uptake of isometamidium and the phenotypic basis of
resistance to this drug. Uptake of isometamidium by sensitive clones of T.
congolense, as determined by fluorescence spectrophotometry, has appeared to
be an active process and to be energy dependent. Reduced uptake of
isometamidium occurred in resistant clones and also appeared to be energy
dependent. Fluorometry appears to be a reliable method for quantifying the level
of isometamidium-resistance expressed by clones of T. congolense. Further
studies are under way to determine the molecular basis of these observations.
EPIDEMIOLOGY OF DRUG RESISTANCE
This area of research endeavours to gain a clearer understanding of the dynamics
of drug resistance in the field. When ILRAD’s chemotherapy program began,
it was uncertain whether homogeneous expression of drug resistance occurred
in any given stock of trypanosomes. Nine clones were therefore derived from
a T. congolense stock (IL 2856), obtained from Burkina Faso, which expresses
a high level of resistance to both diminazene and isometamidium in mice, an
unusual phenotype. All clones were characterized for their sensitivity to dimi-
nazene and isometamidium in mice. Significant clonal variation in resistance
to isometamidium was observed. However, compared to sensitive clones, all
nine  clones derived from IL 2856 expressed a high level of resistance to
isometamidium. Diminazene sensitivity studies produced similar results, with
significant clonal variation in expression of resistance. In addition, all clones
expressed a high level of resistance compared to reference sensitive clones.
Finally, isoenzyme variants for eight enzymes were determined for each of the
nine clones: all expressed the same variants. These studies therefore showed
that T. congolense clones derived from one stock and with an apparent homo-
geneous background can, in the absence of drug selection, express significantly
different levels of resistance to  both  diminazene and isometamidium,  and
express high levels of resistance to both drugs (Peregrine et al., in press).
To determine a possible genetic basis for resistance to isometamidium, nine
clones (subclones) were derived from one of the aforementioned clones (IL
2856 clone 1). The nine subclones were characterized in mice for their sensi-
tivity to isometamidium (Table 1). Seven of the nine subclones expressed a
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significantly lower level of resistance to isometamidium than the parental clone.
Furthermore, there was significant variation in resistance among the subclones.
This suggests that genetic control of this phenotype in T. congolense is unstable.
The latter hypothesis is consistent with recent studies on the instability of
isometamidium-resistance in stocks of T. congolense (Nyeko et al., 1989) and
is currently under investigation.
A final set of studies have focused on T. congolense IL 1180, a clone that
expresses a high level of sensitivity to isometamidium. Over an 18-month
period, a derivative has been produced in vivo that is 200-times more resistant
to isometamidium than IL 1180. This derivative has been shown to be tsetse
transmissible and to produce approximately the same infection rate in the gut,
labrum and hypopharynx of Glossina morsitans centralis as IL 1180. The
clone’s tsetse transmissibility also appeared to be unaltered.
The aforementioned IL 1180 populations are currently being used in a study
to look for biochemical markers that correlate with expression of resistance to
isometamidium. Preliminary results from two-dimensional polyacrylamide gel
electrophoresis analyses have shown that with increasing levels of resistance to
isometamidium there are changes in the expression of certain proteins. Further
work is under way to determine which, if any, of these proteins correlate with
expression of resistance.
MOLECULAR BIOLOGY OF DRUG RESISTANCE
Drug-resistant T. brucei brucei isolates have been examined at the DNA level
for evidence of gene amplification. Initial experiments involved isolation of
DNA from resistant and sensitive trypanosomes, restriction endonuclease di-
TABLE 1. Sensitivity of T. congolense IL 2856 clone 1 subclones to isometamidium
chloride in mice
95% confidence
Population CD50(mg/kg)* interval (mg/kg)
IL 2856 clone 1 5.1 3.2–8.0
IL 2856 subclone 1.1 1.8 1.5–2.1
IL 2856 subclone 1.2 1.4 1.2–1.6
IL 2856 subclone 1.3 1.4 1.2–1.5
IL 2856 subclone 1.4 0.9 0.8–1.0
IL 2856 subclone 1.5 1.9 1.7–2.2
IL 2856 subclone 1.6 3.0 2.5–3.7
IL 2856 subclone 1.7 1.3 1.1–1.4
IL 2856 subclone 1.8 2.7 2.2–3.3
IL 2856 subclone 1.9 1.7 1.5–2.0
*Dose at which 50% of an infected population are cured.
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gestion, gel electrophoresis, Southern blotting and probing with total genomic
32P-labelled DNA from sensitive and resistant isolates. Hybridization to an
apparent extrachromosomal element was detected in tracks of undigested DNA
from the resistant isolate. Further work has shown that this element is DNA,
that the element occurs in the genome of sensitive T. b. brucei but is only found
as an extrachromosomal-type element in the resistant isolate and that clones
from this isolate also contain the element. In addition, presence of the element
appears to coincide with expression of resistance because trypanosomes pas-
saged in the absence of selection appear to have a reduced copy number of the
element. The copy number appears to increase when drug selection is reapplied.
DEVELOPMENT OF DRUG ASSAYS
Aliu and Odegaard (1983) described an ion-pair extraction and high-perform-
ance liquid chromatographic (HPLC) technique for measuring diminazene in
the plasma of treated animals. Professor Aliu is currently at ILRAD to set up
the technique and to determine the pharmacokinetics of diminazene in Zebu
cattle. The data resulting from this study will be used in future experiments
designed to examine whether repeat treatment regimes enhance diminazene’s
therapeutic activity.
ILRAD is also in the process of setting up a cold HPLC technique for
assaying isometamidium levels in cattle sera (Kinabo and Bogan, 1988). It is
also collaborating with the University of Glasgow, Scotland, in the evaluation
of an isometamidium enzyme-linked immunosorbent assay that the University
has developed. It is hoped that both techniques will be used to determine the
pharmacokinetics of isometamidium in cattle.
THE TRYPANOTOLERANT LIVESTOCK NETWORK
Several years ago the International Livestock Centre for Africa (Addis Ababa)
established the headquarters for a Trypanotolerant Livestock Network in Nai-
robi. Members of this network have been studying the productivity of trypano-
tolerant livestock in a number of field sites across Africa. Use of the group’s
extensive data sets is helping ILRAD researchers to determine the absolute
requirements for trypanocides by cattle in the different projects, the associated
increase in productivity and whether drug resistance is a significant problem at
any of the sites. Information from a project in Ethiopia indicates that there may
be a significant problem with resistance to diminazene at that site. For this
reason, field isolates have been obtained from that site and are currently being
characterized for their drug-resistance phenotypes at ILRAD so that the project
may be advised about the most suitable intervention to eliminate the current
problem. Preliminary results indicate a high prevalence of resistance to dimi-
nazene.
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TRAINING AND OUTREACH
Training and Outreach form important parts of the chemotherapy program. Five
students are currently working within the program. They are from Benin, Kenya,
Nigeria, Sudan and Tanzania. Such training will help ILRAD form active
collaborative programs with African universities and organizations involved in
chemotherapy research. Such collaboration is of paramount importance because
only an integrated pan-African trypanosomiasis chemotherapy program can
ensure the long-term efficacy of the trypanocides currently in use.
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Workshop overview: recent developments in
the chemotherapy of African trypanosomiasis
S.L. Croft
London School of Hygiene and Tropical Medicine
Keppel Street
London WC1E 7HT, UK
The first-line drugs for the treatment of malaria, leishmaniasis and African
trypanosomiasis were developed over 30 years ago, whilst chemotherapy
for Chagas’ disease has only become available in the last 15 years. Thera-
pies for all these diseases are blighted by problems of resistance, variable
efficacy between strains or species of the causative organisms, toxicity,
difficulty of administration or a combination of these factors. The recom-
mended drugs used for the treatment of human African trypanosomiasis
remain melarsoprol, suramin and pentamidine (World Health Organization,
1979) , and for animal t rypanosomias is , the sa l ts of homidium,
quinapyramine, diminazene, isometamidium and suramin (World Health
Organization, 1979). However, the last decade has witnessed an enormous
growth in our understanding of the biochemical and molecular processes of
trypanosomes with the revelation of targets for the design and development
of new drugs. Some of these will be described in this workshop along with
recent developments in our understanding of drug resistance and new
approaches to drug delivery.
METABOLIC PATHWAYS
Any strategy to identify novel anti-protozoal drugs must take into account
the metabolic differences between stages of the life cycle and that there is
often a reduction in the complexity of metabolic pathways as parasites are
bathed in a nutritional environment (Fairlamb, 1989). An extensive number
of anabolic, catabolic and regulatory pathways have been identified in
parasitic protozoa that offer chemotherapeutic targets (Fairlamb, 1989).
Carbohydrate metabolism and energy production in the bloodstream forms
of African trypanosomes are reliant upon glycolysis organized in a unique
manner between a reduced mitochondrion, the cytoplasm and the glycosome
(Opperdoes, 1987). This pathway is probably a target for suramin and forms the
basis for several novel approaches (see A.B. Clarkson, P.A.M. Michels and
F.M.D. Vellieux, this volume). The electron transport chain is a target in other
protozoa (see J.F. Turrens, this volume), best illustrated by the naphthoquinones
developed for the treatment of theileriosis and malaria (Hudson et al., 1985).
Nucleic acid synthesis in trypanosomatids also has unique characteristics. These
organisms, being unable to synthesize purines de novo, have evolved a special
salvage pathway with enzymes that have a higher affinity for disruptive purine
analogues than natural precursors. The bifunctional dihydrofolate reductase-
thymidylate synthase (DHFR-TS), an enzyme essential for the formation of
tetrahydrofolate, a co-factor for the synthesis of pyrimidines, is the target for
the antimalarials pyrimethamine and cycloguanil. Recent studies have charac-
terized this enzyme in Leishmania (see S.M. Beverley, this volume), stimulating
further drug design (Sirawaraporn et al., 1988). Nuclear and kinetoplast DNA-
dependent processes are inhibited by many standard trypanocides that interca-
late (phenanthridines) or bind externally to DNA (diamidines) (Williamson,
1979). This may interfere with the functioning of DNA and RNA polymerases
as well as DNA topoisomerases I and II (see T.A. Shapiro, this volume). The
metabolic pathways of polyamine synthesis have been most productive in the
last decade for the identification of new anti-trypanosomal compounds, such as
eflornithine (DL-α-difluoromethylornithine [DFMO]) which is now in exten-
sive clinical trials (see C.J. Bacchi, this volume). Interference with polyamine
synthesis may explain the mode of action of established drugs, e.g., diminazene
(Bitonti et al., 1986). Polyamines have a wide number of regulatory functions
in cells, including, in trypanosomatids, the synthesis of specific thiols (see A.H.
Fairlamb, this volume). Eflornithine is also active against Leishmania, Plasmo-
dium and Pneumocystis carinii. The predominance of ergosterol rather than
cholesterol in the membrane is the basis for the selective toxicity of antifungal
agents in Leishmania and Trypanosoma cruzi such as amphotericin B and the
azole and allylamine sterol synthesis inhibitors (see L.J. Goad, this volume).
Microtubules, an integral part of the trypanosomatid pellicle, flagellum and
mitotic nucleus, are sensitive to phenothiazines and inhibitors of microtubular
disassembly such as taxol. Cellular regulatory and protective processes, many
unique to trypanosomatids, are also important targets. The transmembrane
proton pump in Leishmania, which regulates internal pH and nutrient uptake,
is sensitive to tricyclic antidepressants (Zilberstein and Dwyer, 1984). The
susceptibility of trypanosomatids to oxidant stress has also been exploited either
by using drugs that produce toxic metabolites or radicals, or by lowering the
defence mechanisms of superoxide dismutase or glutathione (there is little or
no catalase). Current interest is focused on the novel intracellular thiol try-
panothione, which has a protective and regulatory role in trypanosomatids (see
A.H. Fairlamb, this volume).
Biochemical studies have revealed many more potential targets, but there is
one final area of cellular metabolism to be considered. The drug uptake process
includes not only transport but also the intracellular metabolism, binding and
distribution  of a drug. This is critical  for  selective  toxicity  and  for some
trypanocides has been studied extensively (Hawking, 1963; Frommel and
Balber, 1987). As far as is known, the antimalarials chloroquine and qinghaosu
owe much of their selective toxicity to specific uptake by infected erythrocytes
rather than any special disruption of a metabolic pathway (see S.R. Meshnick,
this volume).
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DRUG RESISTANCE
Resistance is a major problem in the treatment of many infectious diseases and
for malaria it has been the major stimulus for the discovery of new drugs. The
detection, origins and mechanisms of drug resistance in parasitic protozoa will
be discussed in the Workshop. The term `drug resistance’ covers a wide range
of phenomena, including host-related and parasite-related factors.
Host-related factors that contribute to resistance include (1) pharmacokinet-
ics, for example, poor distribution to infected tissues or intracellular sites or the
variation in drug metabolism between individuals (e.g., mefloquine); and (2)
immunological status, for example, the inactivity of pentavalent antimonials
against diffuse cutaneous leishmaniasis and the diminished activity of suramin,
quinapyramine and DFMO (Bitonti et al., 1986) in animals with a suppressed
immune system.
Parasite-related factors that contribute to resistance include the following.
(1) reduction in drug accumulation, described widely in trypanosomes for
arsenicals (Hawking, 1963), diamidines, phenanthridines, acriflavine (Frommel
and Balber, 1987) and DFMO in resistant T. brucei (Phillips and Wang, 1987),
as well as for some anti-leishmanial compounds (see S.M. Beverley,  this
volume); (2) change in enzyme target, through either an increase in enzyme
levels, shown by DHFR-TS in Leishmania resistance to methotrexate (see S.M.
Beverley, this volume) and Plasmodium resistance to pyrimethamine (see J.
Inselburg, this volume), or changes in enzyme affinity, as shown in P. falci-
parum DHFR-TS due to a single amino acid substitution (see J. Inselburg, this
volume); (3) alteration in drug metabolism, that is, activities of cytochrome
P450 and other detoxifying enzymes that have been reported to be higher in
chloroquine-resistant  strains  of P. berghei (Ward, 1988), or, alternatively,
failure to activate a prodrug, such as in metronidazole resistance; (4) increased
metabolite production or retention, as reported in T. brucei, with increased
levels of ornithine in resistant parasites competing with DFMO for ornithine
decarboxylase (Bellofatto et al., 1987); and (5) use of alternative pathways to
bypass the site of inhibition.
The origins of parasite-related resistance may be (1) natural, as in non-sus-
ceptible strains with no previous exposure to drugs, such as tryparsamide-resis-
tant T. rhodesiense isolated from  animals (Dukes, 1984); (2) due to drug
pressure/exposure; (3) due to cross-resistance, as has been extensively reported
for trypanocides (Hawking, 1963; Frommel and Balber, 1987); or (4) mutagen
induced. The origin of the resistance is important to the field worker, as is the
provision  of  rapid tests  for  the  diagnosis of resistance in isolates (see R.
Kaminsky, this volume). Strategies to combat resistance rely on (1) prevention
through correct chemotherapeutic regimens based on knowledge of drug phar-
macology; (2) combination therapy, most advanced in malaria prophylaxis; and
(3) reversal of resistance, which has recently been experimentally demonstrated
for chloroquine resistance in human and rodent malaria (see D.J. Krogstad, this
volume) using the calcium channel blocker verapamil (Martin et al., 1987) or
the tricyclic antidepressant desipramine (Bitonti et al., 1988), which reduces
the drug efflux. This approach has recently been extended to trypanosomatids
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and may be related to the presence of a multidrug-resistant gene (see I.B.
Roninson, this volume).
DRUG DELIVERY SYSTEMS
Drug delivery systems are designed to improve the therapeutic index of a
compound by increasing efficacy through improved delivery to the site(s) of
infection, protecting the drug from host metabolism, and decreasing drug
toxicity to the host. There are two different types of delivery systems: sustained-
or slow-release systems, designed to maintain a therapeutic drug level, and
site-specific targeting systems. Sustained-release systems have been used for
the prophylaxis of animal trypanosomiasis to reduce both frequency of dosing
and local toxicity. Early  studies  by Williamson  (1970) used  a  depot of a
precipitated complex of suramin with other trypanocides. More recently, try-
panocides, in particular isometamidium, linked to dextran have given protection
against infection in animal models (James, 1978) and reduced local toxicity in
cattle. Studies with biodegradable polymers are under way. Other systems have
been developed for therapy and prophylaxis of malaria, leishmaniasis and
gastrointestinal helminths.
A large variety of delivery systems have been used in drug targeting, broadly
classified as cellular, vesicular, particulate and molecular carriers. The presen-
tations at this Workshop also discuss viral delivery (see S.J. Doxsey, this
volume), more commonly associated with vaccines, and antisense oligode-
oxynucleotides (see J.J. Toulmé and J. Goodchild, this volume), where the aim
is intracellular targeting. The requirement for African trypanosomiasis is a
carrier that can be retained in the circulation, avoiding the reticuloendothelial
system, especially for T. vivax and T. congolense infections, and for the human
disease, a carrier that can help a drug cross the blood-brain barrier. Studies
initiated by Williamson et al. (1981) showed that daunorubicin required a
covalently bound molecule carrier (bovine serum albumin) to show in vivo
activity against T. rhodesiense (see J.B. Mitchell, this volume). A polyglutamic
acid cis-platin complex was more effective and less toxic than free drug against
T. congolense in mice. Drug targeting systems have been used for other
protozoal infections, in particular visceral leishmaniasis where L. donovani
parasites survive in the reticuloendothelial cells of the liver and spleen, cells
which remove liposomes, niosomes and other larger particles from the circula-
tion. Liposomes have been developed for other uses (see B.T. Rouse, this
volume) and formulations containing amphotericin B and doxorubicin are in
clinical trials for the treatment of systemic mycoses and cancer.
CONCLUSION
The identification of a novel compound with exquisite selective activity is only
the first stage in drug development. The pharmacological properties of the
compound also require consideration to ensure optimum delivery and therapeu-
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tic levels at the site(s) of infection. New delivery systems can be designed to
assist this purpose. The problem of resistance can be approached by a more
complete understanding of the interactions between the drug, the parasite and
the host, leading to better usage.
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POLYAMINES AND THEIR SYNTHESIS
Polyamines are small molecules universally required for growth and division
by prokaryotic and eukaryotic cells. The most important polyamines in eu-
karyotes are putrescine, spermidine and spermine, which are believed to have
major roles in cell division, differentiation and the maintenance of essential cell
functions (Pegg, 1986). The molecular underpinnings of polyamine action are
still shrouded, but it is clear that their presence (especially spermidine) is
important for conformational regulation of DNA, elongation and initiation of
protein synthesis and fidelity of translation. Polyamines appear to be essential
for ribosome and transfer RNA (tRNA) structure and function, and exert
dramatic control over proteins such as topoisomerases (Marton and Morris,
1987).
Synthesis of polyamines is closely regulated, with the reactions catalysed by
ornithine decarboxylase (Figure 1) and S-adenosyl-methionine decarboxylase
emerging as the critical steps. Ornithine decarboxylase (ODC) produces putre-
scine from ornithine; S-adenosyl-methionine decarboxylase (SAM DC) synthe-
sizes decarboxylated S-adenosyl-methionine (SAM), which is the aminopropyl
group donor for spermidine and spermine synthesis. Aminopropyl groups are
transferred to putrescine and spermidine by spermidine and spermine synthases,
respectively (Figure 1).
NOVEL ASPECTS OF
POLYAMINE SYNTHESIS IN TRYPANOSOMES
Despite apparent similarities between mammalian and trypanosome polyamine
pathways, subtle differences exist. Trypanosomes synthesize putrescine from
ornithine via ODC, and spermidine from methionine and putrescine by way of
SAM synthase, SAM DC and spermidine synthase (summarized in Bacchi and
McCann, 1987). The origin of ornithine is unclear since Trypanosoma brucei
brucei lacks arginase (J. Garofalo and C.J. Bacchi, unpublished), a major source
of ornithine in mammalian cells. African trypanosomes neither synthesize nor
contain significant levels of spermine. Many cells avidly transport polyamines,
but African trypanosomes do not, unless prior depletion of intracellular levels
FIGURE 1. Polyamine biosynthesis and related reactions in African trypanosomes.
Boxes indicate inhibitors. DFMO: DL- a -difluoromethylornithine, SAM: S-adenosyl-
methionine, SAM DC: SAM decarboxylase, SPD: spermidine, GSH: reduced glu-
tathione, As: arsenical drug, MGBG: methylglyoxal bis (guanylhydrazone), ODC:
ornithine decarboxylase, GSH-SPD-GSH: trypanothione.
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has occurred (Bacchi et al., 1979, 1983). A key aspect of trypanosome polyamine
metabolism is the presence of a unique spermidine-containing peptide, try-
panothione (N1N8-bis [glutathionyl] spermidine), which serves as co-factor for
glutathione reduction and hence is essential in protecting trypanosomes from free
radical damage and other oxidant stress (Fairlamb, 1989).
INHIBITION OF POLYAMINE SYNTHESIS:
RELATIONSHIP TO CHEMOTHERAPY
DL-α-difluoromethylornithine (DFMO; eflornithine) is an enzyme-activated
inhibitor of ODC developed by the Merrell Dow Research Institute in the late
1970s. It is highly specific for ODC and exerts a time-dependent irreversible
inhibition of the enzyme, becoming covalently bonded to the active site (Bey
et al., 1987).
In bloodstream trypanosomes, DFMO rapidly blocks ODC activity, reduces
polyamine content and blocks DNA, RNA and protein synthesis while causing
alterations in morphology of long slender forms, producing cells similar to
intermediate and stumpy forms (Bacchi and McCann, 1987; Giffin and
McCann, 1989). Despite the broad-reaching biochemical consequences of
DFMO treatment, the drug is not overtly cytotoxic.
In model T. b. brucei acute mouse infections, DFMO is curative when a 2%
solution is administered continuously for three days (total dose: 5.3 g/kg/day
[Bacchi et al., 1987]). Prolonged administration of DFMO (4% for four weeks)
is curative in model central nervous system infections (Bacchi et al., 1987), but
the total dose can be reduced significantly if combined with suramin (Clarkson
et al., 1984).
Because of the extensive clinical experience with DFMO as an antitumour
agent, clinical trials on Gambian sleeping sickness were begun in 1981. DFMO
proved largely successful, with greater than 90% of more than 400 patients
responding to the drug, as defined by clearance of trypanosomes from blood
and cerebrospinal fluid and a low incidence of relapse (Schechter and Sjoerd-
sma, in press). Most patients had failed to respond to one or more courses of
treatment with melarsoprol (Mel B), and most had involvement of the central
nervous system at the time treatment was begun. DFMO has recently been
administered intravenously for two weeks (400 mg/kg/day, total dose) followed
by 300 mg/kg/day per os (4 × 75 mg/kg/day) for four additional weeks. This
regimen has proven superior to previous oral dosing protocols, with most side
effects being minor and disappearing on cessation of drug administration. These
studies are detailed in several reviews (Sjoerdsma et al., 1984; Schechter et al.,
1987; Schechter and Sjoerdsma, in press).
Despite the outstanding success of DFMO against disease caused by T. b.
gambiense, the outlook for its use in treatment of East African sleeping sickness
(caused by T. b. rhodesiense) is uncertain. In a limited number of trials in East
Africa, various DFMO regimens, even those employing double the standard
dose, have failed to cure some patients (S. Van Nieuwenhove, P. deRaadt,
personal communications). It is becoming apparent from these initial studies
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that alternatives to single drug therapy with DFMO will be needed for East
African disease.
SPECIFICITY OF DFMO: THE REASON FOR ITS EFFICACY
The surprising activity of DFMO against African trypanosomes has been the
subject of considerable study. DFMO efficacy appears to centre on the following.
(1) DFMO blocks antigenic variation, and a competent immune system is
required to rid the parasites from the host (DeGee et al., 1983; Bitonti et al.,
1988).
(2) In contrast to the mammalian host, in which ODC half-life is less than 1
hour (Pegg, 1986), T. b. brucei blood and midgut forms have ODC which has
a long (greater than 2 hours) half-life (Phillips et al., 1987; Bacchi et al., 1989).
The main structural difference between host and parasite ODC is the lack of a
36 amino acid sequence (`PEST’ sequence) on the C-terminal end of the parasite
ODC, which is one factor associated with a high turnover rate in the mammalian
enzyme (Phillips et al., 1987). The low turnover rate of the parasite ODC implies
a low synthesis rate and this allows more efficient reduction of enzyme activity
by DFMO for a longer time (Bacchi et al., 1989).
(3) The spermidine-containing tripeptide trypanothione is unique to try-
panosomatids (Fairlamb et al., 1985). It is the only substrate for trypanothione
reductase and, in the reduced state, it functions to non-enzymatically reduce
glutathione and maintain the redox balance of the cell. These reactions are
detailed elsewhere in this volume (A.H. Fairlamb). DFMO treatment not only
reduces spermidine content, but also reduces the levels of trypanothione and its
intermediate, glutathionyl-spermidine (Fairlamb et al., 1987). The resulting
stress on the capacity to detoxify free radicals should enhance parasite sensitivity
to agents that produce free radicals, such as nifurtimox (Fairlamb, 1989).
(4) African trypanosomes lack a reservoir of spermine, and appear not to
synthesize it. They also lack the oxidative pathway necessary to convert sper-
mine to spermidine (J. Garofalo and C. Bacchi, unpublished). The persistence
of spermine in DFMO-treated mammalian cells and its catalytic conversion to
spermidine (Pegg et al., 1986) may be one reason why DFMO has been largely
ineffective as an antitumour agent when used in single drug therapy (Schechter
et al., 1987). As noted, uptake of exogenous polyamines in T. b. brucei occurs
at a rate much reduced from that in mammalian cells (Bacchi et al., 1983).
Although DFMO treatment enhances polyamine transport, these factors collec-
tively signal the inability of trypanosomes to sequester physiologically signifi-
cant amounts of exogenous polyamines.
RECENT STUDIES ON THE SUSCEPTIBILITY OF
TRYPANOSOMA B. RHODESIENSE TO DFMO AND ARSENICALS
In view of recent clinical trials in East Africa with DFMO, we have examined
l4 clinical isolates (Uganda, Kenya and Mozambique) from the Kenya Trypano-
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somiasis Research Institute (KETRI) strain bank for susceptibility to trypano-
cides, using these strains as acute laboratory model infections (Bacchi et al.,
1990). To summarize this work, seven isolates (50%) were moderately to highly
refractory to DFMO in comparison to the standard test strain T. b. brucei Lab
ll0/EATRO. Four of l4 isolates (21.4%) were moderately to highly refractory
to melarsen oxide and Mel B. The levels of resistance varied greater than
eightfold in some DFMO-refractory isolates and greater than threefold for the
arsenicals. Since these strains had no prior contact with DFMO, the resistance
attributed to DFMO is constitutive; two of the four arsenic-resistant strains were
isolated from patients who had failed to respond to treatment with Mel B. Using
the same experimental protocol, all the strains, with the possible exception of
one, were susceptible to suramin, indicating that drug inefficacy was not due to
sequestration of parasites in the central nervous system or other tissues inacces-
sible to the drug.
RESISTANCE TO DFMO
Studies have begun to assess potential differences in polyamine metabolism
between DFMO-sensitive and -resistant strains. ODC activity in sensitive and
resistant strains was found to be similar, with specific activities of 40–60 nmoles
CO2/mg protein/hour. Time-dependent Ki values for DFMO (Bitonti et al.,
1985) were similar in both DFMO-sensitive T. b. brucei EATRO 110 and in
DFMO-refractory T. b. rhodesiense isolates (25–50 µM), indicating that differ-
ences in the ODC active site are probably not responsible for the lack of
response to DFMO.
Uptake of DFMO was similar in two sensitive and two refractory strains, in
the range of 600 pmoles/mg protein/hour, when bloodstream trypomastigotes
were incubated in vitro with (3H)DFMO as in Bitonti et al. (1986). However,
one refractory strain did exhibit a 60% reduction in DFMO uptake. Another
potential mechanism accounting for resistance to DFMO may be the signifi-
cantly increased accumulation of polyamines in bloodstream forms of two
refractory isolates upon incubation in vitro with radiolabelled polyamines. Thus
far, two of seven DFMO refractory isolates were found to accumulate polyami-
nes at rates up to four times that of sensitive cells. These studies are preliminary
and full details will be forthcoming in subsequent publications.
RESISTANCE TO ARSENICALS
As noted, four KETRI strains were refractory to melarsen oxide and Mel B. We
began studies comparing sensitive and resistant strains in a trypanosome lysis
assay based on that developed by Clarkson and Amole (1982): bloodstream
forms are incubated in foetal bovine serum with various concentrations of
arsenicals. Drug-sensitive isolates completely lysed within 15 minutes upon
incubation in less than 20 µM melarsen oxide, while refractory strains withstood
30 minutes in 100 µM drug without lysing.
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Since Fairlamb and co-workers have demonstrated that trypanothione may
be a primary target of arsenical drugs in trypanosomes (Fairlamb, 1989; Fair-
lamb et al., 1989), we began examination of total free thiol levels in resistant
and susceptible strains using dithionitrobenzene. Refractory strains had a three-
fold increase in total thiol levels above those measured in sensitive strains (1–2
nmoles/108 cells), which indicates an increased ability to withstand arsenic-in-
duced trypanothione loss and still maintain redox function (Fairlamb et al.,
1989). However, initial analyses of trypanothione, glutathionyl-spermidine and
glutathione, using high-performance liquid chromatography methodology and
monobromobimane as a fluorescing agent (Fairlamb et al., 1989), indicated that
the levels of these intermediates were similar in arsenic-resistant and arsenic-
susceptible strains. These findings do not exclude trypanothione as a target for
arsenical drugs, but do indicate the importance of further studies centring on
spermidine content and the interconversion of oxidized and reduced try-
panothione in arsenic-resistant strains.
CONCLUSIONS
In these studies we have begun to examine the basis for resistance to DFMO
and arsenicals observed in clinical isolates. Possible mechanisms of resistance
to DFMO include reduced uptake of the drug and increased uptake of polyami-
nes. Overproduction of ODC or significant lack of response of the enzyme to
DFMO does not appear to be a factor in resistance in these isolates.
Resistance to arsenicals is easily demonstrable by in vivo mouse testing and
verification by lysis assay. The reason(s) for resistance is not yet apparent but
may be based on the metabolism of trypanothione or the presence of additional
thiol targets in these strains.
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Interaction of trypanocidal drugs with the
metabolism and functions of trypanothione
A.H. Fairlamb
Department of Medical Parasitology
London School of Hygiene and Tropical Medicine
Keppel Street
London WC1E 7HT, UK
In mammalian cells, one of the primary means of defence against damage by
oxidants and other toxic substances involves the tripeptide glutathione (γ-glu-
tamyl-cysteinylglycine [GSH]) and its ancillary enzymes glutathione reductase,
glutathione peroxidase and glutathione-S-transferases. Trypanosomes and
Leishmania are uniquely different from the mammalian host in that they do not
contain glutathione reductase (Fairlamb and Cerami, 1985), an enzyme crucial
to these processes. Instead, trypanothione (N1,N8-bis [glutathionyl] spermid-
ine; T[SH]2) (Fairlamb et al., 1985), which is the principal low-molecular
weight thiol in logarithmically growing trypanosomatids (Fairlamb, 1989), acts
in concert with a flavoprotein disulphide oxidoreductase, trypanothione reduc-
tase (Shames et al., 1986; Krauth-Siegel et al., 1987), subsuming the role of
GSH and glutathione reductase in maintaining the correct intracellular redox
balance in these organisms. Similarly, current evidence suggests that, at least
in Trypanosoma brucei and Crithidia fasciculata, the role of GSH and glu-
tathione peroxidase in the removal of hydrogen peroxide (H2O2) and other
alkylperoxides has been replaced by T[SH]2 and trypanothione peroxidase(Penketh and Klein, 1986; Henderson et al., 1987a). Indirect evidence suggests
that this may be the case in Leishmania species and T. cruzi as well (Penketh et
al., 1987). Trypanothione and its precursor metabolite N1-glutathionylspermid-
ine (Fairlamb et al., 1986) may also be involved in regulation of intracellular
levels of unconjugated spermidine in C. fasciculata (Fairlamb, 1988b; Shim and
Fairlamb, 1988). Whether this finding has any relevance to the medically
important parasitic trypanosomatids is not clear at present. A summary of the
overall metabolism and functions of trypanothione is illustrated in Figure 1 and
the reader is referred to a number of reviews for more detailed information
(Fairlamb and Henderson, 1987; Fairlamb, 1988a, 1989).
DRUGS INTERACTING WITH THE
BIOSYNTHESIS OF TRYPANOTHIONE
Trypanothione is synthesized from its precursor amino acids (ornithine, methi-
onine, glutamate, cysteine and glycine) as illustrated in Figure 1. The biosyn-
thetic pathway as far as GSH and spermidine is identical to that of mammalian
cells, whereas the formation of trypanothione via the intermediate N1-glu-
tathionylspermidine is unique to trypanosomatids (Fairlamb et al., 1986). Al-
though these latter reactions do not appear to be inhibited by any of the existing
trypanocidal compounds (Fairlamb et al., 1986), they clearly represent a poten-
tially novel target for drug development.
Two classes of trypanocidal drugs, the fluorinated analogues of ornithine and
the diamidines, inhibit two rate-limiting enzymes in polyamine biosynthesis.
Alpha-difluoromethylornithine (DFMO) selectively inhibits the first enzyme in
the pathway (ornithine decarboxylase [ODC]; see C.J. Bacchi, this volume),
FIGURE 1. Metabolism and functions of trypanothione, showing possible sites of
action of trypanocidal compounds. The boxed insert illustrates   futile redox-cycling'
by nitro compounds (RNO2) ultimately forming hydrogen peroxide (H2O2) and hy-
droxyl radical (OH.). BSO: buthionine sulfoximine, DFMO: difluoromethylornithine,
R–As–
–
O: melarsen oxide, MEL T: trypanothione-melarsen adduct, PUT: putrescine,
SPD: spermidine, GSH and GSSG: glutathione and its disulphide, GSH-SPD: glu-
tathionylspermidine, T(SH)2: dihydrotrypanothione, T(S)2: trypanothione disulphide,
SAM: S-adenosylmethionine, dSAM: decarboxylated S-adenosylmethionine, MTA:
methylthioadenosine. Reactions 2, 5 and 7 are non-enzymatic; reaction 4, try-
panothione peroxidase; reaction 6, trypanothione reductase. Reproduced from Fair-
lamb (1989).
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leading to a multiplicity of subsequent events, including: a decrease in try-
panothione and other pathway intermediates (Fairlamb et al., 1987); an inhibi-
tion of macromolecular biosynthesis (Bacchi et al., 1983), including variant
surface glycoprotein (Bitonti et al., 1988); and biochemical and morphological
changes associated with differentiation to forms resembling the non-dividing
short, stumpy form (De Gee et al., 1984; Giffin et al., 1986; Giffin and McCann,
1989). Two other factors have been implicated in the selective toxicity of
DFMO to African trypanosomes: clearance by the host’s immune system (De
Gee et al., 1983; Bitonti et al., 1986b) and the prolonged half-life of T. brucei
ODC (Phillips et al., 1987; Bacchi et al., 1989), with the presumption that T.
brucei ODC turns over at considerably slower rates than the mammalian
enzyme. Whatever the cause of selective toxicity, partial depletion of try-
panothione per se seems unlikely to account for the rapid trypanocidal activity
of DFMO in vivo. However, the pronounced synergism between DFMO and
arsenical drugs (Jennings, 1988a, 1988b) is likely to occur by this mechanism
(see below). Similarly, the report that Berenil® or pentamidine inhibits S-ade-
nosyl-methionine decarboxylase in T. brucei (Bitonti et al., 1986a) could
explain the synergism between DFMO and diamidines (McCann et al., 1983).
DRUGS INTERACTING WITH OXIDANT DEFENCE
MECHANISMS OF THE PARASITE
A wide range of anti-parasitic compounds are thought to be selectively toxic by
means of oxidant stress, that is, by promoting the formation of reactive species
of oxygen (superoxide, singlet oxygen, hydrogen peroxide and hydroxyl radi-
cals) or other radical species (Docampo and Moreno, 1984a, 1984b, 1986). For
example, the nitrofuran drugs, nifurtimox and nitrofurazone, are thought to
undergo `futile-redox cycling’ by enzymatic 1-electron reduction of the nitro
group with subsequent reoxidation in the presence of molecular oxygen to
regenerate the parent drug and form superoxide (O2-; see boxed area, Figure 1).
Superoxide and H2O2 are maintained at low concentrations in trypanosomes by
means  of superoxide dismutase  (Le Trant et al., 1983) and trypanothione
peroxidase (Henderson et al., 1987a), respectively. However, if the parasite’s
ability to remove these compounds is exceeded, then hydroxyl (OH .) and other
radical species are formed by the Haber-Weiss reaction. The sulphydryl groups
of glutathione and trypanothione serve as a non-enzymatic second line of
defence; if swamped, radical damage to other vital cellular components such as
DNA and membrane lipids will ensue. Although the identity of the parasite
enzymes catalysing redox-cycling of these drugs has not been established,
trypanothione reductase has weak nitroreductase activity with nifurtimox or
nitrofurazone (Henderson et al., 1988). This observation has been exploited to
rationally design a series of `subversive-substrates’ (Henderson et al., 1988),
as will be described below.
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DRUGS INTERACTING WITH TRYPANOTHIONE
AND TRYPANOTHIONE REDUCTASE
The purification, properties and substrate specificity of trypanothione reductase
have been reported for C. fasciculata (Shames et al., 1986; Henderson et al.,
1987b) and T. cruzi (Krauth-Siegel et al., 1987), and recently, the gene for
trypanothione reductase from T. congolense has been cloned, sequenced
(Shames et al., 1988) and expressed in Escherichia coli (Sullivan et al., 1989).
A partial gene sequence for trypanothione reductase from L. donovani has also
been reported (Taylor et al., 1989). Comparison of the amino acid sequences
for trypanothione reductase and glutathione reductase suggests a possible
explanation for the pronounced difference in specificity for their disulphide
substrates (T[S]2 and GSSG, respectively). X-ray crystallographic studies on
the binding of GSSG to glutathione reductase indicate that Arg37 is in Coulom-
bic interaction with the glycine carboxylate group of the GS-I peptide (the half
of GSSG covalently bound to glutathione reductase during catalysis) (Karplus
et al., 1989). In trypanothione reductase, where the substrate contains no Gly-I
carboxylate, Arg37 is exchanged for a Trp (Shames et al., 1988). This difference
in substrate-specificity, together with the less discriminatory nature of sub-
strate-binding in trypanothione reductase (Henderson et al., 1987b), has been
exploited to develop a series of substituted naphthoquinones and nitrofurans.
These `subversive substrates’ not only inhibit reduction of trypanothione disul-
phide, but also act as redox-cycling agents producing O2- and H2O2, thus
subverting the enzymes’ normal anti-oxidant function (Henderson et al., 1988;
Jockers-Scherubl et al., 1989). Computer-assisted molecular modelling will no
doubt aid in further improvement of the trypanocidal activity of these and other
inhibitors.
Trypanothione (T[SH]2) has also been demonstrated to interact with the
trivalent arsenical drug melarsen oxide to form a stable adduct (Mel T, Figure
1) (Fairlamb et al., 1989). When bloodstream forms of T. brucei are exposed to
either melarsen oxide or melarsoprol in vitro, Mel T is the only arsenical
derivative detectable in acid-soluble extracts of the cells. Thus, trypanothione
would appear to be a primary target for these drugs, although the subsequent
sequence of events leading to cell lysis is not yet understood. On the one hand,
arsenicals could deplete T[SH]2 by forming Mel T, which in turn competitively
inhibits trypanothione reductase (Ki = 9 µM), interfering with the protective
functions of T[SH]2. On the other hand, T[SH]2 could act to sequester arseni-
cals, thereby preventing them from binding to other target protein sulphydryl
groups. Regardless of the correct interpretation of these observations, syner-
gism between DFMO and arsenical drugs (Jennings, 1988a, 1988b) would
appear to involve DFMO-induced depletion of T[SH]2.
In summary, trypanothione and its related metabolism presents several novel
and unique areas for drug development. A number of existing drugs, including
DFMO, melarsoprol, the diamidines, nitrofurazone and nifurtimox, have inhibi-
tory effects on different aspects of trypanothione metabolism and function,
thereby offering a rational biochemical basis for understanding the synergistic
activity between these apparently unrelated classes of drugs.
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Inhibitors of sterol biosynthesis in
Trypanosomatidae and their potential for
chemotherapy
L.J. Goad
Department of Biochemistry
University of Liverpool
P.O. Box 147
Liverpool L69 3BX, UK
The drugs in routine clinical use for the treatment of leishmaniasis and try-
panosomiasis have undesirable toxicity and the disadvantage that they must be
administered parenterally. The urgent need for new, orally active
chemotherapeutic drugs against these diseases has been highlighted in reviews
on the chemotherapy of leishmaniasis (Berman, 1988) and trypanosomiasis
(Gutteridge, 1985). Ideally, a drug is required that is inhibitory to some specific
biochemical process unique to the parasite. In the search for effective new
chemotherapeutic agents, attention has focused recently on antifungal com-
pounds. These drugs are attractive because they have already undergone exten-
sive toxicity testing, many can be administered orally, they have favourable
pharmacokinetic properties and they are already commercially available, thus
reducing costs of development.
The antifungal drugs belonging to the azole and allylamine groups of com-
pounds are effective because they are inhibitors of sterol biosynthesis. Choles-
terol is biosynthesized by man, but in fungi the major sterol produced is the
C28-compound ergosterol. The antifungal compounds are effective
chemotherapeutic agents because the sterol pathway in fungi is considerably
more sensitive to inhibition by these drugs than is cholesterol production in
human cells. The imidazoles and triazoles (e.g., ketoconazole and itraconazole)
are inhibitors of a cytochrome P450-dependent sterol 14α-demethylase. This
enzyme catalyses the oxidative removal of the 14α-methyl group, which is an
essential step in the conversion of the precursor, lanosterol, into the major
fungal sterol, ergosterol (Mercer, 1984; Vanden Bossche, 1988). Inhibition of
this enzyme causes a depletion of ergosterol and an excessive accumulation of
unusual 14α-methylsterols in the fungal cell. It is considered that this change
in sterol composition has adverse effects on membrane integrity and function,
with consequent suppression of growth. The allylamines (e.g., naftifine and
terbinafine) block sterol synthesis at the squalene epoxidation step, which is a
necessary prelude to squalene cyclization to produce lanosterol, which is the
first cyclic precursor of ergosterol (Ryder, 1988). In this case, the depletion of
ergosterol is accompanied by a build-up of a large quantity of squalene, which
again is believed to result in membrane disruption and inhibition of fungal
growth (Ryder, 1988).
Several studies have revealed that ketoconazole, an imidazole derivative, is
active against Leishmania species. It inhibited proliferation of L. mexicana
mexicana promastigotes (Berman et al., 1984), L. mexicana mexicana, L.
tropica and L. donovani amastigotes in human and mouse macrophages (Ber-
man, 1981, 1982; Berman and Lee, 1984) and L. donovani in golden hamsters
(Raether and Seidenath, 1984). Its effectiveness in man was also indicated by
successful treatment of cutaneous and mucocutaneous lesions (Urcuyo and
Zaias, 1982; Weinrauch et al., 1983a, 1983b). Investigations on the sterol
biochemistry of Leishmania have shown the locus of ketoconazole action to be
the sterol biosynthetic pathway. Detailed analysis of the sterol composition of
promastigotes of several Leishmania species identified the major sterols as
ergosterol and ergosta-5,7,24(28)-trien-3β-ol, with the latter compound usually
predominating, particularly in L. mexicana mexicana (Goad et al., 1984, 1985a).
A number of other minor sterols were also identified, including lanosterol, a
precursor of sterols found in fungi. From the sterol composition and results of
labelling studies with (2-14C)mevalonic acid, the sterol biosynthetic pathway
shown in  Figure 1 has  been  deduced (Beach et al., 1988), which  closely
resembles that operative in fungi (Mercer, 1984). However, promastigotes
grown in a medium with added serum, or amastigotes cultured in macrophage
cells, also contain a significant amount of cholesterol which is of exogenous
origin from the serum or macrophages (Goad et al., 1984, 1985a; Beach et al.,
1988).
When L. mexicana mexicana promastigotes were exposed to ketoconazole, their
growth was retarded and radioactivity from (2-14C)mevalonic acid accumulated in
a sterol fraction with the chromatographic properties of 4α-methylsterols which
act as precursors to ergosta-5,7,24(28)-trien-3β-ol and ergosterol (Berman et al.,
1984; Goad et al., 1985a; Beach et al., 1988). The main accumulating sterol was
identified (Goad et al., 1985a) by 1H and 13C nuclear magnetic resonance and mass
spectrometry as 4α,14α-dimethy lcholesta-8,24-dien-3β-ol. It was accompanied
by smaller amounts of 4α,14α-dimethy lergosta-8,24-dien-3β-ol (obtusifoliol),
14α-methylcholesta-8,24-dien-3b-ol and 14α-methylergosta-8,24(28)-dien-
3F"Symbol"b-ol (see Figure 1). Similar effects of ketoconazole on sterol synthesis
have been demonstrated in several strains of Old and New World Leishmania
species (Beach et al., 1988). The appearance of 14α-methylsterols was accompa-
nied by  a  dramatic decrease in  ergosterol  and ergosta-5,7,24(28)-trien-3β-ol
(Beach et al., 1988). Moreover, ketoconazole was also effective in blocking sterol
production in L. mexicana mexicana amastigotes cultured in murine macrophage
cells, again with accumulation of 4α,14α-dimethy lcholesta-8,24-dien-3β-ol (Ber-
man et al., 1986). The ketoconazole-induced changes in sterol composition of
Leishmania thus parallel those observed in treated fungi and reveal the suscepti-
bility of the 14α-methylsterol 14α-demethylase to azole inhibition, presumably
through the cytochrome P450 system. Similar effects on sterol biosynthesis and
inhibition of growth have been demonstrated with the triazole antifungal, itracona-
zole, when tested against promastigotes of 36 strains of Leishmania (Beach et al.,
1988), but fluconazole was much less effective. The anti-leishmanial activity of
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FIGURE 1. Sterols of Leishmania and postulated biosynthetic pathway. (1) Lanosta-8,24-dien-3 b -ol (lanosterol); (2) 4 a ,14 a -dimethy
lcholesta-8,24-dien-3 b -ol; (3) 4 a ,14 a -dimethy lergosta-8,24(28)-dien-3b -ol; (4) 14 a -methylcholesta-8,24-dien-3b-ol; (5) 14 a -methyler-
gosta-8,24(28)-dien-3F"Symbol"b-ol; (6) cholesta-8,24-dien-3 b -ol (zymosterol); (7) ergosta-8,24(28)-dien-3 b -ol (fecosterol); (8)
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itraconazole, together with inhibition of the sterol pathway, has also been demon-
strated against amastigotes of L. mexicana mexicana (Hart et al., 1989).
The antifungal compounds that inhibit sterol biosynthesis and have been
tested against Leishmania are the allylamines. Terbinafine (SF86-327) effec-
tively retarded growth of L. mexicana mexicana promastigotes and, as in fungi,
inhibited squalene epoxidase, causing an accumulation of squalene and a
decrease in the sterol content of the cells (Goad et al., 1985b; Beach et al., 1989).
Naftifine and terbinafine were also active against growth of L. major amastig-
otes in human monocyte-derived macrophages (Berman and Gallalee, 1987).
It is now becoming clear that Leishmania have a sterol biochemistry, and
requirements for sterol to support growth, which are remarkably similar to
fungi. The need for sterol during cell proliferation may be to fulfil two functions.
The first is a `bulk’ role for incorporation into newly formed membranes. In
fungi it is suggested that the reduction in ergosterol and the appearance of
abnormal amounts of 14α-methylsterols in response to azole treatment has a
disruptive effect on membrane integrity and function. It is speculated that the
14α-methyl group of the accumulating sterols does not permit correct alignment
of the sterol in the membrane for interaction with the fatty acyl chains of the
phospholipid components (Bloch, 1983; Weete, 1987). The second need may
be for small amounts of specific sterols with a C24 substituent, such as ergos-
terol, to act in a `metabolic’ role to stimulate some essential process(es) required
for cell division. This would be analogous to the `sparking’ or `synergistic’ role
played by ergosterol in yeast proliferation (Pinto and Nes, 1983; Ramgopal and
Bloch, 1983; Rodriguez et al., 1985; Weete, 1987), where the sterol stimulates
phospholipid synthesis (Kawasaki et al., 1985), polyphosphoinositol metabo-
lism (Dahl and Dahl, 1985), and phosphatidylinositol kinase and protein kinase
activities (Dahl et al., 1987).
The potential value of ketoconazole for the treatment of Old and New World
cutaneous leishmaniasis has been examined by a number of groups. Somewhat
mixed results are reported, but treatments with a positive response (Urcuyo and
Zaias, 1982; Weinrauch et al., 1983a, 1983b; Belazyoug et al., 1985; Jolliffe,
1986; Viallet et al., 1986; Dutz et al., 1987; Weinrauch et al., 1987; Saenz and
Berman, 1988) outweigh the negative results (Weinrauch et al., 1983a, 1983b;
Dan et al., 1986; Jolliffe, 1986; Kubba et al., 1986) by about 2:l, although the
fact that cutaneous leishmaniasis can often self-cure in a few months to a year
indicates that caution is needed when interpreting data. One report has also
indicated encouraging results using itraconazole (Dedet et al., 1986), but
clinical trials with the allylamine terbinafine are awaited with interest.
Some observations on the effects of ketoconazole on promastigote cultures
and the sterol metabolism of amastigotes may be relevant to the apparent failure
of some cases of cutaneous leishmaniasis to respond to ketoconazole treatment.
First, the growth of some species (L. braziliensis and L. donovani) is somewhat
more sensitive to inhibition by low doses of ketoconazole than is growth of
others (L. aethiopica, L. major, L. tropica and L. mexicana mexicana). Strains
of some of the less sensitive Leishmania species can be subcultured repeatedly
in the presence of ketoconazole, in a medium containing serum, with growth
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rates about 30–60% of the untreated controls (Beach et al., 1988). The sterol
composition is changed dramatically with a massive build-up of 14α-methyl-
sterols and a significantly increased cholesterol content derived by absorption
of the serum cholesterol from the medium (Beach et al., 1988). The normal
sterols, ergosterol and ergosta-5,7,24(28)-trien-3β-ol, are reduced to just a few
percent of the total sterol. It appears that these cultures may have adapted to use
the accumulated 14α-methylsterols, perhaps in conjunction with the exogenous
cholesterol, to meet the bulk sterol function in the membranes. The traces of
ergosterol and ergosta-5,7,24(28)-trien-3β-ol still produced, or possibly the
14α-methylergosta-8,24(28)-dien-3F"Symbol"b-ol that accumulates, may be
adequate to satisfy the `metabolic’ role to sustain cell proliferation (Beach et
al., 1988). It is possible that development of tolerance to sublethal concentra-
tions of ketoconazole in leishmaniasis patients may occur and this needs to be
considered as a possible explanation for treatment failures. A resistance to
terbinafine has also been noted, in this case with a build-up of squalene in the
Leishmania cells but with sufficient sterol still being produced, and supple-
mented by cholesterol absorbed from the medium, to maintain growth (Beach
et al., 1989).
The second point concerns the possible ability of the amastigotes to use
sterols derived from the host macrophage. Analysis of the amastigote sterols of
L. mexicana mexicana and L. braziliensis guyanensis showed that they had a
rather different sterol composition from that of the promastigotes. Ergosterol
and ergosta-5,7,24(28)-trien-3β-ol were much reduced compared to the promas-
tigotes, while two C29-sterols, stigmasta-5,7,24(28)-trien-3β-ol and stigmasta-
7,24(28)-dien-3β-ol, recognized as only trace components in promastigotes,
appeared in substantial amounts (Borelli, 1987). Cholesterol and desmosterol
(cholesta-5,24-dien-3β-ol), products of macrophage sterol biosynthesis, were
present in amastigotes together with ergosta-5,24(28)-dien-3β-ol in L. mexi-
cana mexicana and in addition ergost-5-en-3β-ol and ergosta-5,22-dien-3β-ol
in L. braziliensis guyanensis.
As indicated in Figure 2, it can be postulated that the latter three sterols can
be produced by the amastigote using the desmosterol obtained from the macro-
phage. This transformation would not be susceptible to ketoconazole inhibition
and could provide 24-alkylated sterols suitable to fulfil the `metabolic’ role.
Cholesterol obtained from the macrophage could then meet the `bulk’ mem-
brane sterol requirement and so permit the amastigote, in its host macrophage
environment, to evade the toxic effects of ketoconazole.
The epimastigotes of Trypanosoma cruzi, the causative organism of Chagas’
disease, have a sterol composition rather similar to Leishmania, with ergosterol
and ergosta-5,7-dien-3β-ol as major sterols but with considerably enhanced
amounts of the C29-sterols stigmasta-5,7,22-trien-3β-ol and stigmasta-5,7-
dien-3β-ol (Karn et al., 1969; Beach et al., 1986; Goad et al., 1989). Sterol
biosynthesis in this organism is also very sensitive to azole compounds. Both
ketoconazole and itraconazole inhibited the 14α-demethylation step, leading to
a build-up of the precursor 24-methylenedihydrolanosterol and a decline in the
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C28- and C29-sterols (Beach et al., 1986; Goad et al., 1989). There was a
coincident reduction in growth rate of the epimastigotes (Beach et al., 1986),
and amastigotes in VA-13 cells (human diploid lung cells) did not survive
ketoconazole (5 ng/ml) treatment (Goad et al., 1989). Both sterol synthesis and
growth of epimastigotes were less sensitive to fluconazole treatment (Goad et
al., 1989).
These results with T. cruzi suggest that azoles may prove effective for
chemotherapy, and indeed promising results are now appearing showing that
ketoconazole and itraconazole are very active against T. cruzi infections of mice
(Raether and Seidenath, 1984; McCabe et al., 1984, 1986, 1987). However,
there are reports of failure of ketoconazole against chronic murine Chagas'
disease (McCabe, 1988) and a murine infection of T. brucei (Jennings, 1988).
Terbinafine has been shown to inhibit proliferation of the epimastigote and
amastigote forms of T. cruzi and, moreover, to potentiate the anti-trypanosomal
activity of ketoconazole, thus pointing to the possibility of effective combined
therapy with these drugs (Urbina et al., 1988).
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`We know a great deal and understand nothing.’ This quote from a recent Trends
in Biochemical Sciences book review is appropriate for an introduction to a
discussion of mitochondrial function in African trypanosomes. The situation
has improved, however, with the recent addition of a key finding: the role of
coenzyme Q (CoQ) in the electron transport system of these mitochondria.
Starting with this, we have reinterpreted a 25-year accumulation of data to draw
a new picture of the metabolic processes in bloodstream-form trypanosome
mitochondria.
One of the most widely recognized peculiarities of bloodstream trypanosome
biochemistry is the so-called glycerophosphate oxidase (GPO) system. This is
responsible for the cyanide-insensitive respiration of African trypanosomes and
is supposed to be unique to these cells. Another interesting feature is the
mitochondrial differentiation that occurs during transformation from blood-
stream to procyclic forms. The generally accepted outline is that tricarboxylic
(TCA) acid cycle enzymes are synthesized and begin to function quite early
during differentiation, but oxidative phosphorylation does not begin until later
because it is dependent on the subsequent development of a functional cyto-
chrome chain. Exactly how a partial TCA acid cycle is to function prior to the
development of cytochromes, and to what purpose, is a problem that has not
been addressed.
A common error made in discussions of bloodstream-trypanosome mito-
chondria is the statement that they are physiologically inactive: the rate of
respiration in bloodstream mitochondria is, in fact, fifty times greater than that
in the cells of the mammalian host. The overall role of this respiration has been
understood since Grant and Sargent (1960) first described what they called the
α-glycerophosphate (glycerol-3-phosphate) oxidase system 30 years ago. A
catalytic amount of dihydroxyacetone phosphate (DHAP) is reduced to
glycerol-3-phosphate (GP) by the NADH produced by glycolysis. This step is
required for regenerating the NAD+ needed to support the continued glycolysis
upon which these cells depend. The DHAP used in the production of GP is
catalytic because it is promptly reoxidized to DHAP. The reduction of DHAP
by NADH occurs in the glycosome, a specialized microbody, and the reoxida-
tion to DHAP occurs in the mitochondrion. This `GP shuttle’ of electrons from
the glycosome to the mitochondrion is shown in Figure 1. Although Grant and
Sargent (1961) were not aware that the reoxidation of GP to DHAP occurs in
the mitochondrion, they knew that at least two enzymes were involved: a
dehydrogenase and an oxidase. Opperdoes et al. (1977) demonstrated that the
reoxidation of GP occurs in the mitochondrion and Fairlamb and Bowman
(1977) described the dehydrogenase as a typical FAD (flavin adenine dinu-
cleotide)-containing mitochondrial enzyme. A suggestion was made that the
dehydrogenase and oxidase components are linked by CoQ (Meshnick et al.,
1978). Results from our studies on inhibition of glycolysis suggested that
inhibitors of respiration were CoQ analogues and thus acted as inhibitors by
interfering with the transfer of electrons from the dehydrogenase to the oxidase
(Grady et al., 1986b). The concept of CoQ involvement was partially derived
from results of workers studying a plant system that was sensitive to similar
inhibitors, notably salicylhydroxamic acid and related N-aryl hydroxamates
(Rich et al., 1978). A conclusion by plant biochemists that the salicylhydrox-
amic-acid-sensitive system in plants was CoQ mediated was also speculative,
but this role has recently been convincingly demonstrated (Bonner et al., 1986).
We examined the role of CoQ in the trypanosome system because this was
important for work aimed at interfering with its function as an approach to
chemotherapy (Clarkson et al., 1989a). We confirmed an earlier observation
(Folkers et al., 1983) that Trypanosoma brucei brucei contains CoQ9 and
determined the concentration to be 206 ng/mg protein. We showed that the
redox state of this coenzyme is dependent on respiratory function in a manner
consistent with it serving as an electron carrier between the dehydrogenase and
oxidase components of the mitochondria. The action of salicylhydroxamic acid
on the redox state of CoQ is consistent with interference in the reoxidation of
this coenzyme after reduction by the dehydrogenase. Extraction of T. b. brucei
with acetone to remove CoQ9 inhibited respiration, which could be partially
restored by the addition of CoQ9 to the extracted cells. Dispersal of mitochon-
drial components by the detergent digitonin inhibited respiration and this could
be partially reversed by liposomes, which provide a site for reassociation.
Incorporation of CoQ into the liposomes enhanced this reversal. We synthesized
an analogue of CoQ9 that contains an unbranched alkyl chain in place of the 45-
carbon isoprenoid chain; we refer to this compound as decyl-CoQ. This substi-
tution provides a degree of water solubility such that decyl-CoQ can be used in
aqueous buffer to measure the activity of a ubiquinol oxidase independent of a
dehydrogenase. Chemically reduced decyl-CoQ supported salicylhydroxamic-
acid-sensitive oxygen uptake in the absence of GP. Non-reduced decyl-CoQ
relinked digitonin-dispersed components of the mitochondria, fully reversing
digitonin inhibition of GP-supported respiration.
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Figure 1. Bioenergetic pathways of Trypanosoma brucei brucei including the partial TCA cycle and NADH hydrogenase-associated
oxidative phophorylation of transitional intermediate and short, stumpy forms.
From the findings reported above, we conclude that CoQ9 links the dehydro-
genase and oxidase components of the mitochondria. This defines the trypano-
some terminal oxidase as an alternative oxidase. In contrast to what is generally
assumed, the cyanide-insensitive respiratory system is therefore not unique to
bloodstream African trypanosomes but is a conventional CoQ-mediated elec-
tron transport system, the only unusual feature being the terminal oxidase
employed. We refer to this oxidase as the trypanosome alternative oxidase
(TAO). We use the term TAO to replace GPO because GPO implies that the
entire trypanosome respiratory system is unique, whereas TAO correctly iden-
tifies the only unusual feature of this respiratory chain.
To provide a  further comparison of the plant and parasite  systems, we
examined the effect of a wide range of compounds we had previously found to
be inhibitors of parasite respiration (Clarkson et al., 1981; Grady et al., 1986a,
1986b) for their effect on the plant system (Clarkson et al., 1989b). Every class
of compound that inhibited parasite respiration also inhibited the plant system,
thus supporting the similarity of these alternative oxidases. However, the
relative degree of inhibition among the inhibitors varied between plant and
parasite. We had found that increasing the length of the alkyl side chain greatly
increased activity against the parasite (Grady et al., 1986a, 1986b) but this was
not as important in the plant system. We concluded that the parasite and plant
alternative oxidases are similar but the milieu, the inner mitochondrial mem-
brane, of the two systems is different.
Monoclonal antibodies were recently prepared against the alternative oxidase
of Sauromatum guttatum (voodoo lily) (Elthon et al., 1989). These monoclonals
also revealed the alternative oxidase of Neurospora crassa on Western blot
analysis (Lambowitz et al., 1989). We performed a Western blot analysis of T.
b. brucei mitochondria with these monoclonals and it showed a band at 36.5
kilodaltons, the molecular weight of both the voodoo lily and N. crassa alter-
native oxidases. Not only are the plant alternative oxidase and TAO functionally
equivalent, but the structure of these enzymes is apparently very highly con-
served. Other evidence indicates that the plant enzyme is a single polypeptide
and ultrafiltration data support this conclusion for the parasite system. These
similarities are especially interesting because the presence of an alternative
oxidase has never before been reported in any protozoan or metazoan.
As shown in Figure 1, the TAO provides a substitute for a cytochrome chain
in transferring electrons from CoQ to molecular oxygen. In the general mito-
chondrial electron transport chain, the action of Complex I, that is, NADH
dehydrogenase, is to transfer electrons to CoQ while concomitantly pumping
protons from the matrix, thus creating an electromotive force across the inner
mitochondrial membrane. This electromotive force is used by the oligomycin-
sensitive ATPase to generate ATP. In trypanosomes, the presence of an oli-
gomycin-sensitive ATPase had already been demonstrated, although it had been
presumed to be non-functional in bloodstream cells (Opperdoes et al., 1976).
The presence of a partial TCA cycle had also been demonstrated by the
cytochemical detection of NADH-dependent diaphorase activity in the mito-
chondria of intermediate and short, stumpy bloodstream forms (Giffin and
McCann, 1989). Furthermore, intermediate and short, stumpy cells had been
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shown to be able to depend on a TCA cycle intermediate, α-ketoglutarate, as
an energy source (Vickerman, 1965; Bowman et al., 1972; Flynn and Bowman,
1973), which implies the function of at least a partial TCA cycle. Through the
use of the vital stain rhodamine 123, we were able to show that intermediate
and short, stumpy cells generate an electromotive force and that this can be
blocked by salicylhydroxamic acid or rotenone, thus indicating that the electro-
motive force is dependent on both Complex I and the TAO (Bienen et al., 1989).
Furthermore, α-ketoglutarate-dependent motility is also blocked by rotenone
and by salicylhydroxamic acid. Taken together, these results support the overall
metabolic scheme shown in Figure 1.
In summary, the demonstration that bloodstream trypanosome respiration is
dependent on a CoQ-mediated electron transport system has led to a better
understanding of African trypanosome physiology. These data, old data show-
ing the presence of F1F0 ATPase, other old data showing the ability of transi-
tional cells to use TCA intermediates, and our rhodamine 123 uptake data have
together produced a new picture of mitochondrial function. Based on this new
picture, a better estimate can be made of the range of biochemical effects
expected of chemotherapeutic agents that block the TAO. We also found a
strong similarity among the TAO and the alternative oxidases of phylogeneti-
cally diverse cells. Perhaps the most interesting result is the potential of a better
interpretation of both physiological and molecular biological data relating to
the processes involved in parasite differentiation between mammalian and
insect vector forms.
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Trypanosoma cruzi is the causal agent of Chagas’ disease, an endemic disease
in Central and South America affecting more than 15 million people. T. cruzi
can infect a variety of mammals, including dogs and cats. Mammals other than
man may therefore serve as reservoirs, thereby increasing the chances of
infecting vectors and spreading the disease at a faster rate than if man were the
only host (Beaver et al., 1984). Chagas’ disease in man initially presents as an
acute form lasting 20 to 30 days, progressing into a chronic form after this period
(Beaver et al., 1984). The acute phase can be treated with very toxic drugs (such
as nifurtimox [Docampo and Moreno, 1984]) and may be fatal if untreated
(Beaver et al., 1984). Once the disease becomes chronic, there is no effective
treatment, and it is fatal after several years due to extensive damage to vital
organs such as the heart, colon and brain (Beaver et al., 1984).
Like most eukaryotic cells, T. cruzi has many characteristics in common with
mammalian cells. A rational way to develop a non-toxic treatment against the
parasite is to identify major differences in metabolic pathways between the
parasite and the host and to develop inhibitors against these pathways.
Energy metabolism is probably one of the best targets, since prolongation of
a parasitic infection depends upon the parasite producing enough energy to
propagate itself. Unlike other trypanosomes, T. cruzi depends upon cyanide-
sensitive respiration (i.e., a mitochondrial cytochrome electron transport sys-
tem) for survival throughout its life cycle. As a consequence, the parasite is
more efficient in obtaining energy from substrate oxidation and better adapted
for living intracellularly in the host cells.
Several differences in the mechanisms of energy conservation between T.
cruzi and the mammalian host have been identified and may become useful
targets for designing effective chemotherapeutic agents. This paper summarizes
some of these differences between parasite and host that are shared among
members of the genus Trypanosoma.
As  with  most trypanosomatids, T. cruzi has a glycosome  (Cannata  and
Cazzulo, 1984a) which contains most of the glycolytic enzymes (Fairlamb and
Opperdoes, 1986). In the glycosome, glucose  is oxidized to phosphoenol-
pyruvate (PEP) through the same reactions described for glycolysis in mam-
mals. After  this point, there are  several differences in energy metabolism
between host and parasite. In mammals, subsequent to synthesis of PEP, the
next reaction in the glycolytic pathway is catalysed by pyruvate kinase, an
enzyme that is missing in several trypanosomatids (Fairlamb and Opperdoes,
1986). Even though this enzyme is present in T. cruzi epimastigotes, it has very
low activity (Juan et al., 1976), and the relative contribution of this step to the
process of aerobic glycolysis seems to be negligible (Cannata and Cazzulo,
1984a). Instead, most PEP is used by the enzyme PEP carboxykinase, producing
oxaloacetate as the product (Cannata and Cazzulo, 1984a). Oxaloacetate is in
turn the substrate of the glycosomal malate dehydrogenase, a reaction that
requires NADH. This reaction is favoured by its low free energy (–8.1 kcal/mol)
and the accumulation of NADH during the oxidative step of glycolysis. Thus,
malate rather than pyruvate is the main product of glycolysis in these parasites,
similar to what has been reported for other members of this genus (Fairlamb
and Opperdoes, 1986).
In mammalian cells, glycolysis leads to the formation of pyruvate, which is
further oxidized to acetyl-CoA in the mitochondria by pyruvate dehydrogenase,
producing NADH. Acetyl-CoA reacts with oxaloacetate to produce citrate,
which is oxidized back to oxaloacetate in the Krebs cycle. During this process,
NAD+ is reduced in three different reactions and reoxidized by the respiratory
chain. In T. cruzi mitochondria, most of the steps where NADH would be
produced seem to be missing. The enzymes pyruvate dehydrogenase and α-ke-
toglutarate dehydrogenase have not been detected in T. cruzi (Cannata and
Cazzulo, 1984b; Adroher et al., 1988). The enzyme isocitrate dehydrogenase
exists but is NADP+, rather than NAD+, dependent. However, the activity of
several enzymes of the Krebs cycle are up to 25-fold higher in metacyclic
trypomastigotes than in epimastigotes (Adroher et al., 1988), suggesting that
parts of the Krebs cycle are operational and that their activity is required. In
summary, the main product of glycolysis in T. cruzi (as well as in T. brucei) is
malate rather than pyruvate, which upon entering the mitochondrial matrix is
unlikely to be used by the Krebs cycle at the same rate as in the mammalian
mitochondria.
When malate enters the mitochondrion of T. cruzi, it may be dehydrated to
fumarate (a reaction with an equilibrium constant very close to 1) if oxaloacetate
(the product of malate oxidation) is not removed efficiently. The Krebs cycle
may continue in reverse through the reaction catalysed by the enzyme NADH-
fumarate reductase. This enzyme is very active in both T. brucei procyclic
trypomastigotes and T. cruzi, with activities comparable to the rate of oxygen
consumption by intact cells (Table 1; Boveris et al., 1986; Turrens, 1987, 1989).
The product of this enzyme is succinate, which can be oxidized efficiently in
the respiratory chain back to fumarate through succinate dehydrogenase (Table
1). In addition, T. cruzi may secrete succinate, indicating that the product of the
enzyme fumarate reductase has a dual role in the intermediary metabolism of
these parasites. Through this enzyme, fumarate may be used directly as a
substrate for energy production or as a sink of reducing equivalents (NAD[P]H),
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thus explaining how these parasites can either oxidize or accumulate and secrete
succinate depending on their metabolic needs.
The mitochondrial cytochrome electron transport system also presents some
peculiarities when compared with the mammalian system. In trypanosomes with
a functional electron transport system (i.e., T. cruzi and T. brucei procyclic
trypomastigotes), oxygen consumption is insensitive to rotenone, suggesting
that either the segment between NADH-dehydrogenase and ubiquinone is
somehow different from mammalian mitochondria or that most oxygen con-
sumption is dependent upon succinate oxidation rather than NADH oxidation.
The second possibility may occur in intact cells since most of the NADH-pro-
ducing enzymes of the Krebs cycle appear to be missing (see above) and an
active fumarate reductase may keep producing succinate. However, studies
using isolated mitochondrial fragments from either T. brucei or T. cruzi indicate
that they do not oxidize NADH at significant rates (Boveris et al., 1986;
Turrens, 1989). We proposed the scheme drawn in Figure 1 as a model
respiratory chain for T. cruzi and T. brucei procyclic trypomastigotes, in which
most of the reducing equivalents are channelled to fumarate, producing succi-
nate, which in turn is oxidized by succinate dehydrogenase. We have recently
reported additional data for T. brucei procyclic trypomastigotes using either
intact or permeabilized cells, also suggesting that in intact cells succinate may
be the major oxidizable substrate (Turrens, 1989).
There is evidence that the mitochondrial membrane of trypanosomes contains
an active NADH-dehydrogenase. The transcription product of a gene that may
code for a subunit of NADH-dehydrogenase from maxicircles of T. brucei
kinetoplasts has been isolated from different forms of the parasite (Jasmer et
al., 1985; Feagin et al., 1986). Moreover, a NADH-dehydrogenase activity
TABLE 1. Mitochondrial activities in Trypanosoma cruzi epimastigotes. For these
experiments, the cells were frozen and thawed and disrupted by passing the homogen-
ate three times through a 24-gauge hypodermic needle. The `mitochondrial fraction’
was isolated by centrifugation at 12,000 g for 10 minutes.
Specific activity
Enzyme (mU/mg protein)
Oxygen consumption by intact cells 12 ± 2
NADH-dehydrogenase* 180 ± 8
Succinate dehydrogenase 17 ± 2
Fumarate reductase 18 ± 3
NADH-dependent H2O2 production 2.3†
Cytochrome oxidase‡ 0 ± 0
*Determined as NADH-ferricyanide reductase.
†Average of two experiments.
‡Determined using horse heart cytochrome c as substrate. The content of cytochrome
a611 was 0.16 nmol/mg protein.
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(determined as NADH-ferricyanide reductase) is present in T. cruzi (Boveris et
al., 1986) (Table 1), but its specific function is not clear. The NADH-dehydro-
genase may transfer electrons to the terminal electron donor of the NADH-fu-
marate reductase rather than to ubiquinone.
If the enzyme fumarate reductase is vital for the life cycle of these cells, the
inhibition of this enzyme should be trypanocidal. We tested several inhibitors
of the NADH-fumarate reductase of Haemonchus contortus developed at
Merck, Sharp and Dohme Laboratories and found six compounds (Figure 2)
that were effective inhibitors of the enzyme in T. brucei procyclic trypomastig-
otes. These compounds were added to cultures of either T. cruzi epimastigotes
or T. brucei procyclic trypomastigotes. Four of them were effective against both
trypanosomatids (Table 2).
The same inhibitors were tested on the electron transport chain of rat heart
mitochondria, to see how specific they were against trypanosomes (Table 2).
The experiments suggested that these inhibitors of NADH-fumarate reductase
may be useful agents against trypanosomes, either in vivo or for blood banks.
The mode of trypanocidal action of these drugs is under investigation. Some of
the drugs may also inhibit the enzyme succinate dehydrogenase, thereby inhib-
iting cell growth by blocking succinate oxidation.
FIGURE 1. Suggested role for the enzyme NADH-fumarate reductase in the mitochon-
dria of Trypanosoma cruzi epimastigotes and T. brucei procyclic trypomastigotes.
According to this scheme, succinate appears as both a respiratory substrate and a final
sink of reducing equivalents to be exported out of the cell.
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Although more research is needed to fully understand the mechanism of
aerobic glycolysis and energy conservation in T. cruzi, it is clear that there are
significant differences with the well-characterized mammalian systems that are
FIGURE 2. Molecular structures of six inhibitors of the enzyme fumarate reductase
from Trypanosoma brucei procyclic trypomastigotes, four of which also inhibit T. cruzi
epimastigote growth in culture.
TABLE 2. Effect of several inhibitors of the enzyme NADH-fumarate reductase on
cultured Trypanosoma cruzi epimastigotes and T. brucei procyclics and on two en-
zymes of the electron transport chain of rat heart mitochondria. The values indicate the
concentration of drug that inhibits either cell growth or electron transport by 50%.
NADH oxidase Succinate oxidase
T. cruzi growth T. brucei growth in rat heart in rat heart
Drug in culture in culture mitochondria mitochondria
L-092,201 10 2 4 > 30
L-341,758 24 2 > 30 No effect
L-341,837 60 15 > 30 No effect
L-584,128 No effect 4 No effect No effect
L-612,901 60 3 No effect No effect
L-624,671 32 7 > 30 No effect
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worth studying not only for their potential pharmacological applications, but
also for their unique biochemical characteristics.
ACKNOWLEDGEMENTS
The authors thank Dr. Michael Fisher from Merck, Sharp and Dohme Labora-
tories for supplying the fumarate reductase inhibitors used in this work. This
work was supported in part by a grant from the United Nations Development
Programme/World Bank/World Health Organization Special Programme for
Research and Training in Tropical Diseases (# 870264) and by a research grant
from Merck, Sharp and Dohme Laboratories.
REFERENCES
ADROHER, F.-J., OSUNA, A. and LUPIAÑEZ, J.A. 1988. Archives of Bio-
chemistry and Biophysics 267: 252–261.
BEAVER, P.C., JUNG, R.C. and CUPP, E.W., eds. 1984. In: Clinical Parasi-
tology. Philadelphia: Lea and Febiger, pp. 55–100.
BOVERIS, A., HERTIG, C.M. and TURRENS, J.F. 1986. Molecular and
Biochemical Parasitology 19: 163–169.
CANNATA, J.J.B. and CAZZULO, J.J. 1984a. Molecular and Biochemical
Parasitology 11: 37–49.
CANNATA, J.J.B. and CAZZULO, J.J. 1984b. Comparative Biochemistry and
Physiology 79B: 297–308.
DOCAMPO, R. and MORENO, S.N.J. 1984. In: Pryor, W.A., ed. Free Radicals
in Biology, 6th edition. New York: Academic Press, pp. 243–288.
FAIRLAMB, A.H. and OPPERDOES, F.R. 1986. In: Morgan, M.J., ed. Carbo-
hydrate Metabolism in Cultured Cells. New York: Plenum Press, pp.
183–224.
FEAGIN, J.E., JASMER, D.P. and STUART, K. 1986. Molecular and Bio-
chemical Parasitology 20: 207–214.
JASMER, D.P., FEAGIN, J.E. and STUART, K. 1985. Molecular and Cellular
Biology 5: 3041–3047.
JUAN, S.M., CAZZULO, J.J. and SEGURA, E.L. 1976. Acta Physiologica
Latinoamericana 26: 424–426.
TURRENS, J.F. 1987. Molecular and Biochemical Parasitology 25: 55–60.
TURRENS, J.F. 1989. Biochemical Journal 259: 363–368.
INTERMEDIARY METABOLISM
54
Characterization of trypanosomal
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THE GLYCOSOME: METABOLIC
COMPARTMENTALIZATION IN TRYPANOSOMES
In trypanosomes, as in all other members of the protozoan order Kinetoplastida
examined, a unique form of metabolic compartmentalization is found. The
majority of the glycolytic enzymes, responsible for the conversion of glucose
into phosphoglycerate, are contained within a microbody-like organelle, called
the glycosome (Opperdoes and Borst, 1977).
It has been suggested that cells may use microbodies to sequester certain
enzymatic systems when an obvious advantage can be gained (Borst, 1989).
One example is enzymes that deal with toxic or reactive metabolites, such as
peroxidase and catalase found in microbodies often called peroxisomes. Other
examples are increasing the flux through a pathway by clustering its enzymes
within an organelle or creating a special environment in a compartment of the
cell to allow reactions that in the cytosol could normally not occur. These two
latter advantages may have been the evolutionary force for the development of
the glycosome. Glycolysis is a pathway of vital importance to trypanosomes,
particularly of the genus Trypanosoma, comprising the well-studied parasites
that are responsible for important diseases such as sleeping sickness and
nagana. These parasites, when they live in the bloodstream of the mammalian
host, are entirely dependent on the conversion of glucose into pyruvate for their
energy supply. In this stage of the life cycle, they lack a functional Krebs cycle
and the mitochondrial system for oxidative phosphorylation. Their dependence
on an inefficient energy production is compensated for by an extremely high
glucose consumption (Opperdoes, 1987). The sequestering of the glycolytic
enzymes within an organelle most likely contributes to this high glycolytic flux
by locally increasing the concentration of metabolites (Misset et al., 1986).
Moreover, the capacity to maintain substrate concentrations, phosphate poten-
tial and redox state within the glycosome at levels different from those in the
cytosol can significantly change the equilibrium state of some reactions. This
is particularly the case under anaerobic conditions, when net ATP synthesis
during the conversion of glucose into pyruvate and glycerol is made possible
by the reversal of the glycerol kinase reaction as a result of the high concentra-
tion of glycerol-3-phosphate and the low ATP/ADP ratio in the glycosome
(Visser et al., 1981; Hammond et al., 1985; Opperdoes, 1987).
The glycolytic pathway is a potential target for trypanocidal drugs for two
reasons: first, because glycolysis is of vital importance for the energy supply of
bloodstream trypanosomes, and second, because the glycolytic enzymes may
be expected to have some structural features not present in the proteins of the
mammalian host due to the large phylogenetic distance between trypanosomes
and mammals (Sogin et al., 1986) and the unique cellular location of the
enzymes in the parasite. The proteins are encoded in the nucleus, synthesized
on free ribosomes and then transported into the glycosome (Clayton, 1987; Hart
et al., 1987). This transport is not accompanied by any detectable processing of
the polypeptides, indicating that a targeting signal has to be present in the
structure of the mature protein.
CHARACTERIZATION OF THE GLYCOLYTIC
ENZYMES OF T. BRUCEI
As part of our search for specific features in the glycosomal proteins of the
parasite not shared by its host counterparts, we have purified all nine glycosomal
enzymes involved in glucose and glycerol metabolism of T. brucei (Misset et
al., 1986). Cytosolic forms that were found for two glycolytic en-
zymes—glyceraldehydephosphate dehydrogenase (cGAPDH) and phospho-
glycerate kinase (cPGK)—have been purified as well (Misset et al., 1977;
Misset and Opperdoes, 1987). In addition, the genes for several glycolytic
enzymes have been cloned and sequenced. These include the genes for the
glycosomal enzymes glucosephosphate isomerase (Marchand et al., 1989),
fructose-biphosphate aldolase (Clayton, 1985; Marchand et al., 1988),
triosephosphate isomerase (Swinkels et al., 1986), glyceraldehydephosphate
dehydrogenase (Michels et al., 1986) and phosphoglycerate kinase (Osinga et
al., 1985), as well as genes for two enzymes located in the cytosol, cGAPDH
(M. Marchand and P. Michels, unpublished) and cPGK (Osinga et al., 1985),
and also the gene for pyruvate kinase (S. Allert and P. Michels, unpublished),
a glycolytic enzyme that is present only in the cytosol. The structural and
functional properties of the purified enzymes, including their primary structures
predicted from the gene sequences, were compared with each other and with
those of the glycolytic enzymes of other organisms. The overall sequence
similarity of the trypanosomal enzymes to those of other organisms is rather
limited: the positional identity of the amino acid sequences varies between 38%
and 57% for the different enzymes, regardless of whether the comparison is
made with other eukaryotic organisms or with prokaryotes. As for the subunit
composition, with the exception of hexokinase, most glycosomal enzymes have
an organization comparable with the mammalian ones (Table 1). However,
significant differences are found in the subunit masses: all Trypanosoma gly-
cosomal enzymes, except triosephosphate isomerase, have subunits that are 1–5
kilodaltons larger than their cytosolic counterparts from other organisms (Table
1). These larger subunits are due to the presence of unique insertions or
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TABLE 1. The subunit and native molecular weights of the glycosomal enzymes from Trypanosoma brucei* and those of their cytosolic
homologues from mammalian cells
Native Mr (kilodalton) Subunit Mr (kilodalton) Subunit composition
Enzyme† T. brucei T. brucei Mammalian T. brucei Mammalian
Hexokinase 295 ± 12 (4) 50.3 ± 0.8 (10) 97–110 6 1
Glucose-P isomerase 105 ± 6 (5) 62.4 ± 1.6 (8) 59–61 2 2
Phosphofructokinase 196 ± 15 (3) 50.3 ± 0.8 (10) 79–84 4 4
Aldolase 157 ± 3 (3) 40.5 ± 0.5 (9) 39–40 4 4
Triose-P isomerase 55 ± 0 (3) 27.0 ± 0.5 (8) 26–28 2 2
Glyceraldehyde-P
dehydrogenase 139 (1) 38.5 ± 0.5 (10) 36–37 4 4
Phosphoglycerate kinase 48 ± 4 (2) 47.0 ± 0.7 (11) 43± 46 1 1
Glycerol-3-P-dehydrogenase 66 ± 6 (3) 37.2 ± 0.7 (9) 33–35 2 2
Glycerol kinase 82 (1) 52.5 ± 0.4 (8) No data 2 No data
*Data from Misset et al., 1986.†P: phosphate.
(1) Opperdoes and Borst, 1977.
(2) Borst, 1989.
(3) Opperdoes, 1987.
(4) Misset et al., 1986.
(5) Visser et al., 1981.
(8) Hart et al., 1987.
(9) Clayton, 1987.
(10) Misset and Opperdoes, 1987.
(11) Misset et al., 1977.
extensions of the glycosomal proteins (Figure 1). Furthermore, all glycosomal
proteins except glucosephosphate isomerase are characterized by an excess of
basic residues, which confer a very high isoelectric point (pI 8.7–10.0) to the
proteins. These pIs are significantly higher than those of the cytosolic isoen-
zymes cGAPDH and cPGK (pI 7.9 and 6.2, respectively) and those reported for
the corresponding enzymes of any other organism. Modelling of the amino acid
sequences of three glycosomal proteins (triosephosphate isomerase, glyceral-
dehydephosphate dehydrogenase and phosphoglycerate kinase) into a three-di-
mensional structure, using the structural information of the homologous enzyme
from other organisms, indicated that many of the additional charged residues
form a particular spatial configuration in the proteins: two clusters of charges
on the protein's surface separated from each other by a distance of 40 Å
(Wierenga et al., 1987). This configuration may be common to all glycosomal
proteins, because clusters of positively charged residues, specific for the T.
brucei enzymes, could also be recognized in the primary structures of fructose-
biphosphate aldolase and glucosephosphate isomerase, despite the overall neu-
tral charge of the latter enzyme. In contrast, they were not detected in T. brucei's
cytosolic enzymes cGAPDH, cPGK and pyruvate kinase (Figure 1). It has been
proposed that these unique charged patches constitute the signal that directs the
proteins to the glycosome after their synthesis in the cytosol (Wierenga et al.,
1987). However, a serious objection arguing against this hypothesis is the
observation that no charge differences exist between the glycosomal and cyto-
FIGURE 1. Schematic representation of unique features associated with the glycolytic
enzymes of Trypanosoma brucei. The bars represent the amino acid sequence of the
respective enzymes and their size has been drawn relative to the length of the polypep-
tide chain. Black blocks indicate the position and size of trypanosome-specific amino
acid insertions and extensions. Dots represent residues with positive charge. Arrow
heads indicate the position of deletions.
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solic phosphoglycerate kinase (PGK) isoenzymes of Crithidia fasciculata
(Swinkels et al., 1988), an organism related to T. brucei. Because the only major
difference between these two proteins is a C-terminal extension, Swinkels et al.
(1988) drew the conclusion that the topogenic signal should be located at the
carboxy-terminus of that protein. Interestingly, a stretch of amino acids was
found in the C-terminal sequence of the T. brucei glycosomal phosphoglycerate
kinase with considerable similarity to a peptide in the N-terminal extension of
glycosomal glucosephosphate isomerase. However, a search for similar pep-
tides in other glycosomal proteins has not yet led to the unambiguous identifi-
cation of a common, putative topogenic signal.
The functional properties of most of the purified glycosomal enzymes have
been analysed in detail (Misset et al., 1977; Cronin and Tipton, 1985, 1987;
Lambeir et al., 1987; Misset and Opperdoes, 1987; Marchand et al., 1989; M.
Callens, A.-M. Lambeir, D. Kuntz and F. Opperdoes, unpublished). These
analyses  have  shown that the  kinetic parameters  of  some of the enzymes
(glucosephosphate isomerase and triosephosphate isomerase) are very similar
to those of their mammalian counterparts, whereas other enzymes (hexokinase,
fructose-biphosphate aldolase, glyceraldehydephosphate dehydrogenase and
PGK) display more unusual characteristics. This dissimilar kinetic behaviour
may be attributed to the participation of residues in  the catalytic process
different from their mammalian counterpart, such as differences in residues
either at the active-site, or in residues that may play a role in binding of the
co-factors. Detailed knowledge of the three-dimensional structures of the gly-
cosomal proteins will be required to interpret the kinetic differences between
these enzymes and their homologues from other organisms.
SUMMARY
Analysis of the cell biology of trypanosomes has shown that glycolysis is of
vital importance for the energy supply of these organisms. Moreover, most of
the enzymes of the glycolytic pathway appear to be organized in a unique
manner, that is, in a microbody called the glycosome. Further unravelling of the
glycolytic process, using the approaches of enzymology and molecular biology,
demonstrated that the glycosomal enzymes in T. brucei have a number of
unusual structural and functional features. These features may be involved in
the entry of the proteins into the organelle, in their functioning within the
specific environment, or they may simply be the result of the large phylogenetic
distance between these protozoans and all other organisms studied so far.
Whatever their function and origin, these unusual features are potential targets
for compounds that should specifically block the parasite’s glycolysis without
interfering with the pathway of the mammalian host’s cell. A more detailed
analysis of the special aspects of some glycosomal enzymes of T. brucei, by
crystallographic methods, and examples of the design of selective inhibitors
that should specifically interact with those aspects, are described by F.M.D.
Vellieux (this volume).
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INTRODUCTION: RATIONAL DRUG DESIGN
AND TRYPANOSOMIASIS
Because X-ray crystallography can be used to determine three-dimensional
structures of biomacromolecules at close to atomic resolution, this technique
can be used for the rational design of drugs (Hol, 1986). To understand how this
is possible, it is useful to consider a `rational drug design cycle’ (Figure 1).
Analysis of the three-dimensional structures of a well-chosen target protein
complexed with several inhibitors will reveal their modes of binding. Computer
graphics and theoretical calculations can be used to propose modifications of
these inhibitors. Promising compounds are then synthesized and tested for
inhibitory activity, and the three-dimensional structures of the target protein
complexed to these new inhibitors are examined. In this manner, our under-
standing of the mechanisms by which inhibition takes place can be increased
until we are able to obtain very selective inhibitors. We are using this approach
for the design of new drugs against sleeping sickness.
Sleeping sickness is considered by the World Health Organization to be one
of the major tropical infectious diseases, and has been included in the United
Nations Development Programme/World Bank/World Health Organization
Special Programme for Research and Training in Tropical Diseases. The causa-
tive agent of sleeping sickness is a unicellular protozoan, Trypanosoma brucei,
which is transmitted by the tsetse fly. When present in the bloodstream of the
human host, the single mitochondrion of trypanosomes is inactive, and these
protozoa depend entirely on glycolysis for survival. In trypanosomes, unlike
other organisms, an essential part of glycolysis takes place in a peroxisome-like
organelle, the glycosome (Opperdoes and Borst, 1977), in which nine of the
glycolytic enzymes are sequestered (Table 1).
The  glycolytic enzymes can be  purified by chromatographic techniques
(Misset et al., 1986). Since interference with glycolysis will rapidly kill the
parasites (Clarkson and Brohn, 1976; Fairlamb et al., 1977), the nine glycolytic
enzymes have been selected as a target for protein-structure-based drug design.
GLYCOSOMAL ENZYMES AS TARGETS FOR DRUG DESIGN
There are three general areas of possible interference with the proper function-
ing of the glycosomal enzymes in the trypanosome:
FIGURE 1. The protein-structure-based drug design cycle.
TABLE 1. The nine glycosomal enzymes from Trypanosoma brucei involved in the
glycolytic pathway
Subunit
Molecular Number of
Name abbreviation weight Subunits pI
Hexokinase HK 49.500 6 10.0
Glucosephosphate isomerase PGI 52.500 2 7.5
Fructosephosphate kinase PFK 49.000 4 8.7
Fructose-biphosphate aldolase ALDO 39.000 4 9.1
Triosephosphate isomerase TIM 27.000 2 9.8
Glyceraldehydephosphate dehydrogenase GAPDH 37.000 4 9.3
Phosphoglycerate kinase PGK 48.000 1 9.4
Glycerol phosphate kinase GK 41.000 2 9.0
Glycerol phosphate dehydrogenase GDH 33.000 2 10.0
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• prevention of entry into the glycosome, since these enzymes are synthesized
in the cytosol and subsequently imported into the glycosomes (Hart et al.,
1987)
• prevention of assembly into multimers, since eight of the nine glycolytic
enzymes function as multimers (Table 1)
• inhibition of catalytic activity by blocking the active site
Due to space limitations, we will refrain from discussing interference with
the assembly of glycolytic enzymes in this short communication. To interfere
with import of glycolytic enzymes into the glycosome, the topogenic signal for
import must be known. The following are two hypotheses about this.
(1) Glycosomal enzymes from T. brucei contain clusters of positive charges
at their surface, or `hot spots’, which are missing in the mammalian enzymes.
These hot spots have been proposed to be the import signal into the glycosome
(Wierenga et al., 1987b). Compounds designed as potential hot spot ligands
were found to specifically inhibit the trypanosomal enzymes (Opperdoes et al.,
1989), and crystallographic studies of glycosomal triosephosphate isomerase
complexed with these compounds have been initiated to shed light on the
mechanism of inhibition.
(2) Recent sequence comparison studies have revealed the existence of a
short fragment with significant sequence similarity in both the C-terminal
extension of glycosomal phosphoglycerate kinase (gPGK) (Osinga et al., 1985)
and in the N-terminal extension of glycosomal glucosephosphate isomerase
(gPGI) (Marchand et al., 1989) (Table 2). Such a peptide sequence could be the
signal that directs these  two proteins to their biological compartment, the
glycosome. This attractive hypothesis is supported by the presence of a C-ter-
minal extension in phosphoglycerate kinase from the trypanosome-related
Crithidia fasciculata, which contains a similar peptide sequence (Swinkels et
al., 1988).
The testing of these hypotheses will require an ingenious experimental set-up
to overcome the problems created by the fragility of purified glycosomes.
CRYSTALS OF GLYCOSOMAL ENZYMES FROM T. BRUCEI
The third area of interference with trypanosomal glycolytic enzymes is selective
inhibition of the catalytic mechanism. Crystallization of trypanosomal enzymes
is quite difficult owing to the small amounts of material available. So far, our
crystallization experiments have yielded useful crystals for three of the nine
TABLE 2. Alignment of the C-terminal segment of glycosomal phosphoglycerate
kinase with the N-terminal segment of glycosomal glucosephosphate isomerase
Protein Residue numbers Putative import signal sequence
Glycosomal phosphoglycerate kinase 421–433 A V V S Y A S A G T G T L
Glycosomal glucosephosphate isomerase 12–24 L A A S P A S G G S A S I
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glycosomal enzymes, namely, triosephosphate isomerase, glyceraldehydephos-
phate dehydrogenase and hexokinase. Crystals of hexokinase were obtained
very recently and have only been partially characterized.
X-RAY CRYSTALLOGRAPHIC STUDIES OF GLYCOSOMAL
GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE
FROM T. BRUCEI
Two crystal forms were grown from glycosomal glyceraldehyde-3-phosphate
dehydrogenase (gGAPDH) samples (Read et al., 1987). For crystal form II,
synchrotron radiation was essential to obtain data to 2.82 Å resolution. With
these data, Read et al. (unpublished results) were able to solve the gGAPDH
structure using the molecular replacement method (Rossman, 1972), with the
structure of the similar enzyme from Bacillus stearothermophilus (Skarzynski
et al., 1987) as a search model. The asymmetric unit of this crystal form contains
six gGAPDH monomers, or 1.5 GAPDH tetramers having a total molecular
weight of approximately 220 kilodaltons.
While refinement of this crystal form is in progress, we are exploring
possibilities of obtaining data for gGAPDH inhibitor complexes. In particular,
we are using the very rapid Laue data collection method (Campbell et al., 1987)
(in collaboration with Dr. J. Hadju, University of Oxford) to collect data for the
form I GAPDH crystals. We were able to collect a partial 3.2 Å resolution data
set using four film packs, and we are currently attempting to solve this gGAPDH
structure using the molecular replacement method.
Even in the absence of a fully refined structure, the amino acid sequence
obtained by Michels et  al. (1986) allowed us to make  general statements
concerning the type of molecules that may selectively inhibit the glycosomal
enzyme. Comparison of the NAD binding site in GAPDH, using both human
and T. brucei sequences (Tso et al., 1985; Michels et al., 1986), revealed that
most residues in the neighbourhood of NAD are identical, except near the
adenine binding pocket (Table 3). Thus, interesting candidates for the develop-
ment of drugs targeted against gGAPDH would be NAD analogues suitably
modified at the level of the adenine moiety.
TABLE 3. Residues in the vicinity of the adenine moiety of NAD which differ between
glycosomal and human glyceraldehyde-3-phosphate dehydrogenase
Trypanosoma brucei Human
ASN 7 ASP 7
VAL 36 ASN 33
ASN 39 PHE 36
GLN 90 GLU 78
ASN 92 ASP 80
LEU 112 VAL 100
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CRYSTALLOGRAPHIC STUDIES OF GLYCOSOMAL
TRIOSEPHOSPHATE ISOMERASE FROM T. BRUCEI
Glycosomal triosephosphate isomerase (gTIM) crystals were grown from 2.4
M ammonium sulphate solutions (Wierenga et al., 1984). A total of 600 m g of
protein were required to establish crystallization conditions and to solve the
structure to 2.4 Å resolution (Wierenga et al., 1987a). Subsequently, 1.83 Å
resolution data were collected using synchrotron radiation. The native gTIM
structure is nearing the completion of its refinement, and has an R-factor of
19.3% for data between 6.0 and 1.83 Å resolution. The model comprises 286
water molecules, plus a sulphate ion bound in the active site of subunit 2.
Following the development of a procedure to transfer crystals from the
ammonium sulphate mother liquor to solutions of polyethylene glycol
(Schreuder et al., 1988), inhibitor binding studies could be initiated. X-ray data
FIGURE 2. The observed interactions between the bound inhibitor D-3-phosphoglycer-
ate and the active site residues of glycosomal triosephosphate isomerase.
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for three inhibitors (D-glycerol-3-phosphate, D-3-phosphoglycerate and 3-
phosphopropionate) complexed with gTIM are now available. From these
studies, a detailed picture of the binding mode of the inhibitors is emerging:
each of these inhibitors contains a phosphate group that binds at the sulphate
ion binding site, and recognition of the inhibitor by gTIM involves several
hydrogen bonds with the enzyme (Figure 2). Also, the gTIM loop comprising
residues 170 to 180 partially blocks the entrance of the active site cavity.
With our current knowledge we are now able to use the gTIM structure to
design inhibitors that extend out of the active site region. These inhibitors may
allow us to bridge the active site with those surface residues that differ between
mammalian and trypanosomal TIM (Table 4).
This new generation of TIM inhibitors will be one step further in the path
leading to new anti-trypanosomal drugs, since they should be more specific for
the parasite enzyme.
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In vitro techniques for identifying and
quantifying drug resistance in Trypanosoma
brucei brucei
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Drug resistance in African trypanosomes is only one of many possible expla-
nations for the failure of treatment with trypanocides in the field. Even if drugs
are accurately administered, it has yet to be shown whether the parasites have
developed a degree of resistance to the drugs or whether the apparent `resis-
tance’ is due to other factors, such as the inaccessibility of trypanosomes in host
tissues to trypanocidal drug concentrations. Detailed laboratory investigations
on drug resistance have been largely restricted to experiments using mice. To
maintain drug-resistant trypanosomes in vitro would facilitate detailed studies
on the mechanisms of such resistance in the parasites. However, a number of
difficulties and questions such as the isolation and initiation of in vitro cultures
from mammalian hosts, the effect of in vitro cultivation on the stability of drug
resistance, and the expression of drug resistance in vitro have to be solved before
in vitro techniques can be used to study drug resistance in African trypano-
somes.
INITIATION OF IN VITRO CULTURES
The low parasitaemias that usually occur in the natural host have been found
insufficient to initiate Trypanosoma brucei brucei bloodstream-form cultures.
Successful initiation of in vitro cultures required a minimum inoculum of
2 × 103-1 × 105 trypanosomes/ml, separating parasites from mouse blood during
a rising parasitaemia (Hirumi et al., 1977; Baltz et al., 1985). A novel technique
for the successful initiation of bloodstream-form cultures has been applied by
direct inoculation of a drop of infected blood into feeder-layer-containing
culture wells (Zweygarth et al., 1989). Briefly, blood samples were aspirated
with a 5 or 10 µl Eppendorf pipette and each was transferred into a well of a
culture plate containing feeder-layer cells. The blood was deposited in a corner
at the bottom of the wells. This technique has been improved so that it was
possible to isolate T. b. brucei from pigs and cattle with low parasitaemias,
undetectable in wet blood films, using feeder-layer cell cultures and axenic
conditions (Zweygarth and Kaminsky, in press). After successful initiation of
cultures, trypanosome populations were continuously propagated in vitro in a
cell-free system (Kaminsky and Zweygarth, 1989b).
STABILITY OF DRUG RESISTANCE
Adaptation of any parasite to in vitro culture conditions is associated with a
selection for a variety of parameters such as fast growth. Therefore, we inves-
tigated whether in vitro cultivation of trypanosomes changed their sensitivity
to drugs. The susceptibility of a multidrug-resistant T. b. brucei stock was
examined before and after in vitro propagation as bloodstream forms in the
absence of any drug, and after full cyclical development in vitro. There was no
significant change in susceptibility to diminazene aceturate, quinapyramine
sulphate, suramin, Mel B or isometamidium chloride following in vitro main-
tenance (Kaminsky and Zweygarth 1989a; illustrated in Figure 1). These obser-
vations confirm earlier  results  showing  that  transmission  of  trypanosomes
FIGURE 1. Schematic diagram demonstrating the stability of drug resistance after in
vitro propagation. R: resistant to drug in mice, S: susceptible to drug in mice.
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through tsetse flies did not change their drug sensitivity pattern (Gray and
Roberts, 1971; Schonefeld et al., 1987).
EXPRESSION OF DRUG RESISTANCE IN VITRO
The next step towards the development of in vitro assays for the identification
and quantification of drug resistance in trypanosomes was to clarify whether drug
resistance can be demonstrated in vitro. T. brucei stocks with different drug
susceptibilities to diminazene aceturate and isometamidium chloride were
adapted to in vitro culture conditions. The effect of the drugs on the trypanosomes
was investigated in vitro and compared with the drug susceptibilities in mice.
Procyclic forms are not usually exposed to trypanocides; for in vitro drug
testing, they nevertheless have several advantages over bloodstream forms: easy
maintenance (no incubator and no CO2-enriched atmosphere required) and the
possibility of direct isolation from tsetse flies. When procyclic forms were
incubated for 48 hours at 27 °C with various concentrations of isometamidium
chloride, the growth of trypanosomes was inhibited. The growth of the drug-re-
sistant T. b. brucei stock CP 547 was less inhibited by isometamidium than that
of susceptible stocks. However, growth of the resistant stock CP 2469 and clone
2469/cl 1 was inhibited in the same manner as that of susceptible stocks. Thus,
procyclic forms do not seem to be suitable for the differentiation of drug-sus-
ceptible from drug-resistant trypanosomes.
Growth inhibition, however, is a suitable parameter to distinguish between
susceptible and resistant trypanosomes when the assay is applied on blood-
stream trypomastigotes. Differences in diminazene aceturate-induced growth
inhibition after incubation for 24 hours with various concentrations of drug can
be demonstrated graphically (Figure 2). In the 24-hour growth inhibition, there
were only minor differences in EC50 values for isometamidium chloride.
However, concentrations of 0.001–0.1 µg/ml inhibited susceptible and, to a
lesser degree, drug-resistant stocks (CP 547 and CP 2469). Thus, differences in
growth inhibition due to isometamidium occurred when trypanosomes were
incubated with drug concentrations (0.001–0.05 µg/ml) below the EC50 values
(Kaminsky et al., 1989).
T. b. brucei stocks that were propagated in vitro as bloodstream forms in the
presence of drugs for a period of 10 days differed greatly in their viability. In
contrast to susceptible trypanosomes, the drug-resistant stocks CP 547 and CP
2469 were propagated without loss of viability in the presence of 0.01 µg/ml
diminazene  aceturate  or 0.0001–0.001 µg/ml isometamidium chloride. This
long-term viability assay offers an alternative to the 24-hour growth inhibition
assay, for it does not necessarily require feeder-layer-free culture conditions.
However, if trypanosome isolates have been adapted to cell-free cultures, the
24-hour growth inhibition assay using bloodstream forms appears to be a rapid
and reliable test to distinguish between drug-resistant and drug-susceptible T. b.
brucei stocks (Kaminsky et al., 1989).
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FIGURE 2. Growth inhibition of Trypanosoma brucei brucei stocks produced by
diminazene aceturate after incubation in culture medium containing various concen-
trations of drug for 24 hours at 37 °C in 4% CO2 in air. The number of trypanosomes
was determined with a Coulter counter and compared with control cultures. R: resistant
to diminazene aceturate in mice, S: susceptible to diminazene aceturate in mice.
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The family Trypanosomatidae includes a number of parasitic haemoflagellates
pathogenic to man and animals. Each of these protozoa has a single mitochon-
drion, which contains a unique type of DNA called kinetoplast DNA (kDNA;
see Simpson [1987] and Ryan et al. [1988] for reviews on kDNA). This DNA
is in the form of a single network of thousands of topologically interlocked DNA
circles, a structure unique in nature.
The complex nature of kDNA structure and replication creates an unusually
high demand for topoisomerase activity. The topoisomerases are enzymes that
can supercoil, relax, catenate, decatenate, knot and unknot circular DNA mole-
cules (Maxwell and Gellert, 1986). Such enzymes undoubtedly function at
several steps in the minicircle replication process, probably play an important
role in maxicircle replication, and are likely to be involved in the division of
double-size networks. In addition to these enzymatic functions, type II topoi-
somerases in the mitochondria of trypanosomes might have a structural role
(analogous to the topoisomerase in the scaffold of mammalian nuclei [Earnshaw
et  al.,  1985]), perhaps  tethering  replicating  free  circles  to the  network or
constraining the network to one region of the mitochondrion. A type II topoi-
somerase has been purified from Crithidia fasciculata, a related kinetoplastid
organism. On the basis of immunofluorescence microscopy, this enzyme local-
izes to two distinct sites at the periphery of the kDNA network (Melendy et al.,
1988).
In bacteria and higher eukaryotes, the function and the mechanisms by which
topoisomerases act have been greatly clarified by inhibitor studies (Drlica and
Franco, 1988). Certain antibacterial agents (Gellert et al., 1977) and a variety
of intercalative and non-intercalative antitumour agents (Chen et al., 1984;
Tewey et al., 1984a) stabilize a `cleavable complex’ between  the type II
topoisomerase and its DNA substrate; a covalent protein-DNA adduct is trapped
upon denaturation of the complex with sodium dodecylsulphate.
VP16-213 TRAPS A MINICIRCLE DNA-PROTEIN COMPLEX
To explore for a drug-sensitive mitochondrial type II topoisomerase in Trypa-
nosoma equiperdum, freshly harvested trypanosomes in tissue culture medium
were exposed to VP16-213 (for experimental details see Shapiro et al., 1989),
a potent and highly specific inhibitor of eukaryotic nuclear type II topoisom-
erases (Chen et al., 1984). The DNA was purified and resolved by agarose-gel
electrophoresis. To examine minicircle DNA, a Southern blot was probed with
32P-labelled T. equiperdum minicircle DNA. Figure 1a, lane 1, depicts the
normal distribution of DNA among the major components of the free minicircle
pool (networks do not enter the gel); the predominant free forms are nicked or
uniquely gapped circles (II), linearized circles (III) and covalently closed circles
(I). VP16-213 perturbed this distribution, causing an increase in the mass of the
free minicircle DNA population, most strikingly in the linearized form (Figure
1a, lane 7). These drug-induced linearized minicircles are protein-linked. If
proteinase K treatment was omitted, the aqueous phase after phenol extraction
contained essentially no linear forms (data not shown). Exonuclease treatment
demonstrated that the protein trapped from the mitochondria of VP16-213-
treated cells is linked to both 5’ ends of the linearized minicircles (data not
shown).
SUSCEPTIBILITY TO OTHER TYPE II
TOPOISOMERASE INHIBITORS
Live trypanosomes were exposed to various compounds known to affect type
II topoisomerases in other systems. These compounds included inhibitors of
gyrase (oxolinic and nalidixic acids) (Gellert et al., 1977), agents active against
eukaryotic type II topoisomerases (the epipodophyllotoxins, 2-methyl-9-hy-
droxyellipticine, 4’-[9-acridinylamino]-methanesulphon-m-anisidine and acri-
flavine) (Chen et al., 1984; Riou et al., 1986) and novobiocin (which competes
with ATP for binding to both prokaryotic and eukaryotic type II topoisomerases,
but does not stabilize cleavable complexes [Hsieh and Brutlag, 1980]). The
compounds were tested at concentrations reported to be effective against intact
cells in culture or in animals. Like VP16-213 (Figure 1a, lane 7), the other
inhibitors of eukaryotic type II topoisomerases promoted minicircle DNA-pro-
tein complex formation (Figure 1a, lanes 3 to 6). However, novobiocin or
compounds known to generate DNA-protein complexes with gyrase (nalidixic
and oxolinic acids) (Figure 1a, lane 2, and data not shown) did not cause
significant cleavage of T. equiperdum minicircles. Recent studies have shown
that some anti-trypanosomal drugs (including Berenil®, Samorin®, ethidium
bromide and pentamidine), at concentrations of 10 µM or less, promote minicir-
cle linearization. This suggests that the mitochondrial topoisomerases may be
a target for these drugs.
MINICIRCLE CLEAVAGE PATTERNS
The sites of minicircle cleavage were mapped by digesting DNA samples from
control or drug-treated cells with Bgl II (an enzyme that cuts minicircles once
at nucleotide 345; see map, Figure 2). The linearized minicircles naturally
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FIGURE 1. Type II topoisomerase inhibitors generate protein-bound linearized
minicircles. Trypanosoma equiperdum in medium were treated for 30 minutes at 37 °C
with drug or with solvent, as indicated. (Panel a) The sodium dodecylsulphate lysate
was digested with proteinase K, then with RNase A and RNase T1. After phenol
extraction and ethanol precipitation, the DNA from 3 × 107 cells was electrophoresed
in a 1.5% agarose gel with buffer containing 1 m g/ml ethidium bromide, transferred to
a nylon membrane, and probed with 32P-labelled minicircle sequence. (Panel b) An
equal quantity of each sample was digested with Bgl II before electrophoresis in a 2%
agarose gel with buffer containing 1 m g/ml ethidium bromide. I: Covalently closed
minicircles, II: minicircles containing nicks or small gaps, III: linearized minicircles.
Arrows indicate origin.
Panel a. Lane 1: DNA from control cells, lane 2: from cells treated with nalidixic acid
(400 m M), lane 3: from cells treated with acriflavine (50 m M), lane 4: from cells treated
with 2-methyl-9-hydroxyellipticine (5 m M), lane 5: from cells treated with 4'-(9-ac-
ridinylamino)-methanesulphon-m-anisidine (6 m M), lane 6: from cells treated with
VM-26 (100 m M), lane 7: from cells treated with VP16-213 (100 m M). Samples from
cells treated with dimethyl sulphoxide or with drug solvent were identical to control
DNA (lane 1).
Panel b. Lanes 1 to 7: Bgl II digests of DNA as described in Panel a (the autoradiograph
was exposed for 3 hours). Lane 8: same as lane 1 except autoradiograph was exposed
for 16 hours. Size markers are indicated.
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present in samples not treated with drug create a distinct pattern of bands (Figure
1b, lane 8; these bands are not detectable in the shorter exposure shown in lane
1). More complex patterns are generated by drug treatment (Figure 1b, lanes 3
to 7). As anticipated, digests of DNA from cells treated with compounds that
do not generate linearized minicircles (nalidixic acid, Figure 1b, lane 2, and
longer exposures) display only the  natural ' cleavage pattern like that in lane 8.
As has been reported for other cell types, and with purified nuclear type II
topoisomerases in vitro, drugs of different chemical classes generate strikingly
different cleavage patterns (Tewey et al., 1984b). Interestingly, within the
FIGURE 2. Map of cleavage sites induced in Trypanosoma equiperdum kinetoplast
DNA minicircles by VP16-213. This map is based on the published nucleotide se-
quence (1012 base pairs); numbering begins at the Hinf I site (Barrois et al., 1981).
 Natur al' sites (produced by sodium dodecylsulphate lysis in the absence of drug) are
indicated by outward pointing arrows. VP16-213-induced breaks are depicted by
inward pointing arrows; heavy arrows represent major cleavage points.
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resolution of agarose-gel electrophoresis, drugs appear to enhance the `natural’
cut sites, perhaps by stabilizing type II topoisomerase at these preferred loca-
tions. Figure 2 is a map of naturally occurring and VP16-213-induced cleavage
sites in T. equiperdum minicircles.
CONCLUSIONS
Treatment of intact T. equiperdum with compounds known to be active against
mammalian type II topoisomerases results in DNA  cleavage after  sodium
dodecylsulphate lysis. Because minicircle DNA is present in the cleaved com-
plex, the type II topoisomerase that has been trapped must be mitochondrial in
origin. As is characteristic of the type II topoisomerase-DNA complexes that
have been evaluated, the enzyme from T. equiperdum mitochondria binds to
both 5 ends of the substrate DNA. Gyrase inhibitors, even at concentrations
25-times greater than those effective against Escherichia coli (Wolfson and
Hooper, 1985), do not promote minicircle linearization or give evidence of type
II topoisomerase inhibition. In terms of inhibitor susceptibility, the mitochon-
drial type II topoisomerase of T. equiperdum appears to resemble most closely
the type II topoisomerase in the nuclei of higher eukaryotes, rather than gyrase,
the type II topoisomerase of prokaryotes.
Interference with mitochondrial type II topoisomerase activity can explain the
well-documented effects of some of the anti-trypanosomal drugs on kDNA. For
instance, a high proportion of trypanosomes that survive acriflavine treatment
become `dyskinetoplastic’. Dyskinetoplastic cells retain mitochondrial mem-
branes (Trager and Rudzinska, 1964), but the characteristic densely staining
kDNA disc is absent on light or electron microscopy, and no DNA homologous
to minicircle or maxicircle sequences is detectable (Riou and Saucier, 1979).
Acriflavine promotes minicircle DNA/type II topoisomerase complexes (Figure
1a, lane 3), and is an inhibitor of isolated topoisomerase catalytic activity (Riou
et al.,  1986).  It  therefore  seems likely that the genesis of dyskinetoplastic
trypanosomes by acriflavine is mediated, at least in part, by inhibition of
mitochondrial type II topoisomerase activity. As another example, ethidium
bromide and the diamidines interfere at a very early stage, and preferentially,
with the structure and replication of kinetoplast, rather than nuclear, DNA
(Newton, 1974). The basis for this selectivity may reside in selective stabilization
of minicircle DNA/mitochondrial type II topoisomerase complexes.
The type II topoisomerase inhibitors will undoubtedly prove important in
understanding the role of type II topoisomerases in trypanosomes and may also
provide a much needed new approach to anti-trypanosomal chemotherapy.
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Characterization of chloroquine resistance
in Plasmodium falciparum
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Chloroquine is an exceedingly useful antimalarial because it is relatively safe
for children and pregnant women (Schlesinger et al., 1988). It is effective
against all strains of Plasmodium vivax, P. ovale and P. malariae, and against
many strains of P. falciparum (Krogstad and Schlesinger, 1987; Schlesinger et
al., 1988). However, the value of chloroquine as an antimalarial has been
compromised by the increasing prevalence of chloroquine-resistant P. falci-
parum. These strains are now prevalent in South America, Southeast Asia and
sub-Saharan Africa (Krogstad et al., 1988a). In this review, we examine the
action of chloroquine against susceptible P. falciparum, chloroquine resistance
in P. falciparum and the genetic basis of chloroquine resistance.
CHLOROQUINE ACTION AGAINST
SUSCEPTIBLE P. FALCIPARUM
Chloroquine is a diprotic weak base that raises the pH of acid intracellular
vesicles in mammalian cells, as indicated by its two pK values (8.3 and 10.2)
(Roos and Boron, 1981; Krogstad and Schlesinger, 1986a). Although Home-
wood et al. (1972) first postulated that chloroquine might act against plasmodia
by raising vesicle pH, it has not been possible to test this hypothesis until
recently.
Using hypotonic shock, we labelled unparasitized red cells with fluorescein
isothiocyanate linked to dextran, resealed these cells by restoring the osmolality
to normal, and infected them with synchronous cultures of P. falciparum (Krog-
stad et al., 1985). The parasites grew at the same rate as synchronous cultures in
normal red cells and had the same susceptibility (or resistance) to chloroquine
in vitro. After incubation with these red cells, parasites containing vesicles
labelled with fluorescein isothiocyanate/dextran were examined by spec-
trofluorimetry. This revealed that the parasite vesicle has a MgATP-dependent
proton pump similar to that of mammalian acid vesicles. Spectrofluorimetry has
also shown that the concentrations of chloroquine that inhibit parasite growth
raise parasite vesicle pH within 3–5 minutes (Krogstad et al., 1985). These results
suggest that chloroquine acts against the parasite by raising intravesicular pH.
However, they do not establish whether the ability of chloroquine to raise parasite
vesicle pH can be explained entirely by its properties as a diprotic weak base.
To address this question, we have performed two types of experiments: meas-
urements of parasite vesicle buffering capacity and measurements of 3H-chloro-
quine uptake.
The measurements of vesicle buffering capacity indicate that parasite and
mammalian acid vesicles buffer a base equally well in the form of NH4Cl (a
typical weak base). However, with chloroquine, the parasite vesicle buffers the
base load 600- to 800-fold less well than the mammalian vesicle (Krogstad and
Schlesinger, 1986b). Potential explanations for this apparent discrepancy in-
clude a chloroquine-concentrating mechanism that permits the parasite vesicle
to concentrate more chloroquine than predicted by its properties as a diprotic
weak base. We have tested this hypothesis by comparing the uptake of 3H-chlo-
roquine by parasite and mammalian vesicles with that predicted (by the pKs of
chloroquine and the pH of the medium and the vesicle interior) (Roos and
Boron, 1981; Krogstad and Schlesinger, 1986a). These experiments revealed a
600- to 800-fold greater concentration of chloroquine by the parasite than
predicted (Table 1). Taken together, these observations suggest that the parasite
vesicle has a chloroquine-concentrating mechanism that is absent from the
mammalian vesicle, which accounts for its relative inability to buffer a base
load in the form of chloroquine, and thus for the selective action of chloroquine
against the parasite (including its low toxicity for the mammalian host). Recent
studies performed in our laboratory indicate that subcellular preparations of
membrane vesicles obtained from parasitized red cells concentrate chloroquine
with an apparent Km of 21 µM for ATP and with an apparent Vmax of 2.3
pmols/mg protein/hour. These results indicate that it is possible to study the
process of chloroquine accumulation by P. falciparum in a cell-free system.
CHLOROQUINE RESISTANCE IN P. FALCIPARUM
Studies by Fitch (1970) and others have shown that chloroquine-resistant P.
falciparum accumulate less chloroquine than susceptible P. falciparum. How-
ever, the basis for this difference in chloroquine accumulation has been unclear.
Our recent studies have shown that the resistant parasite has an efflux mecha-
TABLE 1. Intravesicular accumulation of chloroquine (mM)*
Cells Observed Predicted
Chloroquine-susceptible P. falciparum 68.7 0.014
Chloroquine-resistant P. falciparum 3.6 0.014
J774.2 macrophages 0.11 0.14
*Data are based on the moles of 3H-chloroquine accumulated divided by the volume
of the intravesicular compartment (Krogstad et al., 1988b).
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nism by which it releases chloroquine 40- to 50-fold more rapidly than the
susceptible parasite (initial chloroquine efflux half-times of 2 versus 75–150
minutes) (Krogstad et al., 1987, 1988a).
We believe that the process of chloroquine efflux is energy-dependent
because it is inhibited by the removal of glucose or by the addition of vanadate
(a broad-spectrum inhibitor of ATPases). In the parasite, the process of chloro-
quine accumulation is also energy-dependent, consistent with a need for ATP
to run the MgATP-dependent proton pump that acidifies the parasite vesicle
(Krogstad et al., 1985).
The phenomena of chloroquine efflux and resistance in P. falciparum are
remarkably similar to multidrug resistance (MDR) in mammalian cells (Fojo et
al., 1985). Indeed, MDR mammalian cells (Chinese hamster ovary cells) handle
chloroquine similarly to the resistant parasite, although the magnitude of the
difference in the efflux rate is smaller (3- to 4-fold, rather than 40- to 50-fold).
Chloroquine efflux is energy-dependent in both systems and is inhibited by
several drugs with calcium channel-blocking activity (verapamil, diltiazem and
TMB-8) (Krogstad et al., 1987). Indeed these agents and anti-cancer drugs
(vinblastine and daunomycin) can reverse chloroquine resistance in both P.
falciparum (Martin et al., 1987) and mammalian cells in vitro. However, none
have yet been shown to be curative for resistant P. falciparum in vivo (Bitonti
et al., 1989).
THE GENETIC BASIS OF CHLOROQUINE RESISTANCE
The genetic basis of chloroquine resistance in P. falciparum is unclear. To
address this question, a cross was performed recently between chloroquine-sus-
ceptible and chloroquine-resistant clones of P. falciparum. Linkage analysis
and chromosome mapping were used to analyse the unique progeny derived
from this cross, as in previous studies of pyrimethamine resistance (Peterson et
al., 1988; Wellems, 1988). These studies revealed no evidence of linkage
between mdr-like genes in the parasite and chloroquine resistance. Although
amplification of mdr-like genes in resistant P. falciparum has been reported by
other investigators (Wilson et al., 1989; Foote et al., 1989), it occurred in both
susceptible and resistant clones derived from the aforementioned cross and was
absent from four of the eight resistant clones. For this reason, we believe that a
rapid diagnostic test to detect chloroquine resistance in P. falciparum cannot be
based on a mdr or mdr-like probe at this time. Our preliminary studies with a
test based on 3H-chloroquine accumulation suggest that such a test can be
performed within 2–3 hours and has a sensitivity to 0.1% parasitaemia (4 × 103
parasites per µl of blood).
SUMMARY
The action of chloroquine on P. falciparum is consistent with its ability to raise
parasite vesicle pH. Several other antimalarials that inhibit parasite growth in
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vitro (quinine and mefloquine) also raise vesicle pH at the same concentrations.
Chloroquine resistance results from an efflux mechanism, which is energy-de-
pendent and remarkably similar to multidrug resistance in mammalian cells.
Both resistances are inhibited or reversed by several calcium-channel blockers
and by anti-cancer agents such as vinblastine.
ACKNOWLEDGEMENTS
We thank Phuc Nguyen-Dinh and C.C. Campbell of the Centers for Disease
Control, for providing clinical isolates of P. falciparum, and Victor Ling, of the
Ontario Cancer Institute, for multidrug-resistant (CHRC5) and susceptible
(AuxB1) lines of Chinese hamster ovary cells. These investigations received
the financial support of the United Nations Development Programme/World
Bank/World Health Organization Special Programme for Research and Train-
ing in Tropical Diseases. They were also supported in part by a US Public Health
Service grant AI 07766 from the National Institute of Allergy and Infectious
Diseases.
REFERENCES
BITONTI, A.J., SJOERDSMA, A., McCANN, P.P., KYLE, D.E., ODUOLA,
A.M.J., ROSSAN, R.N., MILHOUS, W.K. and DAVIDSON, D.E. Jr. 1989.
Science 242: 1301–1303.
FITCH, C.D. 1970. Science 169: 289–290.
FOJO, A.A., AKIYAMA, S.-I., GOTTESMAN, M.M. and PASTAN, I. 1985.
Cancer Research 45: 3002–3007.
FOOTE, S.J., THOMPSON, J.K., COWMAN, A.F. and KEMP, D.J. 1989. Cell
57: 921–930.
HOMEWOOD, C.A., WARHURST, D.C., PETERS, W. and BAGGALEY,
V.C. 1972. Nature (London) 235: 50–52.
KROGSTAD, D.J. and SCHLESINGER, P.H. 1986a. American Journal of
Tropical Medicine and Hygiene 36: 213–220.
KROGSTAD, D.J. and SCHLESINGER, P.H. 1986b. Biochemical Pharmacol-
ogy 35: 547–552.
KROGSTAD, D.J. and SCHLESINGER, P.H. 1987. The New England Journal
of Medicine 317: 542–549.
KROGSTAD, D.J., GLUZMAN, I.Y., KYLE, D.E., ODUOLA, A.M.J., MAR-
TIN, S.K., MILHOUS, W.K. and SCHLESINGER, P.H. 1987. Science 238:
1283–1285.
KROGSTAD, D.J., SCHLESINGER, P.H. and GLUZMAN, I.Y. 1985. Journal
of Cell Biology 101: 2302–2309.
CHLOROQUINE RESISTANCE
88
KROGSTAD, D.J., SCHLESINGER, P.H. and GLUZMAN, I.Y. 1988b. In:
Eaton, J.W. and Meshnick, S.R., eds. Malaria and the Red Cell, Volume 2.
New York: Alan Liss, pp. 53–59.
KROGSTAD, D.J., SCHLESINGER, P.H. and HERWALDT, B.L. 1988a.
Antimicrobial Agents and Chemotherapy 32: 799–801.
MARTIN, S.K., ODUOLA, A.M.J. and MILHOUS, W.K. 1987. Science 235:
899–901.
PETERSON, D.S., WALLIKER, D. and WELLEMS, T.E. 1988. Proceedings
of the National Academy of Sciences of the United States of America 85:
9114–9118.
ROOS, A. and BORON, W. 1981. Physiological Reviews 61: 296–434.
SCHLESINGER, P.H., KROGSTAD, D.J. and HERWALDT, B.L. 1988. An-
timicrobial Agents and Chemotherapy 32: 793–798.
WELLEMS, T.E. 1988. In: Turner, M.J. and Arnot, D. eds. Molecular Genetics
of Parasitic Protozoa. Cold Spring Harbor, New York: Cold Spring Harbor
Press, pp. 30–32.
WILSON, C.M., SERRANO, A.E., WASLEY, A., BOGENSCHUTZ, M.P.,
SHANKAR, A.H. and WIRTH, D.F. 1989. Science 242: 1301–1303.
CHLOROQUINE RESISTANCE
89
The antimalarial mechanisms of chloroquine
and qinghaosu: relevance for trypanosomiasis
S.R. Meshnick
City College of New York
138th Street and Convent Avenue
New York, New York 10031, USA
Attempts to develop synthetic antimalarials began with Paul Ehrlich in the late
19th century. Chloroquine was developed during the Second World War and
soon became the standard prophylactic and therapeutic agent. Chloroquine-re-
sistant strains of Plasmodium falciparum, however, appeared and have now
become quite common. This spurred attempts to develop other antimalarial
agents, including qinghaosu (artemisinin), isolated from Artemisia annua, an
ancient Chinese herbal remedy (for review, see Peters, 1987).
We have been studying the mechanisms of action of both qinghaosu and
chloroquine. We believe that qinghaosu acts via the generation of activated
oxygen, and that chloroquine acts as a DNA intercalating agent. Since African
trypanosomes are known to be sensitive to activated oxygen generators and to
intercalators, studies on these antimalarials may serve as models for similar
studies on anti-trypanosomal drugs.
QINGHAOSU
Activated oxygen species, including superoxide (O2-), hydrogen peroxide(H2O2) and hydroxyl radicals (HO
.), are highly toxic substances that may
mediate the toxic effects of a variety of pharmacological agents and of leuko-
cytes. Since most aerobic cells normally encounter low levels of activated
oxygen, they are equipped with a variety of defensive systems (Fridovich,
1986). These oxidant defences include superoxide dismutase, glutathione per-
oxidase, catalase (Fridovich, 1986), and in trypanosomes, trypanothione per-
oxidase (Henderson et al., 1987).
African trypanosomes and plasmodia are both exquisitely sensitive to acti-
vated oxygen. A variety of activated oxygen generators such as haemin (Mesh-
nick et al., 1977), haematoporphyrin D (Meshnick et al., 1978a), menadione
(Meshnick et al., 1978b) and quinone imines (Grady et al., 1984) have been
shown to have anti-trypanosomal activity in vitro and/or in vivo. Other anti-try-
panosomal agents, such as the arsenicals (Fairlamb et al., 1989) and certain
bis-catechols (Meshnick et al., 1985), may act by inhibiting the oxidant de-
fences of trypanosomes,  namely,  trypanothione and  superoxide dismutase,
respectively.
Qinghaosu contains a dioxygen bridge that has been shown to be essential
for its antimalarial activity. (The analogue deoxyqinghaosu, which has only a
single oxygen bridge, has been shown to be inactive [Brossi et al., 1988]).
Earlier work by Krunkai and Yuthavong (1987), showing that free radical
scavengers antagonize qinghaosu and that oxidants potentiate it, suggested the
participation of activated oxygen in the mechanism of its antimalarial activity.
Our laboratory, in collaboration with laboratories at Oakland Children’s
Hospital and at Peking Union Medical Center, has accumulated several lines of
evidence that qinghaosu is an oxidant antimalarial drug.
First, qinghaosu acts as a classical oxidant in uninfected erythrocytes. Treat-
ment of red cells with qinghaosu, but not deoxyqinghaosu, led to reductions in
cell deformability that are characteristic of oxidant effects, and to an increased
susceptibility to cumene hydroperoxide. Furthermore, qinghaosu but not de-
oxyqinghaosu caused reductions in reduced glutathione levels and increases in
methaemoglobin levels, which are also characteristic of oxidant effects. These
effects were greater in certain oxidant-sensitive red cells such as those contain-
ing haemoglobin AE or EE (Scott et al., 1989).
Second, treatment of infected and uninfected erythrocytes with artesunate, a
water-soluble derivative of qinghaosu, led to the production of thiobarbituric-
acid-reacting substances, which are a characteristic end-product of lipid peroxi-
dation caused by the reaction of activated oxygen and unsaturated fatty acids.
More thiobarbituric-acid-reacting substances were produced in red cells in-
fected with plasmodia than in uninfected red cells (Meshnick et al., 1989).
Third, ascorbic acid and reduced glutathione, two well-known antioxidants,
antagonized the antimalarial effects of qinghaosu in vitro (Meshnick et al.,
1989).
CHLOROQUINE
The mechanism of action of chloroquine remains controversial. During the
1970s and 1980s, most studies suggested that chloroquine exerted its anti-
malarial effect by binding to haemin or by alkalinizing lysosomes (for reviews,
see Fitch et al., 1984; Krogstad and Schlesinger, 1987). However, a great deal
of data had accumulated in the 1950s and 1960s indicating that chloroquine acts
via intercalation into DNA (for review, see Yielding et al., 1971).
The sensitivity of trypanosomes to intercalators is well known. Indeed, the
classic intercalator, ethidium bromide, was first developed as an anti-trypanoso-
mal agent. Acriflavine is also an intercalator with well-known anti-trypanoso-
mal activity (for review, see Meshnick, 1989).
Our laboratory has shown that chloroquine binds to DNA in a salt-dependent
manner. The Kd varies from 27 µM to 2.6 mM, depending on the salt concen-
tration. Unfortunately, the intranuclear concentration of chloroquine in treated
malarial parasites is not known, but assuming it is 10- to 100-times more
concentrated than the serum concentration, 0.03–1.0% of intranuclear binding
sites may be occupied by chloroquine when a parasite is exposed to physiologi-
cal concentrations (Kwakye-Berko and Meshnick, 1989).
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We have also now shown that binding of chloroquine to DNA may potentially
affect DNA function. At concentrations as low as 20 µM, chloroquine prevents
the formation of left-handed DNA helices (Z-DNA), a form of DNA believed
to be important in gene activation.
CONCLUSIONS
Both plasmodia and trypanosomes are sensitive to the toxic effects of interca-
lators and activated oxygen generators. Many of the techniques used to study
the pharmacology of these drugs in malaria have not yet been applied to the
study of anti-trypanosomal drugs. Such studies might aid in the development of
new anti-trypanosomal agents.
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Multidrug resistance genes
in eukaryotic cells
I.B. Roninson
Department of Genetics
University of Illinois at Chicago
Chicago, Illinois 60612, USA
PROPERTIES OF MULTIDRUG-RESISTANT
MAMMALIAN CELL LINES
Selection of mammalian cells for resistance to lipophilic cytotoxic drugs usually
results in cross-resistance to many other drugs, which share little structural or
functional similarity with the primary selective agent. The resulting cell lines
are characterized by resistance to Vinca alkaloids, anthracyclines, epipodophyl-
lotoxins, colchicine, taxol, puromycin, actinomycin D, trimetrexate, gramicidin
D and some other compounds (Riordan and Ling, 1985). This phenomenon of
multidrug resistance (MDR) is of particular significance in cancer chemother-
apy, since it affects the response of tumour cells to some of the most commonly
used  anti-cancer  agents. Multidrug resistance  is associated with decreased
intracellular accumulation of the drugs, due to increased energy-dependent drug
efflux from MDR cells (Dano, 1973). In 1976 Juliano and Ling found that
several MDR cell lines expressed an increased amount of a 170-kilodalton
membrane glycoprotein, termed P-glycoprotein. The presence of P-glycopro-
tein(s) proved to be the most consistent marker of MDR cells, but the role of
this protein in the phenotype of these cells remained unknown before molecular
genetic analysis.
IDENTIFICATION OF GENES RESPONSIBLE
FOR MULTIDRUG RESISTANCE
In 1984 we found that two MDR Chinese hamster cell lines, independently
selected with different drugs, contained commonly amplified DNA sequences
(Roninson et al., 1984). These sequences included a transcribed gene, desig-
nated mdr, whose increased expression is specific to MDR cell lines (Gros et
al., 1986c). Two genes related to the hamster mdr were detected in human DNA,
but only one of these genes, called mdr1, was consistently expressed in different
MDR human cell lines (Roninson et al., 1986). Gene transfer studies demon-
strated that expression of the mdr1 gene was sufficient to produce the complete
MDR phenotype in drug-sensitive cells (Gros et al., 1986a; Ueda et al., 1987).
Furthermore, the phenomenon of preferential resistance to the selective agent,
observed in some MDR cell lines, was shown to result from point mutations in
the mdr1 gene, at least in some cases (Choi et al., 1988). The second human
gene, mdr2, does not appear to provide resistance to lipophilic drugs upon
transfer into drug-sensitive cells (Van der Bliek et al., 1988). In rodent cells,
three mdr genes have been detected. Two of these genes appear to correspond
to the human gene in their structure and ability to confer multidrug resistance;
the third rodent gene corresponds to the human mdr2 (Ng et al., 1989).
STRUCTURE AND FUNCTION OF P-GLYCOPROTEINS
In an independent line of investigation, Riordan et al. (1985) have isolated
cDNA (complementary DNA) clones of hamster P-glycoprotein. P-glycopro-
tein and mdr cDNA  clones  were  found to cross-hybridize, indicating that
P-glycoprotein was the product of the mdr genes (Ueda et al., 1986). Amino
acid sequences of the human and rodent P-glycoproteins were determined by
sequence analysis of mdr cDNA clones (Chen et al., 1986; Gerlach et al., 1986;
Gros et al., 1986b). P-glycoprotein, encoded by the human mdr1 gene, is 1280
amino acids long and consists of two homologous halves (Chen et al., 1986).
Each half of the protein includes a hydrophobic region with six predicted
transmembrane segments and a relatively hydrophilic region, which contains
consensus sequences for a nucleotide-binding site. The hydrophilic regions of
P-glycoprotein share homology with a group of ATP-binding bacterial proteins,
which include energy-coupling subunits of multicomponent periplasmic trans-
port systems for the uptake of various metabolites.  The highest  levels of
homology to P-glycoprotein are found in efflux-associated bacterial proteins
hlyB and ndvA (Higgins et al., 1986; Stanfield et al., 1988). Homology with
bacterial transport proteins and the presence of potential channel-forming
membrane-spanning segments suggest that P-glycoprotein functions as an ac-
tive efflux pump, responsible for the removal of drugs from MDR cells. The
hypothesized efflux pump function of P-glycoprotein has received indirect
confirmation from biochemical studies, in which P-glycoprotein was shown to
bind drugs and to hydrolyze ATP in vitro (Cornwell et al., 1986; Hamada and
Tsuruo, 1988). The role of nucleotide-binding sites in P-glycoprotein function
was demonstrated by site-directed mutagenesis of human mdr1 cDNA. Both
nucleotide-binding sites were found to be required for normal function of
P-glycoprotein (B. Morse and I.B. Roninson, unpublished data).
MDR GENE EXPRESSION IN NORMAL AND TUMOUR
TISSUES
Analysis of mdr/P-glycoprotein expression in normal human tissues revealed
relatively  high levels of expression  in the adrenal cortex,  on  the  lumenal
surfaces of the kidney, liver, colon, jejunum and pancreas, in capillary endothe-
lial cells of the brain and testes, and in placental trophoblasts (Thiebaut et al.,
1987; Sugawara et al., 1988; Cordon-Cardo et al., 1989). These expression
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patterns suggest  that P-glycoprotein-mediated  membrane transport  may  be
involved in a variety of physiological processes. Such processes might include
removal of potentially cytotoxic natural compounds present in the diet, main-
tenance of blood-tissue barriers, regulation of metabolite exchange between
mother and foetus and transport of steroid hormones in the adrenal gland. In
clinical samples of human tumours, high P-glycoprotein expression has been
observed in many untreated tumours, which are known to be non-responsive to
chemotherapy, as well as in treated tumours, where P-glycoprotein expression
was often found to increase after treatment (Goldstein et al., 1989).
MDR GENES IN MALARIAL PLASMODIUM
Resistance of Plasmodium falciparum to chloroquine and other aminoquinoli-
nes was found to be associated with increased drug efflux (Krogstad et al.,
1987).  This efflux  was reversible  by verapamil,  a  drug  known  to  reverse
multidrug resistance in mammalian cells, suggesting that a similar mechanism
may be responsible for chloroquine resistance (Martin et al., 1987). Recently,
two mdr-like genes were isolated from the genome of P. falciparum (Foote et
al., 1989; Wilson et al., 1989). The complete sequence determined for one of
these genes showed identical structural organization and strong homology with
mammalian P-glycoproteins (Foote et al., 1989). This gene was amplified in
two out of five chloroquine-resistant field isolates of P. falciparum (Foote et
al., 1989) and in one mefloquine-selected strain (Wilson et al., 1989). Gene
amplification in these cases was accompanied by increased transcription of mdr.
It remains to be seen if chloroquine resistance in the non-amplified isolates
might be associated with increased transcription or structural changes in the
mdr genes. Thus, P-glycoprotein-mediated active efflux appears to be a general
mechanism for drug resistance in both protozoa and metazoa.
PERSPECTIVES FOR CLINICAL RESEARCH
Development of a molecular diagnostic test for multidrug resistance in cancer,
based on detection of mdr1 messenger RNA (mRNA) or protein expression,
represents the most immediate clinical application of the studies described
above. More ambitious and long-term directions of clinical research involve the
development of novel therapeutic strategies for prevention or reversal of mul-
tidrug resistance in cancer cells, and possibly also of drug resistance in parasites.
One actively pursued strategy involves the use of chemical agents that inhibit
P-glycoprotein function. Most of the known multidrug-resistance reversing
agents appear to function as competitive inhibitors of drug binding and/or
transport by P-glycoprotein (Akiyama et al., 1988). Initial clinical trials using
P-glycoprotein inhibitors have been reported (Dalton et al., 1989), and the
development of improved P-glycoprotein inhibitors is under way. Other ap-
proaches involve inhibition of P-glycoprotein function or selective destruction
of MDR cells using monoclonal antibodies against P-glycoprotein (Hamada and
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Tsuruo, 1986; FitzGerald et al., 1987), and using modified antisense oligonu-
cleotides complementary to mdr1 mRNA in an attempt to selectively inhibit
mdr1 gene expression. Another potential therapeutic approach is based on
introducing a constitutively expressed mdr1 gene into normal bone marrow cells
of a patient prior to chemotherapy, with the aim of reducing bone marrow
toxicity of lipophilic chemotherapeutic drugs.
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Multidrug resistance and gene amplification
in cultured Leishmania: relevance to current
and prospective chemotherapy
S.M. Beverley
Department of Biological Chemistry and Molecular Pharmacology
Harvard Medical School
250 Longwood Avenue
Boston, Massachusetts 02115, USA
At the Department of Biological Chemistry and Molecular Pharmacology at the
Harvard Medical School, we have been investigating the occurrence, biochemi-
cal mechanisms, and genetic basis of drug resistance in laboratory stocks of the
human parasite Leishmania major. We have focused primarily on drugs and
their gene targets as model systems for these processes, including resistance to
the antifolate methotrexate (MTX). The cellular target of MTX is the enzyme
dihydrofolate reductase-thymidylate synthase (DHFR-TS), an essential enzyme
for nucleotide biosynthesis. MTX constitutes a model drug in the sense that
MTX is far more toxic to humans than to Leishmania (Peixoto and Beverley,
1987). However, the success in designing anti-DHFR agents in other organisms
such as malaria and bacteria and the extensive amino acid sequence divergence
between L. major and human enzymes (Beverley et al., 1986) suggest that drugs
directed against the leishmanial DHFR will be feasible (Sirawaraporn et al.,
1988). Our studies of MTX resistance lead to the identification of the amplified
DHFR-TS structural gene, showing that, somewhat paradoxically, studies of
resistance can lead towards improved chemotherapy (even when clinical resis-
tance is not a problem).
There are at least three mechanisms by which resistance to MTX occurs in
Leishmania (reviewed by Beverley et al., 1988):
• amplification of the DHFR-TS gene, encoded on a segment of DNA termed
the R region
• decreased cellular MTX accumulation
• amplification of a region of DNA termed the H region, which is completely
distinct from the R region
We have shown that these three mutations can occur independently or in
combination in the same cell, indicating that the parasite has diverse mecha-
nisms it can marshall to survive chemotherapeutic attack (Ellenberger and
Beverley, 1987, 1989). Amplified DNA such as R or H occurs generally as
extrachromosomal circular DNA, which can be readily detected due to a high
copy number or unusual mobility properties in conventional or pulsed-field
electrophoresis gels (reviewed by Beverley et al., 1988). Gene amplification
has provided a convenient method for directly identifying and then working
with a resistance locus as the absence of methods for genetic manipulations of
trypanosomatid parasites has proven a formidable problem until quite recently.
MULTIDRUG RESISTANCE
AND THE H-REGION AMPLIFICATION
The H region was first observed in cells that also exhibited DHFR-TS gene
amplification, and we were uncertain whether this DNA could independently
mediate MTX resistance or was a non-functional segment of DNA that had
merely been non-specifically co-amplified (Beverley et al., 1984). However,
recent data from several other laboratories as well as our own indicate that this
DNA indeed mediates drug resistance.
The first clue emerged when it was shown that certain unselected laboratory
stocks of the lizard parasite L. tarentolae contained amplified DNA (Petrillo-
Peixoto and Beverley, 1986, 1988; White et al., 1988), which proved to be the
H-region homologue of this species similarly amplified as an extrachromosomal
circular DNA. Not all lines of L. tarentolae carried this amplification, but all
that did had a resistance to MTX that was twentyfold greater than that of the
other lines.  This  indicated  that  H-region  amplification could confer  MTX
resistance. However, we were puzzled why a lizard parasite had become
resistant to MTX. Because MTX is not often used other than in cancer chemo-
therapy, it seemed unlikely that L. tarentolae would ever have been exposed to
this agent.
Concurrent with these studies our laboratory had been selecting L. major for
resistance to numerous drugs, and two of these had developed gene amplifica-
tion that  turned out  to be  amplification of the  H  region  (Ellenberger  and
Beverley, 1989). The  three drugs that resulted in H amplification—MTX,
primaquine (PQ, an 8-aminoquinoline whose target is unknown in Leishmania)
and terbinafine (TB, an allylamine inhibitor of squalene epoxidase)—shared no
obvious structural or pharmacological similarity. When a variety of lines were
tested, it was found that all lines containing H-region amplification were highly
cross-resistant to MTX and weakly cross-resistant to PQ and TB.
This observation of multidrug resistance suggested to us that the L. tarentolae
had actually developed H-region amplification in response to an agent other
than MTX. This situation seemed similar to the emerging story of multidrug
resistance in tumour cell lines, in that overexpression of the mammalian mul-
tidrug resistance gene (often due to amplification) had been shown to lead to
resistance to a spectrum of drugs, with no obvious structural or functional
similarity, by causing decreased drug accumulation (reviewed by Gottesman
and Pastan, 1988).
Accordingly, we characterized MTX and folate transport in L. major promas-
tigotes and then asked whether H-region amplification mediated decreased
MTX uptake. The answer was clearly negative because the H-region amplified
PQ- and TB-resistant lines were completely normal in MTX influx, accumula-
tion and efflux properties (Ellenberger and Beverley, 1989). Verapamil, an
agent that reverses multidrug resistance associated with gene amplification, had
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no effect on the MTX resistance of the H-amplified lines. We went on to show
that the PQ- and TB-resistant lines did not exhibit increased levels of MTX
metabolism, due to increases in the activity of a MTX hydrolase activity present
in wild-type lines or other metabolic alterations (Ellenberger et al., 1989).
Current data suggest that the form of multidrug resistance mediated by the H
region is novel and distinct from that seen in other systems.
The story at this point took an unexpected twist. Lines of L. mexicana selected
for resistance to arsenite also contained an amplification of the H region;
correspondingly, this line was cross-resistant to MTX (Katakura and Chang,
1989; Detke et al., 1989). We then showed that the H-amplified L. major lines
described above were cross-resistant to arsenite as well (Ellenberger and Bev-
erley, 1989), thereby implicating the H-region amplification in resistance to an
astonishingly diverse group of compounds. Since arsenite has certain chemical
similarities with trivalent antimonials, we investigated whether the H-region
amplification could be involved in mediating resistance to these compounds.
Figure 1 shows the results of preliminary studies of the primaquine-resistant
PQ-R30 line, which bears high levels of H-region amplification; this line is
significantly resistant to potassium antimony tartrate. Berman (1982) showed
that clinical isolates resistant to trivalent antimonials were also resistant to
pentavalent antimonials. It will be interesting to test whether H-region ampli-
fication mediates resistance to pentavalent antimonials, especially in the amas-
tigote stage, and whether isolates clinically unresponsive to antimonials show
H-region amplification.
IMPLICATIONS FOR CHEMOTHERAPY
The potential association of H-region amplification and antimonial resistance
is simultaneously a disturbing and exciting finding. Since natural isolates of L.
tarentolae can exhibit H-region amplification, it is possible that natural isolates
of human leishmaniasis also possess this amplification. Moreover, our studies
show that Leishmania possesses a remarkable ability to amplify the H region
locus de novo in response to drug pressure. At a broader level, the overall ability
of the parasites to develop resistance by a plethora of mechanisms to every
compound we have tested suggests that concerns over drug resistance will be
as much a part of the development of a practical anti-leishmanial chemotherapy
as they are of malaria control today.
Our findings are exciting in that very little is known about either the true
cellular target(s) of antimonials or the mechanisms of antimonial resistance.
Analysis of the large collection of H-region amplifications in different species
has allowed us to genetically identify this DNA as a resistance locus. Charac-
terization of the molecules and mechanism of resistance encoded by the H
region should prove informative to questions concerning both resistance and
drug targets. As genetic methods emerge and become more powerful in Leish-
mania, we should be able to extend these studies to the far larger class of
drug-resistance mutations not mediated by gene amplification.
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FIGURE 1. Effect of potassium antimony tartrate on wild-type Leishmania major and
on lines whose H region has been amplified.
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Pyrimethamine resistance
in Plasmodium falciparum
J. Inselburg, M. Tanaka, H. Gu, D. Bzik and W.B. Li
Department of Microbiology
Dartmouth Medical School
Hanover, New Hampshire 03756, USA
Pyrimethamine binds to and inhibits the dihydrofolate reductase activity of the
essential, bifunctional Plasmodium falciparum enzyme dihydrofolate reduc-
tase-thymidylate  synthase  (DHFR-TS) (Ferone et al., 1969; Garrett et al.,
1984). We have been studying pyrimethamine-resistant (PyrR) parasite mutants
with the intention of understanding the mechanism(s) by which resistance is
achieved and to find ways to design a more effective antimalarial. To do this,
we have isolated and examined PyrR mutants (Banyal and Inselburg, 1986;
Inselburg et al., 1987), and have also determined the nucleotide sequence of the
P. falciparum DHFR-TS gene (Bzik et al., 1987). We and others have further
shown that specific amino acid changes, which arise from DHFR gene muta-
tions, are found in P. falciparum PyrR mutants (Cowman et al., 1988; Inselburg
et al., 1988; Peterson et al., 1988). In the study reported here, we further
examined the nucleotide changes associated with pyrimethamine resistance and
found that parasites with such alterations often contained demonstrable changes
in the electrophoretic migration of the chromosome that carries the DHFR-TS
gene.
MATERIALS AND METHODS
P. falciparum parasites Honduras 1 (PyrR), FCR3 (pyrimethamine sensitive
[PyrS]) and FCR3 PyrR mutants D4, D5, D6, D7 and D8 were studied (Inselburg,
1983; Banyal and Inselburg, 1986).
Polymerase chain reaction. Oligonucleotides for primers were derived from
the DHFR-TS sequence of Bzik et al. (1987). The location of primers are
indicated in Figure 1. The specific primer sequences are presented elsewhere
(Gu et al., submitted for publication). The genomic DNA was amplified in a
thermocycler (Ericomp, USA) using Thermus aquaticus polymerase (Perkin-
Elmer Cetus, USA) according to the manufacturers instructions.
DNA sequencing. Sequencing of amplified DNA was by the dideoxy-termi-
nation method using the modified T7 DNA polymerase, Sequenase (U.S.
Biochemicals), as described by Higuchi et al. (1988).
Pulsed-field gel electrophoresis. P. falciparum chromosomes were prepared
in agarose blocks containing approximately 3 × 108 parasites per ml, as de-
scribed elsewhere (Gu et al., submitted for publication), and separated using
contour-clamped homogeneous electric-field electrophoresis (Chu et al., 1986;
Gu et al., submitted for publication). A pulse time of 11 minutes, an electric
field strength of 4 V/cm and a total running time of 149 hours were used for
chromosome separations in this report. The gels were stained with ethidium
bromide (0.5 m g/ml).
Southern blotting and probing of chromosomes. Separated chromosomes
were transferred to Zeta probe membrane (BioRad, USA) using the Southern
blot transfer method after sequentially soaking the gel in 0.25 M HCl at room
temperature for 30 minutes and in 0.4 M NaOH at 4°C overnight. The transfer
was done using 0.4 M NaOH. The blotted DNA was probed with appropriate
32P-labelled DHFR-TS DNA. The 32P-labelled probes were labelled by the
random priming method described by Feinburg and Vogelstein (1983).
RESULTS
We have examined the DHFR sequences in the PyrR Honduras 1 strain, in
several isolates of the original FCR3 strain and in five PyrR mutants of FCR3:
FCR3 clones D4, D5, D6, D7 and D8 (Banyal and Inselburg, 1986). FCR3
clones D4, D5, D6 and D7 were cloned, at intervals, from a culture to which
progressively higher concentrations of pyrimethamine were added. FCR3-D8
was isolated as a clone after treating the culture from which FCR3-D7 was
isolated with the mutagen N-methyl-N-nitro-N é -nitrosoguanidine and then
FIGURE 1. The location of polymerase chain reaction primers used to amplify and
sequence the Plasmodium falciparum DHFR-TS gene. The location and direction of
primers are shown. The base pair locations of point mutations are shown (by heavy
vertical arrows) that encode amino acids 16, 54 and 223. PR are primers used to amplify
the total region. SP are primers used to amplify and sequence the DNA.
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growing the survivors in a culture to which had been added a higher level of
drug. The results of the sequence analyses of the parasites are shown in Table
1. Only those nucleotides and amino acids that are different from the FCR3
sequence are shown.
The original isolate of FCR3-D8, which was obtained from two DNA clones,
is also shown (Inselburg et al., 1988). It differed from FCR3 at amino acids #54
and #223. The recent DNA sequencing of FCR3-D4, D5, D6, D7 and D8, using
DNA amplified by the polymerase chain reaction method, indicated that each
mutant differed from FCR3 at only amino acid #223. The originally sequenced
FCR3-D8 clones were resequenced using the polymerase chain reaction ampli-
fication method and again showed the original two amino acid differences. We
concluded that the extended in vitro cultivation of FCR3-D8 cells without
pyrimethamine led to the selection of the mutant without change at amino acid
#54. The mutation at amino acid #54 had been reported to reduce DHFR activity
in mouse cells by several hundredfold (Howell et al., 1986). We have found
that the new FCR3-D8 culture, unlike the original isolate (Banyal and Inselburg,
1986), had a detectable level of DHFR activity consistent with there having
been a reversion at amino acid #54.
We previously showed that FCR3-D7 contained a gene duplication and
overproduced a DHFR-TS enzyme that had a lower specific activity (Inselburg
et al., 1987). Our sequence analysis indicated that the amino acid sequence
change in the FCR3-D7 DHFR sequence cannot explain its higher level of
resistance than that of FCR3-D4, D5 or D6 and therefore must be related to
some other change(s).
The Honduras 1 DHFR differed from that of FCR3 at two amino acids: #16
and #108.
We have examined the chromosomes of FCR3, FCR3-D4, D5, D6, D7 and
D8 and Honduras 1. The wild type DHFR-TS gene is on chromosome #4. We
found detectable chromosome changes in only the smaller chromosomes of some
of the PyrR FCR3 and therefore have shown only those chromosome separations.
It was noted that there was no longer a structure the size of the FCR3 chromosome
TABLE 1. The locations of amino acid and nucleotide changes in the mutant dihydro-
folate reductase-thymidylate synthase (DHFR-TS) gene
Amino acid number of DHFR
Parasite 16 51 54 59 108 223
FCR3 GTA*(Val) AAT(Asn) GAT(Asp) TGT(Cys) ACC(Thr) TTT(Phe)
Honduras 1 GCA(Ala) AAT(Asn) GAT(Asp) TGT(Cys) AAC(Asn) TTT(Phe)
FCR3-D4-D8 GTA(Val) AAT(Asn) GAT(Asp) TGT(Cys) ACC(Thr) TCT(Ser)
FCR3-D8† GTA(Val) AAT(Asn) AAT(Asn) TGT(Cys) ACC(Thr) TCT(Ser)
*Nucleotides encoding amino acid (Bzik et al., 1987).
†These sequence data are the same as those reported previously (Inselburg et al., 1988).
However, FCR3-D8 cells grown in the absence of pyrimethamine have been found
eventually to lose the mutation affecting amino acid #54.
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#4 in FCR3-D7 and FCR3-D8 (Figure 2). In FCR3-D8, a second small chromo-
some was also seen. We then used a 32P-labelled, cloned DHFR DNA (Bzik et
al., 1987) to probe the chromosomes of FCR3, FCR3-D7 and FCR3-D8 (Figure
3). The DHFR-TS gene in FCR3-D7 was in a chromosome that was larger than
chromosome #4, while in FCR3-D8 the gene was in two chromosomes, one much
smaller and one slightly larger than chromosome #4. Honduras 1 was missing
structures the size of chromosome #4, #5 and #10. The higher levels of drug
resistance shown by FCR3-D7 and D8, which have the same primary DHFR
structure as FCR3-D4, D5 and D6, and the resistance of Honduras 1, therefore
appears to be associated with changes in chromosome #4.
DISCUSSION
We and others have now shown that a number of P. falciparum DHFR mutants
exhibit the PyrR phenotype. It has been suggested that a change of amino acid
#108 was essential for the expression of pyrimethamine resistance (Peterson et
FIGURE 2. Contour-clamped homogeneous electric-field electrophoresis separation
of the small- and intermediate-size chromosomes of Plasmodium falciparum. The
chromosomes were from the following cultures. Lane 1: FCR3, lane 2: Honduras 1,
lane 3: FCR3-D4, lane 4: FCR3-D5, lane 5: FCR3-D6, lane 6: FCR3, lane 7: FCR3-D7,
lane 8: FCR3-D8. Chromosome numbering of some FCR3 chromosomes are on the left
of the figure. The smallest FCR3 chromosome is #1. Chromosomes separated in lanes
1–5 were from one gel and in lanes 6–8 from a second gel.
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al., 1988). The PyrR mutants we have described do not contain such a change.
We also found that in three PyrR mutants containing identical DHFR point
mutations, an electrophoretically detectable change had occurred in chromo-
some #4, the chromosome on which the wild type DHFR-TS gene resides. We
suggest that chromosome-size changes that contribute to either gene duplica-
tions or possible gene regulatory processes probably play an important role in
the development of higher levels of pyrimethamine resistance in the parasite.
In FCR3-D7 the duplicated genetic material resides on one electrophoretically
separable chromosome. In FCR3-D8, DHFR coding sequences reside on two
chromosomes. However, we must confirm that the FCR3-D8 culture was a pure
cloned population since we previously found that the DNA content of FCR3
and FCR3-D8 were about the same, while the enzyme level of FCR3-D8 was
measurably higher.  The  study  of  PyrR mutants  may  provide  an  important
approach to studying the formation of chromosome-size polymorphisms in
malaria.
We also noted that maintaining a pyrimethamine-resistant culture in the
absence of drug (FCR3-D8) led to the selection of a parasite population with a
diminished level of resistance. Similarly, some drug-resistance genotypes in
bacteria are unstably maintained. Thus, control of pyrimethamine usage may
eliminate a selective drug pressure that is required to maintain populations of
FIGURE 3. Hybridization of 32P-DHFR DNA to Plasmodium falciparum chromo-
somes in Southern blots. The blotted chromosomes were derived from the following
cultures. Lane 1: FCR3-D8, lane 2: FCR3-D7, lane 3: FCR3. FCR3 chromosome #4 is
marked on the right.
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some highly resistant organisms and may therefore restore its effectiveness in
some areas where it is no longer effective in the treatment of malaria.
Finally, the demonstrated affinity of pyrimethamine for DHFR has been the
basis for explaining the mechanism of resistance. In preliminary studies that
examined in vivo 3H-pyrimethamine binding to the DHFR-TS protein, we found
that the drug also becomes associated with other parasite and/or red blood cell
proteins. It may prove worthwhile to consider the ability of other parasite proteins
to titrate the drug as another mechanism of pyrimethamine resistance.
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Protein conjugates
as trypanocide delivery systems
J.B. Mitchell
School of Biology and Tropical Diseases
Chemotherapy Research Unit
Sunderland Polytechnic
Sunderland SR1 3SD, UK
Attachment of a drug to a macromolecular carrier system results in substantial
changes in the mechanism of its interactions at the cellular level. Although a
drug with a low molecular weight may enter cells by simple diffusion, the same
drug attached to a macromolecular carrier, such as a protein, enters the cell only
by endocytosis. Because endocytosis can be a cell-specific mechanism, this
provides possibilities for targeting drugs to cells that will endocytose the carrier.
In the design of such drug-carrier systems, it is important that the linkage is
stable in plasma but is susceptible to hydrolysis in lysosomes of the target cells
or organisms.
The work discussed in this paper relates to the antitumour antibiotic, daun-
orubicin. This diffuses into mammalian cells (Peterson et al., 1980), whereas
its macromolecular conjugates are endocytosed by tumour cells and lysed by
lysosomal enzymes to release the drug within the cell (Trouet et al., 1982).
The trypanocidal activity of daunorubicin is greater in vitro than that of any
other drug (Williamson and Scott-Finnigan, 1975), yet in vivo it is completely
inactive (Williamson and Scott-Finnigan, 1978). To investigate this unexpected
difference, Brown et al. (1982) examined the distribution of daunorubicin and
its metabolites in infected mice. They found that drug accumulates in trypano-
somes and in the cellular components of the blood. However, as its concentra-
tion in the plasma declines, so also does its concentration in the trypanosomes.
They also showed, by fluorescence microscopy, that daunorubicin reaches the
nucleus of the trypanosomes in vivo but its concentration in this site declines
rapidly, indicating that adequate concentrations of drug may not be maintained
long enough in the organisms for the trypanocidal effect to be achieved (Brown
et al., 1982).
In attempting to prolong the exposure of trypanosomes to daunorubicin in
vivo, Williamson et al. (1981) investigated the effects of coupling it to macro-
molecules, including the proteins bovine serum albumin (BSA) and ferritin. It
seemed likely that these would act as true carriers because they would be
expected to be endocytosed by trypanosomes (Brown et al., 1965; Langreth and
Balber, 1975; Fairlamb and Bowman, 1977, 1980a, 1980b). Indeed, Fairlamb
and Bowman (1980a) have suggested that suramin, though administered as the
free drug, forms a complex with plasma albumin before being taken up by
endocytosis from the flagellar pocket and subsequently released in secondary
lysosomes.
Williamson et al. (1981) prepared two different daunorubicin-BSA com-
plexes. One, containing stable secondary amine bonds, was inactive; the other,
with a labile glutaraldehyde-produced covalent linkage (D-BSAG), was active
in vitro and retained its activity in vivo. It was, indeed, the first daunorubicin
preparation to clear trypanosomes from the blood of infected mice for prolonged
periods. (Daunorubicin linked by the same method [Hurwitz et al., 1975] to
ferritin was also trypanocidal both in vitro and in vivo [Williamson et al., 1981]).
Daunorubicin has also been covalently linked to BSA by hydrazide and oxime
linkages, which are far more labile than the glutaraldehyde-produced linkages,
and both these conjugates are inactive against trypanosomes in vivo (Hardman
et al., 1983). This supports the hypothesis that the drug is not active while it
remains coupled to its carrier. It must first be released from the conjugate before
its trypanocidal activity is exhibited. However, if it is too readily released,
presumably in the plasma, it will equally fail to exert its effects.
Our investigations into the distribution of D-BSAG in Trypanosoma brucei
rhodesiense from infected mice provide information on the mode of action of
the conjugate in vivo.
After infected mice were given an intraperitoneal dose equivalent to 25
mg/kg daunorubicin, the subcellular distribution of free and bound daunoru-
bicin in trypanosomes was determined (Brown et al., 1981; Golightly et al.,
1983). The nucleus contained 85% of the unconjugated drug whereas the small
particulate (lysosome) fraction contained 75% of the drug-protein conjugate.
(Daunorubicin administered as free drug localizes, and is active, principally in
the nucleus [Brown et al., 1982; Williamson et al., 1983]). We have also
demonstrated that D-BSAG can be cleaved by enzymes contained in lysosome-
rich fractions of trypanosomes obtained from Percoll density gradients. So it
appears that daunorubicin can be released from the conjugate in lysosomes and,
once released, can reach its intracellular targets where it may exert its effects.
In a series of tests we have compared the action of two covalently bound
conjugates of daunorubicin and BSA, D-BSAG (dialysed for several weeks to
ensure the removal of any free daunorubicin) and D-BSAS (a stable succinyl-
linked conjugate) (Arnold et al., 1983). When we looked at the effects on the
ultrastructure of trypanosomes of exposure to various concentrations of free
daunorubicin and the two conjugates for 4 hours in vitro (Golightly et al., 1986),
we found that: (1) segregation of the nucleolus caused by 1 × 10–7 M daunoru-
bicin requires 1 × 10–6 M D-BSAG; (2) complete nucleolar fragmentation
results from 1 × 10–6 M free drug but requires 5 × 10–6 M D-BSAG; and (3)
D-BSAS produces no detectable changes.
When uptake of these same compounds was studied in vitro using fluores-
cence microscopy (Golightly et al., 1985), D-BSAG was observed to be taken
up by the trypanosomes in a similar way to free drug but to a lesser extent and
more slowly.  Fluorescence in  the nucleus,  kinetoplast  and  lysosomes  was
observed in D-BSAG-treated trypanosomes after 3.5 hours, while free drug
produced the same effect in only 15 minutes. (However, the conjugate was
marginally more effective at inducing loss of infectivity in vitro [Golightly et
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al., 1988]). No fluorescence at all occurred in trypanosomes exposed to D-
BSAS, indicating that this stable linked conjugate does not enter the organisms.
It is not surprising, therefore, that this compound failed to affect the ultrastruc-
ture of the trypanosomes. In vivo doses of 10–30 mg/kg D-BSAG cleared
trypanosomes from the bloodstream in 24–48 hours, but after a further 36 hours
parasites reappeared in the bloodstream and multiplied normally (Golightly et
al., 1988). Repeated dosing following initial clearance failed to clear parasites
in the relapsed infection. The high toxicity of daunorubicin is a major problem
of the use of this drug, and its toxicity is not diminished by binding to BSA or
by using multiple dosing regimes.
Multiple dosing of protein-bound drugs could lead to the development of
hypersensitivity and this may influence the clinical applicability of proteins as
carriers in drug-delivery systems. A `single shot’ cure would be the ideal, but
if multiple doses are required, it may be necessary to have a series of complexes
involving the same drug bound to a number of different proteins.
We are now attempting to exploit the fact that cells of the immune system
have the ability to endocytose foreign proteins and are using this to target
protein-bound drugs to the amastigotes of Leishmania, which develop in macro-
phages. We have tested several drugs against L. donovani in infected mice and
obtained the following ED50 figures: pentostam 65 mg/kg, daunorubicin 23.7
mg/kg and D-BSA 11.25 mg/kg. These results give a strong indication that there
is a future for the use of protein conjugates as drug-delivery systems.
SUMMARY
Attachment of the drug daunorubicin to the protein bovine serum albumin by a
labile (glutaraldehyde) linkage (D-BSAG) confers in vivo trypanocidal activity
to a drug otherwise trypanocidal only in vitro. Experimental evidence supports
a lysosomotropic mode of action: free drug can be cleaved from D-BSAG by
isolated lysosomal enzymes of trypanosomes; and in trypanosomes from in-
fected mice treated with D-BSAG, the drug-carrier complex is recovered largely
from  lysosomes while  freed drug is  in the  nucleus. If the bonds between
daunorubicin and the protein are either stable or too labile, the complex is not
trypanocidal. In vitro, trypanosomes are damaged less by D-BSAG than by free
drug. Against L. donovani in vivo the protein-bound form is the more effective,
indicating that better targeting has been achieved. Protein binding does not
diminish the toxicity of the drug in vivo.
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Drug delivery by immunoliposomes
B.T. Rouse*, S.J. Kennell† and L. Huang‡
*Department of Microbiology
University of Tennessee
Knoxville, Tennessee 73996, USA
†Biology Division
Oak Ridge National Laboratory
Oak Ridge, Tennessee 37830, USA
‡Department of Biochemistry
University of Tennessee
Knoxville, Tennessee 37996, USA
Contemporary chemotherapy requires efficient means of delivering drugs to
target tissues so as to minimize toxicity. Drug targeting can either be achieved
by coupling a tissue-specific ligand to the drug, or by using microreservoirs that
are themselves targeted. Intelligent homing devices represent the ideal targeting
strategy, but at present one must arrange for close encounters to occur so that
binding may result. Currently, targeting drug-containing microreservoirs with
antibody represents the most promising strategy, and our approach to this issue
is to use liposomes for the purpose. Such antibody-targeted liposomes are
referred to as immunoliposomes. Numerous methods can be used to prepare
immunoliposomes (Wright and Huang, in press), but the method we developed
and favour uses the N-hydroxysuccinimide ester of palmitic acid to acylate
immunoglobulin (Ig) (Huang et al., 1980). The resulting hydrophobic antibody
intercalates into the bilayers of liposomes. The achievement of optimal coupling
stoichiometry must be ascertained for each antibody and type of liposome, but
typically antibodies retain 20–30% of their binding activity and can be incor-
porated with high efficiency and stability into liposomes (Huang et al., 1982).
Immunoliposomes for drug delivery can be prepared that exhibit a range of
biological properties. To be effective in drug delivery, immunoliposomes must
not only bind to target structures, but they or their contents must also be
internalized and may need to be delivered to certain locations within the cell
(Wright and Huang, in press). The latter activity is best achieved by controlled-
release immunoliposomes, particularly those designed to disrupt in the presence
of particular microenvironments. The value of acid-sensitive controlled-release
liposomes for drug delivery as well as their potential for gene therapy was
recently reviewed (Collins and Huang, 1988).
Drug delivery in vivo with immunoliposomes has many practical problems
to overcome, of which avoiding uptake by the reticuloendothelial system (RES)
and the constraints of anatomical compartmentalization are the most significant
(Collins and Huang, 1988; Wright and Huang, in press). Methods to overcome
both problems are rapidly being developed (Allen and Chonn, 1987). Certain
locations in the body are less constraining, such as the surface of the eye (Norley
et al., 1986) and the lung (Hughes et al., 1989). The latter site represents a
potential target for immunoliposomes placed in the venous circulation since
such vehicles contact the lung before they are subject to entrapment by the RES.
We have developed a monoclonal antibody to an antigen gp112 (Kennel et al.,
1988) found on murine lung capillary endothelial cells that can be acylated to
make immunoliposomes that bind very effectively to the lung (Table 1). This
TABLE 1. Biodistribution of 125I-labelled anti-gp112 labelled liposomes*
Time
Organ† 15 minutes 24 hours 1 week
Lung % per g 670 640 583
ratio‡ 27.9 27.4 24.9
Liver % per g 9.4 4.3 4.5
ratio 0.4 0.2 0.3
Spleen % per g 14 13 10
ratio 0.5 0.5 0.7
*Data modified from Hughes et al. (1989).
†Values are the fraction of the percent of the recovered radioactivity in an organ per
gram of wet weight of tissue. Values are averages of 3 animals per time point. Mice
received tail vein injections of 125I-labelled anti-gp112 or 125I-labelled rat IgG2b of
no known specificity immunoliposomes.
‡Ratio of organ binding by anti-gp112 immunoliposomes to those not specifically
targeted.
TABLE 2. Time course of liposome biodistribution*
% injected dose (minutes)
Tissue Target 1 3 5 10 15 30
Lung anti-gp112 37 34 34 32 31 28
nonspecific 6 3 2 1 1 1
Liver anti-gp112 21 24 24 24 20 17
nonspecific 26 35 37 32 28 22
Blood anti-gp112 12 8 7 5 4 4
nonspecific 6 4 3 2 2 1
*Groups of mice were injected intravenously with a 200 µl inoculum of N-[3-(3-[125I]
iodo-4-hydroxy-benzyl)-propionyl] dipalmitoylphosphatidylethanolamine-labelled
liposomes.
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binding occurs extremely rapidly (Table 2) and liposome components can be
found in the lung seven days after their administration. Specificity of the
reaction was shown in a number of ways. Accordingly, immunoliposomes
targeted with Ig with no anti-lung activity failed to bind to the lung (Table 1)
and the effect could also be blocked by pretreating animals with anti-gp112
ascites fluid but not by pretreating them with other antibodies (Hughes et al.,
1989). Rather surprisingly, lung binding occurred within one minute after
administration (Table 2). We also suspect that specific binding occurs only
during the first few passes of immunoliposomes through the lung. Liposomes
that do not achieve rapid binding are assumed to be entrapped by RES cells in
various organs.
As mentioned above, binding to target structures by immunoliposomes is a
necessary, but not in itself sufficient, requirement for effective drug delivery.
Conditions must be such that the entrapped drug will be released to effect
therapeutic activity. To assess this possibility, we entrapped the anti-herpes
virus drug acycloguanosine in immunoliposomes and determined if the formu-
lation was any more effective at controlling a respiratory infection with herpes
simplex virus than control drug alone or drug administered within untargeted
liposomes. The results of two experiments attest to the superior efficiency of
the drug-containing immunoliposome formulation (Table 3). Currently, we are
optimizing conditions to achieve maximum therapeutic efficiency as well as
attempting to endow liposomes with stealth characteristics so that their uptake
by the RES is minimized and their circulatory time prolonged.
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The use of viral membrane
fusion proteins in drug delivery
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A major obstacle in delivering molecules into cells is the barrier imposed by
the hydrophobic plasma membrane. The membrane is not freely permeable to
ions, solutes, proteins or nucleic acid molecules. In spite of this, enveloped
viruses have evolved an elegant strategy for transferring their membrane-en-
capsulated genome into the cytosol of host cells. They accomplish this by
inducing fusion between viral and cellular membranes. The virus thus serves as
a `transport vesicle’ for delivery of its contents into its host cell.
DELIVERY SYSTEMS IN NATURE:
ENTRY OF ENVELOPED VIRUSES INTO CELLS
After binding to the surface of their host cells, many viruses are taken up by the
cell. The process of internalization is a constitutive cellular function: receptor-
mediated endocytosis via coated pits and coated vesicles (Brown et al., 1983).
The internalization pathway of Semliki Forest virus, which serves as a general
paradigm for viruses with endocytic entry pathways (Helenius et al., 1980;
Marsh and Helenius, 1989), is shown in Figure 1. Once inside the cell, the virus
is delivered to an acid compartment, the endosome (Helenius et al., 1983; Marsh
and Helenius, 1989). Exposure to the acidic environment triggers the viral-me-
diated fusion of endosomal and viral membranes. The fusion event results in
the release of the viral genome into the cytoplasm and begins the infection
process.
In contrast to viruses that require low pH to fuse with target cells are those
that display pH-independent fusion activity. These viruses can penetrate cells
by fusing with the plasma membrane (White et al., 1983; White, in press).
Regardless of pH dependence, the fusion of enveloped viruses with target cells
represents an effective mechanism for introducing the viral contents into the
cytosol.
VIRAL MEMBRANE FUSION PROTEINS
The membrane fusion activity of the enveloped viruses is a property of `fusion
proteins’ on their surfaces (Marsh and Helenius, 1989; White, in press). Some
fusion proteins and their properties are listed in Table 1. They are generally
integral membrane glycoproteins present as oligomers in the viral membrane.
Multiple copies of these spike-like glycoproteins project from the membrane of
the virion, the external spike comprising more than 85% of the protein mass. In
many cases, proteolytic processing is required to produce the fusion-competent
form of the molecule (Marsh and Helenius, 1989; White, in press). The best
characterized spike glycoprotein to date, the haemagglutinin (HA) molecule of
influenza virus, is schematically depicted in Figure 2.
The mechanism by which the viral fusion proteins promote membrane fusion
is currently a topic of great interest. Recent evidence suggests that more than
one molecule is necessary for fusion in the case of the influenza HA (Doms et
al., in press; Stegmann et al., 1989; Ellens et al., submitted for publication). In
FIGURE 1. Uptake of Semliki Forest virus by cultured cells. The virus binds to the cell
surface and moves laterally to coated pits. The virus is internalized by coated vesicles
and transported to endosomes. The low pH of the endosome triggers the viral-mediated
fusion of membranes, resulting in the delivery of the viral genome into the cytoplasm.
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FIGURE 2. Schematic representation of the influenza haemagglutinin molecule. The
molecule is present in the viral envelope as a trimer; a monomer is depicted here for
simplification.  Haemagglutinin is composed  of  two disulphide-linked polypeptide
chains, HA1 and HA2. The binding site is at the tip of the globular head domain. The
hydrophobic N-terminus of HA2 is thought to be responsible for mediating fusion with
target membranes.
TABLE 1. Properties of some viral fusion proteins
pH Fusion Hydrophobic Reconstituted
Dependence Virus Protein fusion sequence into vesicles*
Low pH:
5.1–5.8 Influenza HA N-terminus Yes
(HA1-HA2) of HA2
< 6.2 SFV ENV Internal No
(E1-E2-E3) E1
< 6.2 VSV G Not Yes
Apparent
Neutral pH:
Sendai F Not Yes
(F1-F2) Apparent
HIV ENV N-terminus No
(gp120-gp41) gp41
SFV: Semliki Forest virus, VSV: Vesicular Stomatits virus, HIV: Human Immunode-
ficiency virus.
*Reconstitution of protein with fusion activity under physiological conditions.
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the ectodomains of many fusion proteins, there is a stretch of several apolar
amino acids that seem to be involved in membrane fusion and have thus been
termed `fusion peptides’ (White, in press). A mechanism has been proposed for
haemagglutinin-mediated membrane fusion whereby the `fusion peptide’ is
inserted into the target membrane, perturbing the lipid bilayer and leading to
fusion of the two membranes (Harter et al., 1988; Marsh and Helenius, 1989;
Stegmann et al., 1989). This and other hypotheses are being tested (White, in
press).
ARTIFICIAL DELIVERY SYSTEMS
BASED ON VIRAL FUSION PROTEINS
Soon after the discovery of the fusogenic proteins of viruses, attempts were
made to harness the fusion activity for artificial delivery of drugs and other
molecules into cells (Doxsey et al., 1985; Celis, 1986; Schlegel and Rechsteiner,
1986; Helenius et al., 1987). Three general delivery strategies developed to
exploit the viral fusion proteins are shown in Figure 3 (Helenius et al., 1987).
The fusion protein can be expressed on the target cell (Figure 3a) or reconsti-
tuted into artificial lipid vesicles (virosomes, Figure 3c). Alternatively, intact
virions can be used as fusogens to `bridge’ the delivery vesicles and target cell
(Figure 3b).
To achieve efficient binding and increase the probability of fusion, the
appropriate receptors must be present in high concentrations on the target
membrane. Once bound, the delivery vesicle can be fused with the cell either
by brief acid treatment (low pH-dependent fusion proteins) or by prolonged
incubation at neutral pH (pH-independent fusion proteins). One advantage of
using acid pH-triggered fusion proteins is that molecules are delivered rapidly
and simultaneously into the cells. Each of the three strategies has limitations
and none has emerged as an accepted routine method for efficient bulk delivery.
However, they all have potential for specific applications.
Virus particles as fusogens
Some success has been achieved using intact viruses (usually pH-independent)
as `bridges’ to fuse delivery vesicles with cells (Celis, 1986; Schlegel and
Rechsteiner, 1986). Since a separate fusogen is used, potentially any number of
target cells and delivery vesicles could be employed in vitro. However, our
experience with acid-dependent viruses (Semliki Forest virus, influenza) has
been discouraging owing to the low efficiency of delivery when compared to
the HA-expressing target cell system (see below).
Target cells expressing the fusion protein
We have developed a method for the cytoplasmic delivery of molecules that
uses target cells expressing the influenza HA molecule and erythrocytes as
vesicular carriers (Doxsey et al., 1985; Ellens et al., 1989). Efficient surface
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expression of the cloned HA molecule has been achieved by viral infection or
by establishing permanent cell lines (Sambrook et al., 1985; Whiley and Skehel,
1987) that have been optimized for efficient fusion (Ellens et al., 1989).
Perhaps the single most important aspect of this technique is its high effi-
ciency (Doxsey et al., 1985). We routinely deliver molecules to 80–95% of the
cells in a monolayer. Up to 200 million copies of some proteins have been
introduced into each cell. In addition, delivery is easily controlled, highly
reproducible and not deleterious to the recipient cells. Using this approach, a
variety of macromolecules have been delivered using both erythrocytes (Dox-
sey et al., 1985, 1987) and liposomes (Ellens et al., 1989; Glenn et al., in
preparation) as vesicle carriers.
The utility of the technique for investigating biological problems has been
demonstrated in several studies. We showed that delivery of antibodies to the
clathrin heavy chain inhibited receptor-mediated endocytosis, thus providing
evidence for a direct role for clathrin in endocytosis (Doxsey et al., 1987).
Delivery of erythrocyte-encapsulated oligonucleotides complementary to HA
RNA (antisense RNA [see J.J. Toulmé, this volume]) were shown to inhibit HA
biosynthesis by 60% (S. Froshauer, personal communication).
Liposomes have recently been used to introduce biologically active RNA into
cells (Ellens et al., 1989; Glenn et al., in preparation). Following delivery of
messenger RNA encoding an enzyme, target cells expressed 104 molecules per
FIGURE 3. Three strategies that exploit viral fusion proteins for delivery of molecules
into cells. (a) Target cells expressing the viral fusion protein bind delivery vesicles
containing receptors. (b) Intact viruses act as  bridg es' to fuse delivery vesicles to target
cells. The viral fusion protein binds receptors on both target cell and delivery vesicle.
(c) Fusion proteins reconstituted into vesicles (virosomes) containing the molecules to
be delivered bind to target cells containing receptors.
VIRAL MEMBRANE FUSION PROTEINS
127
A B C
Target cell Target cell Target cell
Delivery
Vesicle Virosome
Virus
Delivery
vesicle
cell. If an RNA amplification vector was used (Xiong et al., 1989), expression
levels were increased by two orders of magnitude. Efficient delivery of nucleic
acids into cells should prove useful for expressing foreign proteins, for deliv-
ering antisense RNAs, and for examining the fate and effect of the delivered
oligonucleotides. Finally, a similar approach has been used to implant lipids
into defined domains of the plasma membrane to study the properties of the
tight junction (Vanmeer et al., 1985, 1986).
The results using HA-expressing cells demonstrate the effective use of viral
fusion proteins in the efficient delivery of macromolecules into cells and the
utility of this strategy in studying a wide range of biological problems. The
technique, however, is limited to the use of cells expressing high levels of
fusogenic proteins.
Lipid vesicles containing viral fusion proteins
Viral fusion proteins reconstituted into lipid vesicles (virosomes) have the
potential to serve as universal carriers for delivery of molecules into any cell
containing the appropriate  receptor. Recent advances in solubilization and
reconstitution methodologies have facilitated the development of virosomes
that have fusion properties comparable to those of the intact virions (Metsikko
et al., 1986; Sechoy et al., 1986; Stegmann et al., 1987) (see Table 1).
A potential limiting factor in this strategy is that virosomes made by these
reconstitution procedures are small (70–130 nm in diameter), so the number of
molecules that can be entrapped and subsequently delivered is few. This may
not be a problem if the delivered molecule is effective at low copy number
(Eiklid et al., 1980) or if the effective concentration of a protein can be increased
by delivering RNAs capable  of self replication (Xiong et al., 1989). One
advantage of the small virosomes is that they can be internalized by endocytosis
and are capable of acid-dependent fusion with internal membranes (Stegmann
et al., 1987). Targeting to specific cell types using antibody-bearing liposomes
has met with some success (Loyter et al., 1986; B.T. Rouse, this volume) and
could be applied to virosome technology. These and other results (Celis, 1986;
Loyter et al., 1986) suggest that this approach is feasible and has potential for
the future.
POTENTIAL USE OF VIRUSES
IN THE CHEMOTHERAPY OF TRYPANOSOMES
Although the use of viruses to deliver toxins or drugs to trypanosomes in vivo
is far from a reality, there is potential for such a strategy starting perhaps with
cells in culture. Trypanosomes have been shown to internalize ligands by
receptor-mediated endocytosis (Coppens et al., 1987; Webster and Grab, 1988)
and thus possess the pathway for virus entry (see above). Virosomes could be
targeted to molecules on the parasite cell surface that are invariant among
different strains of trypanosomes and that are internalized along the endocytic
pathway. Molecules that seem to fulfil these criteria have been found in the
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flagellar pocket of trypanosomes, such as the receptors for transferrin and
low-density lipoprotein (Coppens et al., 1987, 1988; Webster and Grab, 1988).
If access through the narrow mouth of the flagellar pocket is a problem
(Coppens et al., 1988), it may be possible to use pH-independent virosomes or
to fuse acid-triggered virosomes at the cell surface by brief acidification of the
extracellular medium in vitro. This approach could prove useful for studying
cell biological problems of trypanosomes and for drug testing.
Since viruses are natural shuttle vectors for transferring their genome into
host cells, they have been exploited as vectors for introducing foreign genes
into cells (Nichols, 1988; Varmus, 1988). This technology could be applied to
the targeting of toxic molecules to trypanosomes by engineering vectors that
contain genes encoding such molecules (Nichols, 1988; Varmus, 1988; Xiong
et al., 1989). Furthermore, vectors could be engineered to contain nucleic acids
that possess trypanosome-specific replication or splicing sites so they would be
replication-competent only in trypanosomes. Vectors have recently been de-
signed that do not produce infective particles, thus confining molecules to the
targeted cells (Varmus, 1988). Although the success of such an approach is
faced with the same difficulties mentioned above and others (Nichols, 1988;
Varmus, 1988), it has potential.
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The site of action for most drugs is a macromolecule, usually a protein but
sometimes a nucleic acid. Our ability to design drugs from first principles is
limited by a poor ability to predict the interaction of macromolecules with other
compounds. A striking exception is the interaction between nucleic acids by
Watson-Crick base pairing which is the best understood and most predictable
mechanism for molecular recognition and binding in biology.
The first demonstration that this property might be a basis to predict thera-
peutically active compounds used an oligonucleotide complementary to Rous
sarcoma virus RNA to inhibit its replication (Zamecnik and Stephenson, 1978).
Messenger RNA (mRNA) can be inactivated similarly to limit gene expression.
Although subsequent work on the therapeutic uses of complementary or `antis-
ense’ oligonucleotides has concentrated on viruses, the approach should be
applicable to other types of infectious agents and to other clinical conditions
where inhibiting the expression of a particular protein might be beneficial. As
the sequence of the antisense oligonucleotides follows from that of the target
RNA, this approach goes a long way towards rational drug design and, provid-
ing the target sequence is unique, should be highly specific.
There are now sufficient examples in the literature to be sure that `hybridi-
zation arrest’ does work in many model situations, but so far there are no
published examples of its successful use in animals and it is not clear whether
the present compounds have sufficient potency for therapeutic application. The
object of the present paper is to consider the factors that determine the activity
of antisense oligonucleotides and how they may be modified to increase their
therapeutic potential. Reference to the original literature may be obtained in two
recent reviews (Stein and Cohen, 1988; Goodchild, in press).
Oligonucleotides may be grouped into three categories according to their
mechanism of action.
Passive oligonucleotides are conceptually the simplest but mechanistically
may be the most diverse and the least understood. When hybridized to strategic
regions of a messenger or viral RNA, they are presumed to block the action of
ribosomes, spliceosomes and various enzymes or other factors that read or
interact with the RNA. In mRNA, the capped end and AUG initiator codon are
generally the most effective sites. For reasons that will be discussed later, the
phosphate groups are often modified as shown in Figure 1.
Reactive oligonucleotides carry a group such as an alkylating agent or free
radical generator to cross-link or cleave the RNA irreversibly (Knorre and
Vlassov, 1985). Little work has been reported on hybridization arrest with these
derivatives. They may have advantage if activity is limited by dissociation of
the RNA/oligonucleotide hybrid but are likely to be more toxic. The binding
site on RNA is less critical with this category and the next than with the first.
Activating oligonucleotides also lead to irreversible damage to the target
RNA but do so by activating endogenous host cell factors such as ribonuclease
H that cleaves the RNA strand of RNA/oligodeoxynucleotide complexes. This
approach is limited in applicability by the requirement for the appropriate
ribonuclease but it has been claimed that this is widespread. An advantage of
this mechanism is that the oligomer is not degraded by ribonuclease H and so
 cat alyses' the cleavage of more than one equivalent of RNA whereas the
chemically reactive oligonucleotides behave stoichiometrically. Ribonuclease
H will accept phosphorothioate groups in the deoxy strand but not methylphos-
phonates and so the possibilities for modification are more limited in this case.
The activity of an oligonucleotide should be governed largely by its ability
to form the desired hybrid in the target cell. This will depend on chemical and
biological properties of the oligomer as well as the nature and accessibility of
the target sequence.
Factors known to promote hybridization also increase antisense activity.
These include increasing the length of the oligonucleotide, increasing the G–C
content, attaching intercalating groups to shorter oligonucleotides or perform-
ing the assay at lower temperatures. In vitro, preannealing to the target RNA is
generally not necessary for oligomers of chain length 15–20, which is encour-
aging for their use in vivo. Secondary structure within the target RNA can
sometimes inhibit binding but usually only in the case of very stable structures
or poorly binding oligomers.
The oligonucleotide must be long enough to differentiate between RNA
molecules but the chance of forming undesired complexes will also increase
with length. A reasonable compromise is 12–20 nucleotides. Activity generally
increases with length over this range, but to minimize the mass and cost of
material for a therapeutic dose, the chain length should be as short as possible.
FIGURE 1. Internucleoside phosphate modifications used in antisense oligonu-
cleotides. I: unmodified phosphodiester, II: methylphosphonate, III: phosphorothioate,
IV: phosphoramidates.
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Oligonucleotides probably enter cells by both pinocytosis and a cell surface
protein-mediated mechanism. In culture, the intracellular concentration typi-
cally rises to about 10% of that in the medium. Degradation appears to be mainly
by exonucleases and can take from less than 10 minutes to over 24 hours,
depending on the cell. In attempts to increase cellular uptake, molecules are
made more lipophilic with substituents that are either added to the ends or
positioned so as to remove the negative charge from the internucleoside phos-
phates, such as the methylphosphonates introduced by Miller and Ts’o. These
and other modifications to the internucleoside phosphates (shown in Figure 1)
also increase resistance to degradation by nucleases. All of these phosphate
modifications considerably increased activity against human immunodefi-
ciency virus to give complete inhibition of replication at concentrations around
3 µM (Agrawal et al., 1988; Sarin et al., 1988). These derivatives are about as
active in molar terms as AZT but have much larger molecular weights and so
may require larger masses for therapeutic doses.
Of importance for any therapeutic potential are the questions of toxicity and
bioavailability. Even unmodified oligomers were found to be fairly stable at
37 C in whole blood from humans or rabbits. There was no sign of degradation
in 2 hours and substantial amounts of starting material were left after 24 hours.
After intravenous injection of labelled material to rabbits, clearance from the
blood was rapid and label was found distributed fairly evenly in the organs
where it was apparently degraded quite rapidly. After 2 hours, about 20% of the
oligomer was found in the urine still largely intact.
In mice, unmodified oligonucleotides as well as all those modified as shown
in Figure 1 were found to have an LD50 of about 160 mg/kg body weight. Rats
were more resistant.
There are probably three major problems that must be overcome for these
compounds to be used clinically.
• Activity must be sufficient that the required mass of these high molecular
weight compounds does not become excessive. It remains to be seen whether
any of the compounds under investigation are sufficiently active or whether
it will be necessary to develop further generations.
• Present solid support synthetic methods are rapid and highly efficient but the
cost of these compounds is high due to the cost of starting materials. Cur-
rently, the cost for in-house syntheses on the gram scale is estimated at about
US$4 per mg but this has been forecast to fall to US$0.04 over the next 5
years by a company involved in their production.
• Renal excretion is very fast. It was recently reported by J. Walder at a meeting
that this could be decreased considerably by covalent attachment of choles-
terol.
It is encouraging for therapeutic considerations that several diverse chemical
modifications have resulted in increased activity that may make it possible to
tailor these agents to the pharmaceutical requirements. For the goal of rational
drug design, a mechanism of molecular recognition as predictable as Watson-
Crick base pairing is certainly an appealing starting point.
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INTRODUCTION TO HYBRID-ARRESTED TRANSLATION
The formation of nucleic acid/nucleic acid complexes, based on the formation
of double-stranded structures through hydrogen bonds between complementary
nucleic acid bases, is highly specific. The association of a messenger RNA
(mRNA) with a complementary DNA strand can block its translation. This was
first used for gene identification (Paterson et al., 1977). It was also demon-
strated that some prokaryotic genes were regulated by a similar mechanism:
transcripts complementary to part of a mRNA (so-called antisense RNA)
formed duplexes that prevented the synthesis of the encoded protein (Simons,
1988). The expression of numerous genes was then specifically turned off by
artificial antisense  RNAs  equally  well  in  prokaryotic and eukaryotic cells
(Green et al., 1986).
Initially, it was proposed that antisense RNA (DNA) could act as a block to
ribosome scanning or to ribosomal subunit binding. Subsequently, it was
reported that only antisense molecules targeted to the 5’ region of the mRNA
(from the cap to the AUG initiation codon) were able to inhibit translation,
owing to an unwinding activity associated with elongating ribosomes (Melton,
1985; Shakin and Liebhaber, 1986). However, in a few cases, antisenses
complementary to the region downstream of the AUG induced specific inhibi-
tion of protein synthesis concomitant with a decrease of the target mRNA
concentration.  It was demonstrated that the regulation  of  the CII  gene of
bacteriophage λ by the antisense OOP RNA was due to the specific degradation
of the RNA/RNA hybrid by Escherichia coli RNase-III (Krinke and Wulff,
1987). In wheat germ extracts and in injected Xenopus oocytes, RNase-H, an
RNase that cleaves the RNA part of RNA/DNA hybrids, was shown to be
responsible for the degradation of the target mRNA when antisense DNA was
used (Cazenave et al., 1987).
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Synthetic oligonucleotides (oligos) are now easily available. Antisense oligos
were successfully used in cell-free extracts, in micro-injected cells and in
cultured cells (Toulmé and Hélène, 1988). However, their sensitivity to DNases
and their limited uptake by intact cells led to the development of chemically
modified analogues. A number of criteria should be fulfilled to tailor an
antisense oligo (see Table 1).
The specificity of the recognition of the mRNA target is due mainly to the
length of the oligo: in a human cell, a single site will be hit by an oligomer 11–15
nucleotides long, depending on the sequence. The higher the affinity of the
antisense oligomer for the complementary mRNA, the greater the efficiency of
competition with the translational machinery. Lengthening the oligo results in
increased affinity; however, this also reduces the uptake and can affect the
specificity. Alternatively, removal of negative charges in the phosphate back-
bone or linkage to groups that will provide additional energy of interaction
TABLE 1. Criteria and chemical modifications for the design of synthetic antisense
oligonucleotides.
Problems
Specificity (Target recognition)
Affinity (Competition with ribosomes, . . .)
Stability (Degradation by nucleases)
RNase-H induction (mRNA cleavage)
Uptake (Membrane penetration, endocytosis)
Toxicity (Non-specific binding, mutagenicity, carcinogenicity)
Possible solutions
Length
Modified bases
Modified backbone
Intercalating agents
Active groups
Phosphotriesters
Alkylphosphonates
a-oligome rs
Phosphorothioates
Phosphorodithioates
Phosphodie ster
Phosphorothioate
Length/Charges
Hydrophobic groups
Polycations (poly-Lysine)
Lipoproteins
Liposomes
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results in derivatives of higher affinity. An example of such molecules is
provided by oligomers linked to intercalating agents (see below). A number of
chemical modifications have been proposed to overcome the sensitivity of the
natural oligomers to nuclease attack (see Table 1). Unfortunately, some of these
modifications led to inactive antisense oligomers: α-oligomers did not prevent
polypeptide chain elongation, although they did bind to the target sequence with
good affinity, because α-DNA/RNA hybrids are not recognized as substrates
by RNase-H.
One way to increase the efficiency of the antisense molecules is to promote
their uptake by intact cells in order to increase their intracellular concentration.
Neutral derivatives are taken up more efficiently than negatively charged
molecules (see J. Goodchild et al., this volume). In contrast, phosphorothioate
oligomers are trapped in the plasma membrane and penetrate cells very slowly
(Boiziau et al., unpublished results). Linking oligos to a polycation led to
compounds that exhibited anti-viral properties in the nanomolar range (Lemai-
tre et al., 1987). Liposome encapsulation also led to improved uptake (Loke et
al., 1988). Toxicity should be considered: most of the oligos exhibit sequence-
independent inhibition at high concentrations. This is well documented for
phosphorothioate (Cazenave et al., 1989), acridine-linked oligos (Cazenave et
al., 1987) and poly-(L)-lysine conjugates (Lemaitre et al., 1987). However,
toxic doses are at least 100-fold higher than that required for specific inhibition.
Cytotoxic concentrations depend on the oligomer length and sequence. With a
view to therapeutic use, unmodified and phosphorothioate 20-mers were in-
jected into mice: no effect was observed for up to 14 days at a dose of 40 mg/kg
(Agrawal et al., 1988; Sarin et al., 1988).
THE MINI-EXON SEQUENCE:
A TARGET FOR ANTISENSE OLIGONUCLEOTIDES
In trypanosomes and related parasites, gene expression involves discontinuous
transcription followed by trans-splicing of a so-called mini-exon-derived RNA
onto the major exon, giving rise to a sequence, thirty-five nucleotides long in
Trypanosoma brucei, common to all mRNAs (Borst, 1986). Targeting this
region with antisense oligos resulted in decreased, or even abolished, in vitro
translation of T. brucei mRNA (Cornelissen et al., 1986; Walder et al., 1986).
Oligonucleotides linked to intercalating agents
Oligos linked to an acridine derivative (2-methoxy, 6-chloro, 9-amino acridine)
through a pentamethylene linker were shown to bind complementary RNA with
a higher affinity than homologous unmodified ones (Toulmé et al., 1986). This
was ascribed to stacking interactions between the dye and base pairs of the
oligo/RNA duplex. Such modified oligomers, complementary to the T. brucei
mini-exon sequence, were used both in cell-free systems and with procyclic
trypanosomes in culture.
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Effect on in vitro translation. A complementary 9-mer linked at its 3 end to the
acridine derivative (Acr-9Tb) was a more efficient inhibitor of translation in
rabbit reticulocyte lysate than the homologous conventional 9-mer, 9Tb, or even
than an unmodified 12-mer (Verspieren et al., 1987). The inhibition was
specific: this oligomer had no effect on translation of Brome Mosaic Virus
mRNA which do not contain the complementary sequence (Verspieren et al.,
1988). In contrast, a complementary acridine-linked 6-mer (Acr-6Tb) induced
no significant decrease of T. brucei protein synthesis.
Trypanocidal activity. Addition of 100 µM Acr-9Tb to procyclic T. brucei
induced drastic changes in both the morphology and the motility of the parasites,
ultimately leading to cell death. This effect was not seen either with Acr-6Tb
or with non-complementary acridine-linked oligomers. The unmodified 9Tb
had no effect (Verspieren et al., 1987). Therefore, the trypanocidal activity of
Acr-9Tb is due to the presence of a complementary sequence and of the acridine
residue. This suggests that this activity arises from the formation of a specific
complex with the mini-exon sequence. Besides increasing the affinity of the
oligo for the target RNA, acridine was responsible for a longer lifetime of the
molecule in the growth medium because it prevented it being degraded by 3’
exonucleases. Moreover, the kinetics of uptake of Acr-9Tb were quicker than
that of 9Tb (J.J. Toulmé, unpublished results).
Optimization of the target
The inhibitory properties of antisense oligomers depend on the concentration
of the oligo/RNA complex. This will be affected by chemical and physical
characteristics of the oligomer (affinity, stability, uptake; see Table 1). It will
also be affected by factors concerned with the RNA itself. Due to peculiarities
(access and structure), not all the targets are expected to lead to equivalent
inhibitory effects. We performed a detailed study on a series of unmodified
oligos, 9 to 35  nucleotides long,  complementary to T. brucei or T.  vivax
mini-exon sequences (Verspieren et al., manuscript in preparation). On the one
hand, we measured their affinity for RNA by thermal elution of filter-bound
complexes, characterized by Tc, the temperature corresponding to the mid-point
transition. On the other hand, we determined their effect on protein synthesis
in cell-free systems. For most of the oligos, Tc was related to their length, l, and
to their G + C content, x. The amplitude of the protein synthesis inhibition, at
a given oligonucleotide concentration, increased with (l + x) (Figure 1). How-
ever, a few oligomers had a low Tc as compared to ones for which the value of
(1 + x) was similar. This resulted in a reduced antisense effect (Verspieren et
al., unpublished results). All these oligomers were targeted to the 5’ end of the
mini-exon sequence, that is, a region containing modified nucleic acid bases
(Freistadt et al., 1987). In particular, the presence of a modified adenine residue
in the sixth position of the T. brucei mini-exon sequence did not allow efficient
pairing of the opposite thymine, resulting in a weak complex. This was also
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FIGURE 1. Effect of complementary oligodeoxynucleotides on in vitro translation of
Trypanosoma brucei RNA. Total RNAs, extracted from parasites (MITat 1.5; clone
118) grown in mice, were translated in wheat germ extract containing 35S-methionine
in the presence of the indicated oligonucleotide (synthesized on an Applied Biosystems
synthesizer, USA, and purified by high-performance liquid chromatography). Protein
synthesis was quantitated by trichloroacetic acid precipitation and liquid scintillation
counting. Oligonucleotide sequences are given at the bottom of the figure.
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observed with T. vivax RNA, suggesting the presence of modified bases in the
mini-exon of this parasite as well.
TOWARDS ANTISENSE OLIGONUCLEOTIDES OF
IMPROVED EFFICIENCY
The trypanocidal activity of Acr-9Tb was observed only at concentrations
higher than 80 m M. Although the acridine derivative prevented attack by 3'
exonucleases, the phosphodiester backbone could be cleaved by endonucleases.
Efficiency of antisense oligos would be improved if analogues resistant to
nuclease degradation were used. For this purpose, we focused on two different
chemical modifications: phosphorothioate derivatives and a -oligomers (Figure
2). A 17-mer targeted to the coding region of the rabbit ß-globin gene did not
block elongation of the polypeptide chain when the a -analogue (17 a ) was used,
whereas the phosphorothioate congener (17PS) was as efficient as the unmodi-
fied 17-mer (17PO) in wheat germ extracts and more efficient in micro-injected
Xenopus oocytes (Cazenave et al., 1989). These results were explained by the
FIGURE 2. Chemical structure of phosphodiester (top), phosphorothioate (middle) and
a -nucleotide units (bottom).
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long life-time of 17PS as compared to 17PO and the failure of 17α to induce
RNase-H activity.
Modified oligos (α- and phosphorothioate) complementary to the mini-exon
of T. brucei were synthesized. An α-11-mer did not inhibit in vitro translation.
This oligo might bind very weakly, as we failed to detect any signal by thermal
elution of filter-bound complexes. Preliminary experiments performed with
phosphorothioate derivatives (12- and 24-mers) did not indicate a trypanocidal
activity of these oligos below 30 µM, the concentration at which a non-specific
toxicity was observed. Therefore, these modifications did not result in the
expected improvement.
However, recently we demonstrated that an α-16-mer, linked to an acridine
derivative, complementary to the AUG region of the rabbit β-globin gene,
induced a specific inhibition of globin synthesis by a mechanism that remains
to be determined (Boiziau et al., unpublished results). Therefore, it seems that
more efficient antisense oligos could be obtained by introduction of multiple
chemical modifications within the same molecule. In particular, linkage of
cleaving (Verspieren et al., 1988) or photo-crosslinking reagents (Kean et al.,
1988) to antisense oligos could lead to molecules that will permanently block
translation of the target gene.
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Morogoro, Tanzania
Animal trypanosomiasis is one of the most important diseases hindering live-
stock production in Tanzania, where 60% of the country is occupied by savan-
nah tsetse flies. Control methods include attack on the vector by insecticide
application and/or selective bush clearance, and use of trypanocidal drugs for
curative and prophylactic purposes. However, increasing costs of vector-control
methods and fear of the deleterious environmental impact as a result of using
these methods have led to increasing reliance on chemotherapy for the control
of trypanosomiasis.
Drug resistance is one of the most important problems when using chemo-
therapy to combat trypanosomiasis, since the number of drugs available for field
use has remained limited. Monitoring the development of drug resistance is
therefore important in trypanosomiasis control strategies relying on chemo-
therapy.
The author has been involved in studies on chemotherapy for trypanosomi-
asis at the Central Veterinary Laboratory, Temeke, Dar es Salaam; the Centre
for Tropical Veterinary Medicine, Edinburgh, Scotland; and Sokoine University
of Agriculture, Morogoro, Tanzania.
At the Central Veterinary Laboratory we are interested in determining
whether diminazene aceturate can retain efficacy when used over a prolonged
period. This is a continuation of work started by E. Wiesenhutter on dairy farms
in and around Dar es Salaam during the late 1960s. We found that diminazene
aceturate appeared to induce no drug resistance even after many years of regular
use on one particular dairy farm. However, surveillance of drug resistance in
other areas of the country revealed cases of diminazene resistance.
At the Centre for Tropical Veterinary Medicine, studies were carried out using
rabbits to determine the efficacy of treating animals with diminazene aceturate
at different stages of cyclically transmitted Trypanosoma congolense infections.
It was shown that relapse infections occurred in some animals treated 8–10 days
post-infection, when trypanosomal chancres were at their largest. The reason for
the relapses and the relevance of this finding to bovine trypanosomiasis in the
field need to be determined. Studies were also carried out on isometamidium
prophylaxis in rabbits. These studies showed that the duration of prophylaxis
appeared not to depend on the number of infective tsetse bites.
The chemotherapy studies at Sokoine University have two goals: to isolate
putative drug-resistant T. congolense stocks from the field and establish their
sensitivities to diminazene aceturate and isometamidium chloride, and their
pathogenicity. Studies have also been conducted with certain stocks on the
stability of resistance. We found that drug resistance can be stable. For example,
T. congolense ADRI was resistant to 70 mg/kg diminazene aceturate in mice
and maintained this level of resistance after 50 passages in mice.
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Reports have shown that trypanosomes readily take up exogenous 1-acyl-sn-
lyso-phosphatidylcholine (LPHChO) and rapidly hydrolyze it through endo-
genous phospholipase A1 to form free fatty acids and glycerophosphocholine.
At the same time there is a rapid transacetylation of the LPHChO by trypanoso-
mal acyltransferase to form PHChO, which is incorporated into the membrane
of the parasite. These two enzyme systems enable the trypanosome to acquire
the bulk of its fatty acids and choline requirements by exogenous LPHChO.
Thus, if an unusual fatty acid can be incorporated into the LPHChO, the effect
on the trypanosome may be therapeutically beneficial.
Trypanosoma brucei brucei (5× 106/ml) were preincubated in filter-sterilized
modified Eagle’s 199 culture medium supplemented with 0.2 mM mercap-
toethanol, 2 mM pyruvate, 0.01 mM hypoxanthine and 1% essential amino
acids, in an atmosphere of 5% CO2 - 95% air at 37 C for 1 hour. Various
concentrations of the fatty acids were added to the medium and incubated for
another 1 hour. Trypanosome viability was determined by counting the number
of motile parasites using a Neubauer haemocytometer. The EC50 for each
compound, defined as the concentration of the drug that reduces parasite
motility to 50% after one hour’s exposure, was calculated. In a further study
using the more toxic fatty acids and LPHChO derivatives, time-dependent
experiments were performed using the medium supplemented with 15% v/v
horse serum.
Among the C20 polyunsaturated fatty acids, arachidonate (C20:4[n-6]) was
the least toxic tested. The acetylenic analogue, eicosatraynoate, which is a
potent inhibitor of arachidonate metabolism at the level of cyclo-oxygenase and
lypoxygenase, had less effect than arachidonate. On the other hand, eicosapen-
taenoic acid (C20:5[n-3]), which is also an inhibitor of arachidonate metabolism
via the cyclo-oxygenase pathway, showed a marked effect on trypanosome
viability. A similar trypanocidal effect was seen for C20:3(n-3) against C20:3(n-
6). Trypanocidal effects of the n-3 polyunsaturated fatty acids were also ob-
served for the C22 unsaturated fatty acids. Similar toxicities were observed for
the corresponding methyl esters, thus suggesting that the trypanocidal action
could not be accounted for by the detergent-like nature of the fatty acids since
the methyl esters do not have polar heads. The pattern of toxicity may be related
to preferential uptake of polyunsaturated fatty acids between the n-3 and n-6
series. The results with the n-3 LPHChO compounds showed that they also were
potent trypanocides. When the LPHChO of the n-3 series were tested in medium
supplemented with horse serum, the parasites died.
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in a peasant farming community of
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E. Mamo
Institute of Pathobiology
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Addis Ababa, Ethiopia
Large numbers of families have been moved from northern Ethiopia to tsetse-
infested areas of southwestern Ethiopia. Most of the new settlements, as well
as the resident population, cannot undertake viable animal production, mainly
due to health problems. Meat and milk supply is severely short.
The principal animal health problems are trypanosomiasis, tick-borne dis-
eases, fascioliasis and gastrointestinal parasites. There is, in addition, a serious
shortage of feed during the dry season (7–8 months per year), during which
productivity is reported to fall sharply. Hence there is a need to tackle this aspect
along with health-related activities.
The objectives of a proposed project involving Ethiopian universities, the
Ministry of Agriculture  and the Institute of Agricultural Research include
controlling major health problems of farm animals, tackling the dry-season
shortage of feed and improving the general productivity of the animals. The
general strategy that will be adopted is to select communities for new settlers
or local population settlements and to take full responsibility in these commu-
nities for animal health and production parameters.
A source of funds has not yet been identified for this project but there is a
possibility of obtaining financial support from the government and/or one or
more non-governmental agencies. Involvement of bilateral and multilateral
organizations as well as other outside sources would help project members
obtain materials and supplies not available within the country. We hope to
commence the project within the coming year.
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Over the last four years, research on anti-trypanosomal drugs in the Department
of Veterinary Pharmacology at Glasgow University has focused primarily on
isometamidium chloride (Samorin®). This is due to the drug’s apparent supe-
riority in both therapeutic and prophylactic treatments for bovine trypanosomi-
asis. The aspects that we have examined include:
• pharmacokinetics of isometamidium in cattle using high-performance liquid
chromatographic and radioimmunoassay techniques
• adverse reactions, particularly tissue damage in cattle
• toxicological potential of isometamidium residues in edible tissues
The data we have obtained are not sufficient to confirm that isometamidium
residues in edible tissues are not toxic in humans. To obtain more information,
particularly on the molecular mechanisms of toxicity, we are evaluating the
mutagenic potential of isometamidium and other anti-trypanosomal drugs cur-
rently used. We are using bacteria/mammalian microsome tests, incorporating
four strains of Salmonella typhimurium and one strain of Escherichia coli. We
are also evaluating the extent to which isometamidium is excreted in milk of
treated goats and hope to extend these experiments to cattle. In the light of a
recent report that the drug was effective in controlling an outbreak of try-
panosomiasis in pigs at a dose that in other animal species would be lethal (15
mg/kg), we are examining the kinetics of isometamidium in pigs. Finally, we
are attempting to improve the sensitivity and specificity of the current analytical
methods for use in detailed pharmacokinetic and toxicological studies. We hope
that the kinetic and toxicological data obtained will help researchers improve
dosing regimens and assess the risk associated with isometamidium residues in
edible tissues.
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Over the last fifteen years, members of the Department of Veterinary Physiol-
ogy and Pharmacology at the University of Ibadan have been studying aspects
of chemotherapy for animal trypanosomiasis caused by Trypanosoma vivax, T.
congolense and T. brucei. We have carried out studies on the pharmacology of
the currently used veterinary trypanocides, on drug combinations and on the
physiological and trypanocidal effects of local herbal extracts and other agents.
Results of one study showed that the responses to trypanocidal therapy of
two strains of T. vivax (Y58 and Y486) isolated by Leeflang et al. (1976)
differed between themselves (Arowolo and Ikede, 1977, 1980; Arowolo, 1988)
and differed from the response of T. brucei 8/18 in sheep and laboratory rodents.
The use of isometamidium chloride or diminazene aceturate in combination
with α-chlorohydrin (an anti-fertility agent) or its analogue was less efficacious
than the use of trypanocides alone. Similar results were produced using a
combination of salicylhydroxamic acid or glycerol with the above trypanocides
(Arowolo and Uche, 1988). In a few cases these combinations produced toxic
manifestations in the host. Alpha-chlorohydrin, although effective in vitro
against T. vivax Y58, was ineffective in vivo in trypanosome-infected animals
(Arowolo and Heath, 1979).
A study on the chemoprophylactic effects of isometamidium chloride and its
dextran complex in goats experimentally infected with T. congolense indicated
that at a dose of 0.2 mg/kg body weight, no significant prophylaxis was
produced by either preparation. However, use of the dextran complex resulted
in the longest prepatent period and a  relatively insignificant parasitaemia.
Results from this chemoprophylactic study differed from those of a study by
James using rats (1978).
Working on the principle that a chemotherapeutic study is incomplete with-
out a pharmacodynamic study (Albert, 1963), the pharmacodynamic activities
of diminazene, homidium and isometamidium were assessed in animal tissues
in vivo and in vitro. Results from in vitro studies showed that diminazene,
homidium and low concentrations of isometamidium were anti-cholinergic and
anti-histaminic while higher concentrations of isometamidium augmented
cholinergic and anti-histaminic activities. Both homidium and isometamidium
showed anti-adrenaline and anti-serotonin effects while diminazene enhanced
both adrenaline and serotonin (Arowolo and Eyre, 1984). The three trypano-
cides blocked neuromuscular transmission in rats while diminazene (0.4–0.8
mg/ml) depressed rat blood pressure in a dose-dependent manner. In vivo, at a
dose of 3.5 mg/kg body weight, diminazene prolonged the recovery of dogs and
laboratory rodents from thiopental anaesthesia. The same dose of diminazene
also cured and protected infected rats from the deleterious and fluctuating
effects of the parasites on blood pressure. Therapeutic doses of diminazene also
improved depressed liver function in rabbits experimentally infected with T.
brucei (Arowolo et al., 1988).
Further pharmacological studies on currently available drugs and on use of
existing anti-parasitic agents are in progress. Work on herbal extracts is still
preliminary. Epidemiological studies on causes of drug resistance are being
proposed. Our laboratory seeks international and external support and collabo-
ration in its various research activities.
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Chemotherapy at the Kenya
Trypanosomiasis Research Institute
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Kenya Trypanosomiasis Research Institute
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The treatment of trypanosomiasis. both in domestic stock and in human patients,
has been central to the development of the Kenya Trypanosomiasis Research
Institute (KETRI) during the first ten years of its existence. Improved methods
of use for the established human and animal trypanocides, none of which is less
than 35 years old, revised treatment protocols and novel compounds have each
received attention. This program was initiated by a small number of Kenyan
staff who had been compelled to leave the East African Trypanosomiasis
Research Organisation, in Tororo, Uganda, when the responsibility for research
institutes, previously held by the East African Community, devolved to the
individual states of Kenya, Uganda and Tanzania in 1977. This group set out to
create an institute from scratch for which finance, physical facilities, equipment
and staff would be needed. Now, thirty Kenyan scientists work in a modem
purpose-built institute at Muguga, Kenya.
A field station, consisting of staff housing and a laboratory, to study and test
practical and economically viable systems of prophylaxis and treatment in
animals, especially in cattle, camels and goats, was set up for KETRI with
encouragement and assistance from Galana Game and Ranching Ltd. This
station has been staffed for more than ten years by a KETRI team composed of
a senior field officer, an entomologist, a veterinarian, senior supervisory scien-
tists and support staff. The vast area of the ranch (6000 km*), the large cattle
population (25,000 head), a large camel herd (200 ad) and the varied ecolog-
ical zones and weather patterns provided an excellent opportunity to investigate
large-scale livestock management under different levels of tsetse and trypano-
somiasis challenge. Also, in addition to a long-term assessment of tsetse fly
dynamics on the ranch, it was possible to determine the prophylactic needs of
cattle kept in areas in which tsetse fly populations were reduced by odour-baited
insecticide-impregnated targets, or by pour-on insecticides applied to cattle.
The numerous supporters of this long-term series of programs include the Ranch
itself, the Kenya Government, the Overseas Development Administration
(ODA) of the United Kingdom, RMB (Rhone Poulenc Kenya), Bayer East
Africa, Camco and Wellcome Kenya.
Through the Galana connection, KETRI has identified a race of East African
Zebu, the Orma Boran, that exhibit valuable qualities of trypanotolerance. Their
-
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prophylactic needs under medium to heavy trypanosome challenge were found
to be half of those required to protect the improved Boran cattle.
Under these ideal conditions for field experiments, strategies for prophylactic
treatment of cattle exposed to trypanosome challenge were developed and tested
over many years at Galana Ranch, where management standards were high. A
similar system is now under scrutiny at an area of pastoral management and
group ranching systems at Nguruman, funded and staffed by ODA. Such
methods have resulted in considerable savings on trypanocidal drugs for the
livestock producer. (For Galana Ranch, at 1984 prices, the savings were esti-
mated to be US$ 60,000 per year.) A similar approach has resulted in the
development of treatment and prophylactic strategies applicable to camels
infected with Trypanosoma evansi. This research was conducted on camel herds
in northern Kenya in association with a program of the Kenya Arid Lands
Research Station and was funded by RMB (May & Baker, UK). Such systems
are now being disseminated by the use of residential demonstration herds under
the auspices of a non-governmental charity organization (FARM Africa).
A laboratory has been set up to permit research and development of
trypanocidal drugs by Rhone Merieux. A new product, cymelarsan, to treat T.
evansi in camels is in the final stages of development. New formulations of
isometamidium are also being tested.
The fate of trypanocides in body fluids and in tissues can be examined by
both radiolabelled and non-radioactive methods. These methods have been
developed to investigate whether drug use can be improved through more
detailed understanding of the drug’s pharmacokinetics, and also to determine
the safety of these compounds in food products. For these studies, KETRI’s
metabolic stanchions can accommodate up to sixteen adult cattle. These first-
class facilities have been built with funds from the Italian Government through
a division run jointly by the Food and Agriculture Organization and the Inter-
national Atomic Energy Agency. Studies are also conducted on other animal
species and on cattle in the field under tsetse challenge. In addition, new
compounds have been tested in cattle under experimental conditions in the
laboratory and in the field.
The human sleeping sickness treatment centre at Alupe Hospital provides
facilities for patients and conducts surveillance and long-term follow-up of
treated cases that originate from the endemic areas around Lake Victoria in
Kenya and from neighbouring countries. There has been a constant flow of
cases, occasionally reaching epidemic proportions. At Alupe there are staff and
equipment to collect detailed clinical data before, during and after treatment.
New therapeutic agents and regimens are tested in clinical trials at this centre
when patients do not respond to treatment with melarsoprol.
Screening novel compounds for trypanocidal activity and combinations of
the established drugs is conducted in culture, rodents and in monkey models of
the human disease. This program incorporates aspects of work from different
units within KETRI and functions in collaboration with other institutions, both
in Kenya and overseas.
The United Nations Development Programme/World Bank/World Health
Organization Special Programme for Research and Training in Tropical Dis-
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eases has concentrated on the development and use of animal models at KETRI
for screening some 100 compounds in mice infected with T. brucei. It has also
concentrated on treatment trials in a vervet monkey model of T. rhodesi nse
infection, which closely mimics the disease in man. Two hundred and forty
treatment courses have now been administered to primates, the majority of
which were in the late encephalitic stage of the disease. A monkey model of T.
gambiense is being developed.
Trypanosome culture systems have been established with funds from ODA
to enable researchers to study drug activity and to screen T. congolense  isolates
from the field for their level of drug resistance. Similar culture systems have
also been developed for T. brucei, T. evansi and T. simiae. The latter program
is backed by the Free University of Berlin. T. rhodesiense culture has also been
established in collaboration with New York University and Pace University,
funded by a PSTC project of the United States Agency for International
Development. Combined therapies involving DL-a-difluoromethylomithine
(DEMO), melarsoprol, suramin and ifurtimox are being studied in culture,
mice and monkeys inoculated with T. rhodesiense. From the primate studies,
the value of combination therapy was confirmed and the difficulty of treating
certain isolates of T. rhodesiense with orally administered DFMO became
apparent. Apart from drug evaluation and screening procedures, these systems
enable researchers to investigate the mechanisms of action and the metabolic
pathways of certain drugs and their metabolites. Thus, a group of new com-
pounds was found to be active against T. brucei at the Walter Reed Army
Institute for Research. Five of these were evaluated at KETRI with funding from
the United States Medical Research Unit in Kenya and have shown promise in
mice. They will later be tested in primates.
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of diminazene in Trypanosoma congolense-
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Ahmadu Bello University
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Diminazene is a widely used anti-trypanosomal and anti-babesial drug for
which pharmacokinetic data have been determined in goats (Aliu et al., 1984)
and sheep (Aliu and Odegaard, 1985). The range of therapeutic or trypanocidal
plasma levels of diminazene is not known, but doses of 1.0-3.5 mg/kg are
considered curative, while an in vitro concentration of 0.5 µg/ml is trypanocidal
and a feed containing 0.1 µg/ml will eliminate trypanosome infections in tsetse
flies (Hawking, 1963).
Results of pharmacokinetic studies of drugs with half-lives greater than 9 hours
suggested to Baggot (1978) that relatively low multiple doses at appropriate time
intervals are more likely than singlelarge doses to maintain therapeutic blood levels
for a relatively long period and to yield a higher degree of clinical effectiveness.
In goats, diminazene aceturate (Berenil) was found to have a systemic availability
of 50%; a half-life of 21 hours following intramuscular administration of 3.5
mg/kg; and to maintain a trypanocidal plasma concentration for 35.3 hours. Renal
clearance, 0.072 ml/kg/min, accounted for only 11% of total body clearance and
approximately 0.14% was excreted unchanged in milk following an intravenous
dose of 2.0 mg./kg. In sheep, however, after an intramuscular dose of 3.5 mg/kg of
diminazene diaceturate (Ganaseg®), the drug had a systemic availability of 95%.
half-life was 11.5 hours and the total body clearance was 0.89 ml/kg/min.
The objectives of studies to be carried out soon at the International Laboratory
for Research on Animal Diseases (Nairobi) include determination of the phar-
macokinetics and urinary excretion of diminazene aceturate in Zebu cattle and
the efficacy of various Berenil® therapeutic protocols in treating Trypanosoma
Congolense infections in goats that are resistant o diminazene.  - _ _
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An experimental study was conducted in Indonesia using mice to determine the
responses of 27 Trypanosoma  evansi  stocks, isolated in different parts of
Indonesia, to suramin, isometamidium chloride, diminazene aceturate and
quinapyramine sulphate. Mice were inoculated with 1 0 trypanosomes and
treatments administered 24 hours later. Suramin was the most effective of these
drugs: parasites disappeared from the circulation within 48 hours following
treatment. Isometamidium chloride did not effectively control the infections and
most of the mice died with fulminating parasitaemias. Diminazene aceturate
and quinapyramine sulphate were only partially effective. Although not all
isolates of T. evansi  tested were susceptible to suramin, this drug probably
remains the treatment of choice in Indonesia.
WORKSHOP
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Workshop summary
S.L. Croft
London School of Hygiene and Tropical Medicine
Keppel Street
London WClE 7HT, UK
To summarize effectively a meeting in which 20 papers have reviewed widely
different areas of the chemotherapy of African trypanosomes, several other
parasitic protozoa and some aspects of cancer is not possible without greatly
detracting from the substance of the many excellent presentations. A few
general impressions remain.
The first part of the workshop, on trypanosome metabolism, clearly indicated
how our improved understanding of biochemical pathways can lead to the
identification of new targets and the design of new drugs. Some selectively toxic
inhibitors have already been identified, although the new tools for rational
chemotherapy-molecular biology, which can be harnessed to produce pure
parasite protein, and X-ray crystallography and NMR (nuclear magnetic reso-
nance), which can define protein structure-have yet to be fully exploited.
Many of the current lead compounds, for example the pyrazolopyrimidines and
sterol synthesis inhibitors, were identified by a mixture of serendipity, intuition
and an awareness of research in other fields, where an observation on the
activity of one compound prompted a question which in turn led to a rational
examination of related compounds. Because of differences in enzyme structure
(e.g., dihydrofolate reductase), rate of enzyme turnover (e.g., omithine decar-
boxylase), subcellular localization (e.g., glycosome) or molecule (e.g.,
trypanothione), the targets for selective toxicity may vary. Yet these targets are
frequently on pathways that interlink, suggesting possibilities for combination
therapy, a strategy important for enhancing drug potency as well as circumvent-
ing resistance. It is evident from the workshop and from the current scientific
literature that most of these studies have concentrated upon Trypanosoma
brucei  species and that knowledge of similar pathways in T. vivax, T. congolense
and other trypanosome species pathogenic for domestic livestock lags behind.
The mechanisms of drug resistance and cross-resistance in African trypano-
somes are poorly understood. However, the use of molecular and biochemical
techniques to study drug resistance in tumour cells and Plusmodium species has
demonstrated the potential of these approaches. The workshop presentations on
Leishmania  and Plasmodium  have shown that studies on resistance can also lead
to an improved understanding of the mode of drug action and uptake, leading
to improved drug design. This area of research is developing fast, although at
present experiments appear to produce more questions than answers.
The presence of a therapeutic level of a drug at the site of infection is a
reflection of the pharmacological properties of the compound. The last section
of the workshop discussed drug-delivery systems that are used to improve the
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in vivo activity of drugs with poor pharmacological properties. Regardless of
whether the drug-delivery system was most useful for improving targeting to
the infected tissue, to the parasites or to an intracellular biochemical target, it
is clear that in relation to trypanosomiasis, this area of research is in the early
stages and not all systems are suitable to the problems posed by this disease.
The long-term objective of much of the research discussed at the workshop
is the identification of a novel trypanocide. No doubt the rational/semi-rational
approach will identify a selectively toxic compound with good pharmacological
characteristics. However, the cost of drug development for most tropical dis-
eases is not an economic proposition and progress will certainly require close
cooperation among scientists, the pharmaceutical industry and international
organizations. The identification of a drug with broader applications, such as
9-deazainosine, to treat African trypanosomiasis, Chagas’ disease and leishma-
niasis may prove a more attractive proposition for development. If a drug is
already used clinically or has potential against a more profitable disease, the
attraction would be even greater. Several drugs discussed at the workshop,
including allopurinol, ketoconazole and difluoromethylomithine, fall into this
category. It will be interesting to see whether the research on dihydrofolate
reductase, trypanothione and DNA topoisomerase II, discussed at the workshop,
will identify compounds with this broad anti-trypanosomatid spectrum of ac-
tivity. Meanwhile, short- to medium-term advances are possible. Our under-
standing of the mode of action of new and established drugs should suggest
combinations for clinical trial, and new formulations of established drugs
should improve therapeutic levels and reduce local toxicity.
The mood of the meeting was one of optimism and determination, reflecting
the commitment of the participants. It provided an effective forum for exchange
of information, ideas and addresses. Let us hope that the next decade fulfils the
hopes raised by the advances of the last decade.
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